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Abstract
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-1, -4 and - 
5 are secreted enzymes which are members of the glutamyl endopeptidases (GEPs) 
group of ADAMTSs. These enzymes break down chondroitin sulphate proteoglycans 
(CSPGs) which are key components of brain extracellular matrix (ECM). In multiple 
sclerosis (MS), CSPG breakdown by ADAMTSs may enable axonal regeneration or 
conversely it may lead to alterations of the ECM, allowing influx of inflammatory cells 
promoting tissue damage.
ADAMTS-1, -4 and -5 mRNA expression was studied by quantitative real-time PCR 
(qRT-PCR) using the Taqman method in SHSY-5Y and SK-N-DZ human 
neuroblastoma cells, undifferentiated or differentiated to a more neuronal phenotype 
using retinoic acid (RetA). Modulation by pro-inflammatory cytokines ((interleukin-1 
IL-1) or tumour necrosis factor (TNF)), which are involved in the pathogenesis of MS, 
was also studied. As ADAMTS-1 was the most abundant ADAMTS in the neuronal cell 
lines, it was investigated at its protein level in both cell lines by Sodium Dodecyl 
Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) with western blotting. 
Furthermore, the presence of ADAMTS-1 at its mRNA and protein levels was 
confirmed by the small interfering RNA (siRNA) technique in SHSY-5Y cells. Cryostat 
sections of normal and MS central nervous system (CNS) tissue white matter, obtained 
from the UK Multiple Sclerosis Tissue Bank, were used to determine the localisation of 
V0/V2 neoepitopes of versican, derived by ADAMTS cleavage, using 
immunohistochemistry.
SHSY-5Y and SK-N-DZ cells expressed mRNA for ADAMTS-1, -4 and -5. ADAMTS- 
1 expression was significantly increased on cellular differentiation with RetA in SHSY- 
5Y cells. Its expression was confirmed at the mRNA and protein level. IL-1 P and TNF 
had no effect on ADAMTS mRNA expression in SHSY-5 Y cells. However, ADAMTS- 
1 mRNA expression was upregulated by IL-1 p in differentiated SK-N-DZ and there was 
also a significant increase in ADAMTS-4 mRNA expression with TNF treatment. 
ADAMTS-mediated versican breakdown, as determined immuohistochemically by 
versican (V0/V2) neoepitopes expression, was increased in MS brain tissue compared to 
normal brain tissue.
In conclusion, ADAMTS-1, -4 and -5 were constitutively expressed in SHSY-5Y and 
SK-N-DZ neuronal cells. Modulation by the cytokines tested was seen in the SK-N-DZ 
cells. From these in vitro studies, neuronal ADAMTSs in the CNS may have a potential 
role in MS pathogenesis. However further investigation is needed on primary neuronal 
cells and CNS to elucidate the role of neuronal ADAMTSs and their contribution in MS.
ADAMTSs do appear to be involved in increased proteolysis of versican at the known 
cleavage site in human brain tissue as indicated by (V0/V2) versican neoepitopes 
expression. Upregulation of versican (V0/V2) neoepitopes was observed in lesional MS 
sections on immunohistochemistry. These enzymes require further investigation, by 
immunohistochemical methods for co-localisation with versican (V0/V2) neoepitopes in 
MS, to determine which of the ADAMTSs generates these neoepitopes.
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Chapter 1 
Introduction
1
1.1 The Central Nervous System (CNS)
The CNS consists of the brain and spinal cord and is a complex well vascularised 
system that transmits electrical signals i.e. triggering neural functions of 
communication. From histological studies the nervous system can be divided into two 
major cell types: nerve cells (neurons) and supporting cells called glia. The function of 
neurons is electrical signalling and their function differs from glia. Glia do not 
participate directly in synaptic interactions and electrical signalling, they are supportive 
for neuronal cells. They also provide essential resources for repair of damaged CNS by 
promoting re-growth of damaged neurons and enable the CNS environment to be 
tightly regulated in order to permit uninterrupted and efficient neural chemistry (Purves 
et al., 2008).
1.1.1 The Blood Brain Barrier (BBB)
The BBB separates vascular components from the brain parenchyma, impeding the 
entry of detrimental materials. In normal physiological conditions it maintains 
homeostasis, maintaining essential proteins and ionic balances and allowing the 
entrance of essential nutrients. It also prevents access by immune cells. However, 
disruption of the BBB in the CNS may lead to neurological damage. The potential 
source of damage comes from the immune system, with the entry of activated 
lymphocytes into the CNS. The immune system is equipped with numerous effector 
mechanisms and can greatly alter the homeostasis and function of the CNS. 
Autoimmunity and pathogenic infectious agents can all result in acute or chronic 
inflammation within the CNS which subsequently leads to demyelination and axonal 
loss as in multiple sclerosis (Purves et al., 2008).
The BBB is formed by tight adherence of brain endothelial cells lining the cerebral 
micro-vessels. It is a selective barrier that limits or prevents blood-borne molecules 
larger than 0.6 kDa from moving into the brain and protects-the brain from damage, 
toxins or other potentially damaging molecules. The brain “capillary junctions are ~50-
100 times tighter than peripheral micro-vessels as a result of complex tight junctions
(TJs) produced by the interaction of several transmembrane proteins. Transmembrane
proteins occludins, are main contributors to the TJs along with claudins and the
junctional adhesion molecules. Cytoplasmic proteins e.g. zonula occludens protein-1
and -2 link the transmembrane proteins to the actin cytoskeleton allowing paracellular
transport to be modulated in response to different stimuli (Huber et al., 2001, Ballabh et
0 • •  •al., 2004). Despite an estimated total surface area of between 10-20 m of capillaries in 
the human brain, the TJs make the brain practically inaccessible for polar molecules 
unless they are transferred by transport pathways at the BBB that regulate the 
microenvironment of the brain (Pardridge et al., 1990).
There are also adherens junctions, which stabilise cell-cell interactions in the junctional 
zone. Large molecules such as antibodies, lipoproteins, proteins and peptides can also 
be transferred to the central compartment by receptor-mediated transcytosis or non­
specific adsorptive-mediated transcytosis. The receptors for insulin, low-density 
lipoprotein and iron transferrin are all involved in transcytosis.
The BBB contains a thick basal lamina and astrocytic end-feet surround the embedded 
endothelial cells in the basal lamina and provide biochemical support to these cells. The 
perivascular region contains microglia, synaptic terminals, neurons and smooth muscle 
cells as shown in Figure 1.1 (Abbott et al., 2006). This region has been shown to 
contract and regulate the CNS vascular diameter and capillary blood flow, BBB 
endothelial cell differentiation/proliferation and phagocytosis (Rucker et al., 2000).
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Figure 1.1: Cell to cell interactions within blood brain barrier. Different cell types are present 
in the blood capillary walls which communicate with each other. Pericytes are associated with 
endothelium within the endothelial basal lamina. The endfeet of astrocytic glial cells surround 
the endothelial cells in the basal lamina. In the perivascular space are found microglia, the 
synaptic terminals and nerve fibres, and smooth muscle cells. The endothelium can release 
substances to the blood or brain side after receptor activation as indicated by the arrows. 
Receptors can also increase the intracellular Ca2+ concentration (Reproduced with permission 
from Nature Reviews Neuroscience from Abbott et al., 2007).
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1.1.2 Neurons
A typical neuron has four distinct parts; cell body (soma), which is the main part and 
has all the necessary components of the cell, e.g. nucleus containing the DNA, 
endoplasmic reticulum (ER), ribosomes and mitochondria. The dendrites are the 
afferent thin structures of the neurons, frequently arranged around the neuronal cell 
body in the form of dendritic branches. They act to conduct electrochemical signals 
received from other neuronal cells to the cell body from which the dendrites project. At 
the other end of the soma a long unique extension, the axon 1 pm in diameter and up to 1 
m long in humans, conducts the signal away from the soma. The axons of many neurons 
have myelin wrapped around them to form the myelin sheath. This is formed by either 
of two types of glial cell Schwann cells which ensheath axons of peripheral neurons and 
oligodendrocytes which insulate those of CNS neurons. Along the myelinated axons, 
gaps in the sheath known as nodes of Ranvier occur at evenly-spaced intervals. The 
myelination enables efficient and rapid electrical impulse propagation. The 
demyelination of axons is what causes the multitude of neurological symptoms found in 
diseases such as MS (Siegel et al., 2006).
In the human brain generally, there are three types of neurons depending on their 
functions. Motor neurons or multipolar neurons control muscle contractions by carrying 
messages from the CNS to the muscles or glands. Motor neurons include spinal motor 
neurons, pyramidal neurons and Purkinje cells. The second type are sensory neurons or 
bipolar neurons which carry signals from the body's sense receptors, as in the eye and 
ear to the CNS. The third type are the intemeurons these neurons communicate with the 
spinal cord and with the skin or muscle which connect sensory and motor neurons e.g. 
dorsal root ganglia cells (Squire et al., 2003).
1.1.3 Glial Cells
Another cell type in the CNS, are the glial cells and their name came from glia meaning 
"glue". They are known to provide physical and nutritional support for the neurons. 
There are different types of glial cells: Schwann cells, microglia, oligodendrocytes and 
astrocytes. These cell types have been studied extensively and been shown to have 
different functions in the CNS. Astrocytes, under normal conditions have been involved
in glutamate (as a neurotransmitter) uptake, whereby they detoxify it, converting it to 
glutamine (Farina et al., 2007). There is also increasing evidence to suggest astrocytes 
have potential roles in immunity e.g. acting as antigen presenting cells to CD4+ 
helper/inducer cells in vitro by expressing major histocompatibility complex class II 
(MHC II) antigens. Also they can synthesise and secrete cytokines e.g. IL-1, TNF and 
interferon gamma (INFy). Microglia are macrophage-like cells resident within the CNS. 
Microglia are derived from bone marrow stem cells and early during development they 
occupy the CNS and remain quiescent as a resident macrophage population (Federoff, 
1995). These cells can act as antigen presenting cells (APCs) and may have 
proinflammatory effector functions such as secreting cytokines following activation by 
inflammatory stimuli (Kreutzberg, 1996, Shrikant and Benveniste, 1996). Activated 
microglia have been shown to be present within demyelinating lesions and to 
phagocytose myelin debris and express MHC II, suggesting microglia may play an 
important role in the pathogenesis of MS (Loughlin et al., 1993, Aloisi et al., 2000).
1.1.4 The CNS Extracellular Matrix (ECM)
ECM is present in the intercellular spaces between neurons and glial cells to surround 
and support these cells (Figure 1.2) (Celio and Blumcke, 1994, Celio et al., 1998). It is 
known that neurons and glial cells contribute to the secretion of ECM components. 
These are principally proteoglycans (PGs) which consist of a protein core to which 
glycosaminoglycans (GAGs) are bound. They may exist free or in aggregates bound to 
hyaluronic acid. Link proteins are involved in this binding (Neame and Barry, 1993). 
PGs containing the GAG chondroitin sulphate (chondroitin sulphate PGs (CSPGs)) 
predominate and include aggrecan, versican, neurocan, brevican and phosphocan. 
Aggrecan, versican, neurocan and brevican are also known as lecticans or hyalecticans 
as they contain an N-terminal hyaluronic acid binding domain and a C-terminal lectin 
domain (Iozzo, 1998, Yamaguchi, 2000). Through these domains, lecticans interact with 
carbohydrate and protein ligands in the extracellular matrix and act as linkers of these 
extracellular matrix molecules (Yamaguchi, 2000).
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Structurally, CSPGs are highly anionic macromolecules, as a result of sulphate and 
carboxyl groups in their polysaccharide GAG side chains. The GAGs are key 
components of the brain ECM. They are involved in binding cations, e.g. potassium, 
calcium and water also regulating the movement of molecules through the matrix and 
cell adhesion and growth (Bellail et al., 2004). Dermatan sulphate PGs are also present. 
In addition, the ECM contains tenascin-C and -R (Toole, 2000, Toole, 2004).
CNS ECM is deficient in collagen, fibronectin and laminin, the brain has a soft 
consistency when compared to cartilage. The ECM has an important role in 
physiological processes in the brain such as development (migration of neuronal and 
glial precursor cells), repair, proliferation and cell signalling (Bellail et al., 2004). It has 
been reported that during maturation of the CNS, distinctive changes in the composition 
of the molecules of the ECM (lecticans, tenascins and link proteins in brain) occur 
(Milev et al., 1998, Hirakawa et al., 2000). In the developing ECM brain components 
are neurocan, the versican VI splice variant, tenascin-C and. link protein, while 
brevican, versican V2, aggrecan, tenascin-R and link proteins are characteristic 
components of the adult brain ECM (Figure 1.3) (Pesheva et al., 1989, Yamaguchi, 
1996, Schmalfeldt et al., 1998). Also predominantly expressed in the mature nervous 
system are aggrecan, tenascin-N and brain link proteins (Hirakawa et al., 2000, Bekku 
et al., 2003, Neidhardt et al., 2003). Brevican and tenascin-R are considered as specific 
CNS molecules. Similarly, neurocan and tenascin-C are representatives of juvenile brain 
ECM, both proteins decreasing significantly in brain after the first postnatal week 
(Rauch et al., 1991, Dorries and Schachner, 1994).
The main role of CSPGs depends on their interactions with other ECM and neural 
adhesion molecules (Dow and Wang, 1998, Aspberg et al:, 1999). However, PG 
function in the injured adult CNS could differ from that in development and over­
expression in injured CNS ECM may be inhibitory to neurite outgrowth and axonal 
regeneration (Nieto-Sampedro, 1999, Deller et al., 2000, Schmalfeldt et al., 2000, 
Levine et al., 2001). PG expression is affected by a variety of stimuli, including 
cytokines (Jander et al., 2000, Asher et al., 2000). Lecticans can interact with other 
extracellular matrix components such as aggrecan and versican with fibulin family
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members, brevican with sulphated glycolipids and neurocan with members of cellular 
adhesion molecules (Viapiano and Matthews, 2006).
In mammals, lectican family members, aggrecan, versican and brevican have protein 
cores with homologous G1 and G3 domains with GAG side chains attached in the 
central region. They are substrates for the ADAMTS with glutamyl endopeptidases 
(GEPs) activity which include ADAMTS-1, -4 and -5. These lecticans vary in their size, 
number of the chondroitin sulphates and ADAMTS cleavage sites as shown in Figure
1.4 (Zimmermann and Dours-Zimmermann, 2008).
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Figure 1.2: A schematic view of the ECM. Lecticans form complexes with 
hyaluronan (HA) and tenascin-R (TN-R) in the ECM and occupy the spaces 
between neuronal (N) and glial (G) cells (Reproduced with permission from 
Springer from Yamaguchi, 2000).
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Figure 1.3: A schematic presentation of the lectican family members in CNS 
development and adult brain, and their binding to hyaluronan and tenascin 
complexes (Reproduced with permission from Springer from Rauch, 2004).
Furthermore, alternative splicing of versican results in transcripts that encode four 
variants: VO, VI, V2 and V3 (Zimmermann and Ruoslahti, 1989, Ito et a l, 1995, Zako 
et al., 1995). All four isoforms have distinct amino and carboxy terminal globular 
domains (G1 and G3) (Figure 1.4). The G1 domain contains hyaluronan and link protein 
binding sites. The versican isoforms differ in numbers of the GAG chain binding sites 
with VO containing both GAGa and GAGP domains, VI containing only GAGP, V2 
containing only GAGa, and the V3 isoform lacks the entire central domain including 
both GAG a and p domains: the G1 domain is directly followed by the G3 domain 
(Zako et al., 1995). Lecticans, aggrecan and versican are expressed by a wide range of 
tissues (aggrecan by cartilage and CNS and versican by connective tissue, blood vessels, 
brain, kidney and cartilage). CNS-specific proteoglycans are brevican and neurocan 
(Viapiano and Matthews, 2006).
Immunohistochemical studies demonstrated alterations in the composition of the ECM 
in various types of MS plaques. In active and chronic active MS lesions that are 
characterised by a massive influx of inflammatory cells, a decreased immunoreactivity 
of chondroitin and dermatan sulphate proteoglycans was observed. In active lesions, 
white matter-associated proteoglycans accumulate in macrophages, suggesting that 
chondroitin and dermatan sulphate proteoglycans are phagocytosed together with 
myelin or myelin breakdown products. Accumulation of CSPGs around lesions 
contribute to their formation of a barrier to axonal growth (Sobel and Ahmed, 2001). 
Also, Back et al, (2005) observed accumulation of hyaluronan in MS lesions (Back et 
al., 2005).
1.1.4.1 Previous Studies on CSPGs Proteolysis
Previous studies demonstrated that the matrix metalloproteinases (MMPs) were known 
to be responsible for the proteolytic cleavage of versican for example MMP-1, -2, -3, -7 
and -9, have been shown to degrade versican (Perides et al., 1995, Halpert et al., 1996, 
Passi et al., 1999). A subgroup of the ADAMTSs has GEPs activity and members of 
this subgroup have been shown to cleave CSPGs aggrecan, versican and brevican (see
also section 1.5.1). ADAMTS-1, -4 and -5 dependent degradation of aggrecan has been 
demonstrated (Abbaszade et al., 1999, Kuno et al., 2000, Tortorella et al., 2000). 
ADAMTS-5 is a key enzyme in the breakdown of aggrecan in arthritic cartilage 
(Glasson et al., 2005, Stanton et al., 2005). ADAMTS-1, -4 and -9 have been reported 
to mediate versican proteolysis in different tissues including aorta and brain (Sandy et 
al., 2001, Somerville et al., 2003, Westling et al., 2004). Versican can control several 
cellular processes such as adhesion, proliferation, apoptosis, migration and invasion via 
the highly negatively-charged chondroitin/dermatan sulfate side chains and by the 
interactions of the G1 and G3 domains with other proteins (LeBaron et al., 1992, Wight, 
2002).
ADAMTS-1 and ADAMTS-4 have been shown to cleave versican VI in the GAG-P 
binding domain at Glu441-Ala442 resulting in a 70 kDa fragment in human aorta (Sandy 
et al., 2001). Furthermore, Westling et al, 2004 have demonstrated that versican V2 in 
human brain tissue can be cleaved by ADAMTS-4 at the Glu405-Gln406 site within the 
GAG-a binding domain to produce a 64 kDa fragment (Westling et al., 2004). Also it 
has been found that versican (V0/V1) proteolysis via ADAMTS leads to a 70 kDa 
fragment that is essential for the formation and differentiation of endocardial cushion 
mesenchyme (Kern et al., 2007). Another study by McCulloch et al, (2009) suggests 
that ADAMTS-mediated proteolysis of versican is important in limb development and 
the generated fragment could regulate interdigital web regression (McCulloch et al.,
2009).
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Figure 1.4: The basic four lectican family members in humans, aggrecan, brevican, 
versican and neurocan. These share the same features of large CSPGs with G1 and 
G3 domains with regions carrying most of the O- and N-linked oligosaccharides 
and all glycosaminoglycans in between (Reproduced with permission from 
Springer from Zimmermann and Dours-Ziinmermann, 2008)
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1.2 Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and neurological 
disorder which affects mainly the white matter of the CNS (Bebo et al., 1999). MS is a 
complex disease and can have a personal, social and economic load on the society, 
which is estimated ~ £1 million per MS patient (Orton et a l , 2006).
1.2.1 Clinical course of MS
The majority of MS patients present with relapse-remitting (RR) symptoms, which 
starts with sporadic attacks and then periods of remission with partial or complete 
recovery. Symptoms may resolve completely, remission periods can last for months or 
years. Secondary progressive (SP) MS develops in more than half of RR patients. This 
will usually occur 15-20 years after the onset of the disease and involves fewer attacks 
and incomplete recovery. The primary progressive (PP) MS accounts for about 15% of 
MS cases in the UK and involves a progressive accumulation of disability without 
remission periods. Finally, the progressive relapsing (PR) disease is a very rare (< 1%) 
condition where symptoms steadily get worse from the beginning of the disease. Figure 
1.5 shows the clinical course of MS types (Lublin and Reingold, 1996).
1.2.2 Epidemiology of MS
Epidemiological studies have linked viral infections with the aetiology of MS, 
including Epstein-Barr virus (EBV) antigen and Haemophilus influenza, both of which 
can lead to demyelinating disease (Olson et al., 2001). MS is the most common 
neurological disorder among young adults, affecting approximately 2.5 million people 
worldwide. The onset of the disease usually occurs between the ages of 20-40 years old. 
It has a prevalence of 100-150 per 100,000 in the United Kingdom and an annual 
incidence of 7 per 100,000. As is the case with many other autoimmune diseases, MS 
occurs more in females than men. Overall MS affects twice as many women as men 
(MacDonald et a l , 2000).
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Figure 1.5: The clinical course of MS. MS has been classified according to the clinical course 
into different disease phases. 90% of patients show signs of relapsing-remitting disease, which 
starts with acute attacks involving worsening of neurologic functions followed by periods of 
remission (partial or complete recovery). Only 30% remain with this disease course. 
Approximately 60% of people with relapsing-remitting disease develop the secondary 
progressive MS phase where recovery from attacks is incomplete. 10% of patients with what is 
described as primary progressive MS show a steady increase in disability without distinct 
relapses or remissions. Progressive relapsing MS is a very rare condition, characterised by a 
steady progression of clinical neurological damage with relapses and remissions (Adapted and 
redrawn from Lublin, and Reingold, 1996).
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There is a latitudinal gradient in prevalence, independent of genetic factors, with rates 
increasing moving south or north away from the equator. The prevalence of MS varies 
considerably, being highest in northern Europe, New Zealand, Australia, North America 
and Canada. Latitudinal gradients are even described within the UK, with the highest 
rates being observed in Scotland and Northern Ireland. Asia, Africa and South America 
that lie on the equator have low levels of MS (5-10 per 100,000) (Compston et al., 
1998). Migration studies demonstrate that those who emigrate from an area of low- 
prevalence to an area of high-prevalence remain at low risk if they move after 15 years 
of age (Alter et al., 1966).
As the geographical distribution of MS prevalence is increased when approaching the 
poles, this highlighted the interest in low vitamin D levels as a risk factor for developing 
MS (Acheson and Bachrach, 1960). Recently, clinical observations and experimental 
work in vitro and in experimental autoimmune encephalomyelitis (EAE) animal models 
of MS has been reported, which showed that limited exposure to sunlight, which relates 
to vitamin D synthesis, has been associated consistently with an increased risk of 
developing MS (Ascherio et al., 2010, Burton et al., 2010, Solomon and Whitham,
2010). The prospect of a potential tool such as vitamin D supplements to prevent MS is 
tempting, yet challenging to investigate in an intervention study since it would require a 
huge population to measure any effect on MS incidence. However, vitamin D 
supplementation has not only been proposed to prevent MS, but also to attenuate 
disease activity of MS (Goldberg et al., 1986).
1.2.3 Aetiology and Immunopathogensis of MS
Although MS was first described more than 150 years ago, the exact aetiology and the 
pathogenesis are still not fully understood. The incidence of MS in first degree relatives 
is 20 times higher than in the general population, suggesting the influence of genetic 
factors on the disease. Monozygotic twin studies show a concordance rate of 25%. 
Dizygotic twins show a concordance rate of less than 5%. The major causation is 
unknown but may depend on the cumulative effects of both genetic and environmental 
factors (Hafler et al., 2007, Taylor, 2011). In this content, smoking (Pittas et al., 2009)
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and the degree of exposure to microorganisms in early life (hygiene hypothesis) 
(Ponsonby et al., 2005) as well as personal UVR exposure (van der Mei et al., 2003, 
Lucas et al., 2011) are well-established environmental risk factors that significantly 
alter the risk of developing MS.
Treatment to reduce the severity of the disease has been improved substantially but 
there is not yet a cure. An immune reaction to a viral infection where viral proteins are 
similar to self proteins may cause a cross reaction to myelin self proteins, molecular 
mimicry. This may occur early in life, in the periphery, and may initiate an autoimmune 
disease process with a genetic susceptibility. Activated antigen-specific T cells and B 
cells cross the BBB and infiltrate the perivascular space (Hemmer et al., 2006).
Figure 1.6 B shows a schematic view of the immunopathology of the MS lesion. A 
number of immune and CNS cell types are involved in lesion development and repair. T 
cells, B cells and macrophages infiltrate the lesion. CD4+ T cells are located in the 
perivascular cuff. The antigen-specific T cells, guided by chemoattractants, infiltrate the 
lesion in CNS. These cells become reactivated by antigens in association with MHC II 
presented on dendritic cells, B cells, microglial cells and macrophages, and locally 
released cytokines and chemokines attracting macrophages to the lesions and their 
distribution throughout the lesion is reflected in the expression pattern of MHC 
molecules. Macrophages release proinflammatory cytokines (IL-6 and TNF) and toxic 
molecules (nitric oxide). MHC class I is expressed by all cells in the inflammatory 
surroundings of the CNS (Neumann et al., 1995, Dandekar et al., 2001). CD8+ T cells 
infiltrate the parenchyma and, as well as secreting inflammatory mediators, they directly 
attack cells expressing MHC class I such as neurons and oligodendrocytes (Hemmer et 
a l, 2006).
B cells are also present in the perivascular space, where they produce antibodies. These 
antibodies opsonise the antigen expressed on the surface of oligodendrocytes and 
neurons. Bound antibodies can initiate the complement cascade, or induce antibody- 
mediated phagocytosis by macrophages (Alter et al., 2003). Astrocytes proliferate and 
• induce gliosis * at the edge o f the lesion. Following the inflammatory damage, 
oligodendrocytes may proliferate and remyelination of axons in lesions. However the
remyelination is usually incomplete and loss may be irreversible. Overall, the extent of 
inflammation, neurodegeneration and remyelination is heterogeneous between patients 
(Hemmer et al., 2006).
Studies in EAE mainly concentrated on the roles played by CD4+ T cells in MS 
pathogenesis. It is now becoming clear that CD8+ T cells also may play a significant 
role in the disease. It was observed that CD8+ T cell numbers were significantly higher 
than those of CD4+ T cells in MS lesions at all stages of MS (Lucchinetti et al., 2000). 
Numbers of myelin-reactive CD8+ T cells in the peripheral blood of people with MS 
were significantly higher than in individuals without MS (Crawford et al., 2004). 
Another study by Skulina et al, (2004) showed the persistence of clonally expanded 
CD8+ T cells in MS lesions (Skulina et al., 2004).
The mechanism of the BBB breakdown in MS is uncertain but it is thought that the 
exposure of the endothelium to proinflammatory cytokines such as INFy, IL-lp and 
TNF disturbs the BBB by disorganising cell-cell junctions and enhances leukocyte 
endothelial adhesion and migration and increases expression of MHC II (Minagar and 
Alexander, 2003).
Chemokines are composed of a large family of small proteins, which are involved in 
chemoattracting leukocytes into injured tissue (Asensio and Campbell, 1999). 
Chemokines and their receptors have been implicated in migration of mononuclear cells 
under physiological and pathological conditions (Murphy et al., 2000, Zlotnik and 
Yoshie, 2000, Trebst and Ransohoff, 2001).
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Figure 1.6: Immunopathogenesis in MS. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Neuroscience (Hemmer et al., 
2006.
A) MS is believed to be initiated in genetically susceptible individuals when 
infected by infectious agents that contain protein sequences cross-reactive 
with self-myelin. APCs present the antigen and activate myelin-reactive cells 
in the periphery. These cells cross the blood brain barrier and enter the CNS. 
Within the CNS, myelin-reactive Thl-cells interact with microglia (localised 
APCs) presented antigens and secret inflammatory cytokines causing 
demyelination. B) A schematic view of the immunopathology of the MS 
lesion. Infiltration of the T cells, B cells and macrophages in the perivascular 
lesion. As a result, an inflammation cascade is initiated with the release of 
inflammatory mediators and proteases that damage oligodendrocyte-formed 
myelin sheaths.
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It has been shown that the release of MMPs may facilitate the infiltration of activated 
immune cells into the CNS parenchyma by breaking down proteins, glycoproteins and 
PGs present in the basal lamina including type IV collagen and heparan sulphate 
proteoglycan of the BBB (Maeda and Sobel, 1996). Following migration into the CNS, 
activated T cells initiate an inflammatory process triggered by specific antigen. 
Immunological effector mechanisms include activation of microglia and infiltrating 
macrophages by T cell cytokines which may lead to ECM damage and demyelination. 
Recognition of myelin proteins e.g. myelin-associated glycoprotein (MAG), myelin 
basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) as foreign leads 
to myelin damage (demyelination) and subsequently axonal damage and loss 
(Grigoriadis et al., 2004). This damage causes a large variety of symptoms such as 
vision impairment, bladder or bowel dysfunction, motor symptoms (eg. weakness and 
spasticity), sensory symptoms (e.g. numbness and dysaethesia), tremor and ataxia and 
other symptoms such as fatigue and cognitive impairment.
Other factors which have also recently been associated with people with MS are the 
selective loss of immunologic self-tolerance of the myelin-reactive T cells. Although 
autoreactive T cells are present in both healthy individuals and patients with 
autoimmune diseases, autoreactive T cells found in patients with autoimmune disorders 
are more easily activated compared with those from normal subjects. Active 
suppression by CD4+CD25+ regulatory T cells has a significant role in immunologic 
tolerance in vivo. Their deletion causes spontaneous autoimmune diseases in mice 
(Sakaguchi, 2000). Human CD4+ regulatory T cells expressing high levels of CD25 are 
suppressive in vitro and mimic the activity of murine CD4+ CD25+. Furthermore, 
immunisation of animals with suppressor T-cells can prevent the development of EAE, 
an animal model of MS (Suri-Payer et al., 1998). People with MS show a significant 
reduction in the numbers and function of CD4+ CD25hl regulatory T cells from the 
peripheral blood compared to non-MS individuals (Viglietta et al., 2004).
21
1.2.3.1 Toll-like Receptors (TLRs) in MS Immunopathogenesis
Normally, when pathogens invade the CNS, the innate immune system provides a rapid 
but relatively nonspecific response to neutralise the infection via Toll-like receptors 
(TLRs). Due to this moderately nonspecific response, local tissue injury can occur 
(Lehnardt et al., 2003). If infection persists, adaptive immunity, which involves T and B 
cell activation, can provide a delayed but more specific response that is typically less 
destructive to the host tissue. An exception to this theory is with autoimmune disease 
where adaptive immunity promotes extensive host tissue damage. In general, however, 
the immune system provides a response that is progressively more specific to pathogens 
and less destructive to host tissue. An innate immune response is also provoked in non- 
infectious CNS injury or disease, including neurodegenerative diseases (Zhang et al.,
2005, Boillee et al., 2006, Yoshiyama et al., 2007, Giunta et al., 2008), stroke (Cao et 
al., 2007, Lehnardt et al., 2007, Tang et al., 2007), spinal cord trauma (Kigerl et al., 
2007), spinal nerve damage (Kim et al., 2007) and tumour infiltration (Hussain et al.,
2006, Curtin et al., 2009).
Innate immune activation in MS is indistinguishable from that associated with 
microbial exposure. The rapidity of resident immune cell activation is similar, for 
example occurring within 5 minute of spinal cord injury (Pineau and Lacroix, 2007) and 
within 8 minute of lipopolysaccharide (LPS) exposure (Clark et al., 2006). The 
underlying stimulus is that injured tissue or cells release, secrete, or synthesise 
molecules associated with damage, that communicate the presence of injury to the 
innate immune system.
In addition to lymphocytes that control adaptive immune responses, dendritic cells and 
tissue macrophages that regulate innate immune responses also play a role in controlling 
MS disease pathogenesis. These cells express pattern recognition receptors (PRRs) 
including TLRs that recognize pathogen-associated molecular patterns (PAMPs) present 
on the surface of pathogens. Also, endogenous molecules created upon tissue injury, 
called damage-associated molecular patterns (DAMPs) are ligands for TLRs and signal 
the risk of either infection or injury to the organism. Following ligand binding to TLRs, 
innate immune cells produce proinflammatory cytokines and can serve as antigen
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presenting cells (APCs) to T cells to recognize antigens (Takeda and Akira, 2005, 
Hacker et al., 2006). These receptors represent a key molecular link between tissue 
injury, infection, and inflammation. Thus, TLRs play an important role in linking the 
innate to the adaptive immune response (Bell et ah 2005).
DAMPs include endogenous molecules released by activated cells and ECM molecules. 
These molecules which are generated upon tissue injury activate TLRs. One of the first 
endogenous TLR activators recognised was the heat shock protein 60 (HSP60), which 
was shown to induce cytokine synthesis and to induce an inflammatory response. TLR 
activators that have been associated with MS are HSPs and high-mobility group box 
(HMGB1) protein. HMGB1 protein, originally described as a DNA-binding protein that 
facilitates transcription, can also be released extracellularly during acute inflammatory 
responses. Exposure of neutrophils, monocytes, or macrophages to HMGB1 results in 
an enhanced expression of proinflammatory cytokines (Park et al., 2004). Other TLR 
activators linked to MS are ECM molecules such as tenascin-C, versican and fragments 
of hyaluronan which may promote an inflammatory response (Piccinini and Midwood, 
2010).
1.3 Cytokines in MS
It seems that immunoregulatory cytokines play a significant role in MS pathogenesis. 
Cytokines are derived principally from activated T-cells, activated in the lymphoid 
tissue. An excess of the proinflammatory cytokines leads to changes in the blood brain 
barrier which activated T-cells are then able to penetrate. The antigen presenting cells 
e.g. microglia and endothelial cells present the antigen to activated T- cells. CD4+ T- 
helper (Th) cells differentiate into Thl cells and Th2 cells depending on the cytokine 
milieu. These subsets differ from each other in their cytokine production and in their 
function. Thl cells regulate cellular immunity e.g. viral immunity and delayed type 
hypersensitivity while Th2 cells control humoral immunity and have a role in fighting 
parasitic infections. Proinflammatory cytokines IL-1, TNF, IL-2 and INFy produced and 
released are involved in the pathogenesis of many CNS diseases including MS (Merrill
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et al., 1992). Thl cells activate macrophages and microglia to produce proinflammatory 
cytokines (IL-1 and TNF) and toxic molecules such as nitric oxide.
Activated astrocytes, due to their ability to secrete cytokines, play a significant role in 
triggering and maintaining immune responses in the brain. IL-1 and TNF modulate 
apoptosis of CNS cells and lymphocyte differentiation and infiltration (Kim, 1996). The 
Thl cytokines, lymphotoxin (LT), INFy and IL-2 are upregulated in MS. In contrast, T- 
cells producing Th2 cytokines (IL-4, IL-5, IL-6 and IL-10) are non encephalitogenic 
and possess the capacity to induce resistance to EAE (Ramirez and Mason, 2000). An 
exception to this, reported by Lafaille et al (1997), was that MBP-specific Th2 cells 
have the capacity to cause EAE in immunodeficient mice (Lafaille et al., 1997). Other 
findings, obtained with both EAE models and people with MS indicate the involvement 
of IL-17, produced by the Thl 7 cells another subset of T-helper cells, which in addition, 
toThl cells are thought to be critical in MS (Hofstetter et al., 2009). In MS increased 
numbers of mononuclear cells have been shown to express IL-17 mRNA in the 
peripheral blood (Matusevicius et al., 1999). Also these cells have been shown to 
migrate across the BBB (Kebir et al., 2007). People with MS, have also been shown to 
have elevated IL-17 levels in their cerebrospinal fluid (Ishizu et al., 2005) and IL-17 
protein is restricted to active areas of MS lesions (Tzartos et al., 2008).
1.3.1 The Interleukin-1 (IL-1) Family
IL-1 is a 17-kDa protein that is mostly produced by monocytes and macrophages but is 
also produced by endothelial cells, B cells, and activated T cells (Kennedy et al., 1992, 
Bauer et al., 1993). IL-1 family members are expressed at low concentrations within the 
normal CNS but their expression is rapidly up-regulated by various experimental brain 
insults e.g. ischaemia, trauma, hypoxia, EAE and neurotoxic or inflammatory stimuli. 
Interleukin-1 alpha (IL-1 a) and IL-1 P are members of the IL-1 family and bind to the 
same receptors (80 kDa cell surface receptor IL-1RI). A second, 68 kDa receptor (IL- 
1RII) also binds IL-1, but lacks an intracellular domain and does not initiate signal 
transduction. IL-1 p is considered to be more important than IL-1 a because it is able to 
modulate cerebral functions during systemic and localized inflammation (Gosselin and
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Rivest, 2007). Pro-IL-lp must be cleaved by the enzyme caspase 1, to produce the 
active form and allow cellular release (Thomberry et al., 1992). The third member of 
the IL-1 family is IL-1 receptor antagonist (IL-lra). It blocks IL-1 action by binding to 
IL-1 receptors but does not induce any intracellular signal (Gibson et al., 2004). In 
normal physiological conditions in the CNS, IL-1 p is expressed at low concentrations, 
but it is upregulated in response to pathological CNS injuries (Giulian et al., 1989).
Hauser et al., (1990) investigated the cytokines IL-1 p, TNF, and IL-6 by specific 
radioimmunoassays in the cerebrospinal fluid (CSF) of people with MS and other 
neurologic diseases. There was an increase in IL-1 p in people with active MS compared 
with other neurologic diseases (Hauser et al., 1990). IL-1 p also has been reported to be 
increased in the CSF of MS patients and EAE animals (Wang and Shuaib, 2002). 
Chronic expression of IL-1 in rat brain results in extensive demyelinating lesions, 
mimicking MS and IL-ra decreases disease progression in EAE.
1.3.2. Tumour Necrosis Factor (TNF)
Tumor necrosis factor (TNF) is a protein produced by monocytes, macrophages and a 
wide variety of other cell types in response to other cytokines. In contrast, lymphotoxin 
(LT) is a 25-kDa glycoprotein but it is lymphokine cytokine. Both TNF and LT are 
homologous (28%) in their amino acid sequences and formerly these were known as 
TNFa and TNFP respectively. As they have common cell surface receptors, it is thought 
that all cellular responses mediated through TNF are also mediated by LT (Chaturvedi 
et al., 1994).
TNF can be synthesised in the CNS by microglia, astrocytes, and some populations of 
neurons (Lieberman et al., 1989, Morganti-Kossman et al., 1997, Chung et al., 2005). 
TNF has been suggested as an important mediator of MS pathogenesis (Wajant et al., 
2003, Shen and Pervaiz, 2006, Wallach et al., 1999). It is synthesized as a trimeric type 
II transmembrane protein precursor and cleaved by TNF alpha converting enzyme 
(TACE; ADAM-17) to a 51 kDa (3x17. kDa), soluble circulating protein. Both the 
transmembrane and soluble forms of TNF are biologically active (MacEwan, 2002).
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TNF binds to two receptors (TNFRI [p55] and TNFRII [p75]), which initiates 
intracellular signalling (Viviani et al., 2004). The resultant gene expression modulation 
can contribute to inflammation and hence TNF is described as a pro-inflammatory 
cytokine. A study done by Hauser et al. (1990) shown that TNF was found more 
frequently in active MS than in other neurologic diseases. Gregersen et al, (2000) 
demonstrated that TNF was localised to microglial cells in mice post-ischaemia 
(Gregersen et al., 2000).
TNF is expressed by macrophages, astrocytes, microglia and endothelial cells in chronic 
and active MS. Furthermore, MS studies demonstrate that there is a correlation between 
TNF concentration and severity of the disease (Matusevicius et al., 1996).
1.4 ADAM-17
The ADAMs (a disintegrin and metalloproteinases) are a family of transmembrane and 
secreted proteins with important roles in regulating cell phenotype via their effects on 
cell adhesion, migration, proteolysis and signalling. The ADAMs belong to the M12B 
adamalysin protease subfamily in the MEROPS classification (Rawlings et al., 2008), 
which contains the closely related snake venom reprolysins and the ADAMTSs. 
ADAMs are multi-domain proteins with a pro-domain, metalloprotease, disintegrin, 
cysteine-rich, epidermal growth factor (EGF)-like, transmembrane and cytoplasmic tail 
domains. The functional ADAM metalloproteinases are involved in "ectodomain 
shedding " of growth factors, cytokines, receptors and adhesion molecules. Proteins can 
be cleaved and thereby released (shed) from the plasma membrane by these proteases or 
sheddases. TACE or ADAM-17 is a well known sheddase which is involved in 
releasing soluble TNF from its membrane-bound precursor (pro-TNF) (Moss et al., 
1997, Black et al., 1997).
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ADAM-17 is responsible for the cleavage of a wide variety of substrates involved in 
inflammation including transforming growth factor-alpha (Pro-TGFa), p75 (Peschon et 
al., 1998) and p55 TNF receptors (Reddy et al., 2000), the chemokine (fractalkine) 
(Garton et al., 2001) and amyloid precursor protein (Garton et al., 2001). The release of 
TNF from different cells occurs in response to injury or infection and plays an 
important role in the adaptive immune response to these conditions. However, TNF can 
also be produced in excess and can cause tissue damage. Generation of soluble TNF by 
ADAM-17 cleavage has been found to have a pathogenic role in CNS inflammatory 
responses involving MS (Kieseier et al., 2003, Plumb et al., 2006).
1.4.1 ADAM-17 and the CNS
Within the normal CNS, ADAM-17 expression has been observed in astrocytes and 
endothelial cells using double indirect immunofluorescence and confocal microscopy 
(Goddard et al., 2001). Plumb et al (2006) observed expression of ADAM-17 in 
activated macrophage/microglia and parenchymal astrocytes in MS white matter (Plumb 
et al., 2005, Plumb et al., 2006). Its expression is upregulated in active MS lesions and 
in EAE. Expression levels correlated with disease activity indicating that it may be 
involved in disease pathogenesis (Plumb et al., 2005, Plumb et al., 2006). ADAM-17 
expression by astrocytes and activated macrophage/microglia may therefore allow 
shedding of TNF producing soluble proinflammatory TNF. ADAM-17 cleavage of TNF 
has several proinflammatory effects including increased endothelial cell attachment of 
inflammatory cells via upregulated adhesion molecules, chemotaxis, migration and 
BBB disruption (Dobbie et al., 1999). Alternatively, it may induce a beneficial immune 
response by causing apoptosis of auto-reactive T cells as seen in experiments on the MS 
animal model EAE (Probert and Akassoglou, 2001, Weishaupt et al., 2004).
1.5 ADAMTSs
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) are a 
group of Zn-dependent, secreted, multidomain enzymes in family M l2 of Clan MA
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belonging to the same subfamily (B) of metzincin proteins as ADAMs, the adamalysins 
according to MEROPS database (Rawlings et al., 2010). ADAMTS-1 was first 
described by Kuno et al, (1997) identified as a novel murine complementary DNA 
(cDNA) expressed in a cachexigenic adenocarcinoma cell line. There are 19 known 
ADAMTSs identified in humans, numbered 1-20 (ADAMTS-5 protein is the same as 
ADAMTS-11) (Figure 1.7) and their known functions include cleavage of the ECM 
proteoglycans (aggrecan, versican and brevican), collagen processing, organogenesis, 
anti-angiogenesis and blood coagulation homoeostasis.
1.5.1 ADAMTS Subgroups
ADAMTS proteins can be divided into seven divisions, according to their structural 
characteristics and activities (targeted substrates) (Jones and Riley, 2005). The members 
of ADAMTS-1, -4, -5, -8, -9 and -15 forms a subgroup that is able to cleave the major 
cartilage proteoglycan aggrecan from which they derived the name aggrecanases. They 
also have a more general name, which is hyalectanases due to their ability to cleave 
substrates of the hyalectan (lectican) family of proteoglycans, including aggrecan, 
versican and brevican (Gao et al., 2002). They have GEP activity, cleaving peptide 
bonds at the carboxyl end of the glutamate residue. The GON-ADAMTSs are 
ADAMTS-9 and -20. ADAMTS-20 shares its modular arrangement with that of the 
long isoform of ADAMTS-9, having 14 C-terminal thrombospondin (TSP)-repeats and 
a gon domain (Somerville et al., 2003, Llamazares et al., 2003). Moreover, though 
ADAMTS-9 is classified as a GON-ADAMTS with ADAMTS-20, it too is able to 
cleave aggrecan at the Glul771-Alal772 bond and versican at the Glu441-Ala442 
(Somerville et al., 2003).
Another, well-defined, subgroup contains ADAMTS-2, -3 and -14 which are 
procollagen N-proteinases. ADAMTS-13 is in a category on its own and is involved in 
the blood coagulation hemostasis as the von Willebrand factor (vWF) cleaving protease. 
The remaining ADAMTS members form a subgroup called ‘others’, whose members 
are further divided into four pairs (ADAMTS-18 and -16, ADAMTS-19 and -17, 
ADAMTS-12 and -7, and ADAMTS-10 and -6) based on their structural characteristics.
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1.5.2. The Domain Structure of the ADAMTS Proteins
The main difference between ADAMs and ADAMTS is that ADAMs are 
transmembrane proteins while the ADAMTSs are secreted proteins, which bind to the 
ECM. ADAMTSs consist of prodomain, metalloprotease and disintegrin domains, but 
lack the ADAMs’ transmembrane domain. The thrombospondin motif(s), present on the 
C-terminal side of the disintegrin domain of ADAMTS also distinguishes them from 
ADAMs (Figure 1.8) and are thought to function, with the disintegrin domain, in 
binding to the ECM.
The molecular structure of the ADAMTS proteins can be subcategorized into domains. 
The ADAMTSs are synthesized as inactive zymogens. From the N- to the C-terminus, 
they each consist of: a signal peptide, a prodomain, a metalloproteinase catalytic domain, 
a disintegrin-like domain, a central thrombospondin (TSP)-repeat, a cysteine-rich 
domain, a spacer domain and a variable number of C-terminal thrombospondin (TSP)- 
repeats, which range from 14 C-terminal repeats in the case of ADAMTS-20 to none in 
the case of ADAMTS-4 (Stocker et a l, 1995, Kaushal and Shah, 2000).
1.5.2.1 The Signal Peptide and Prodomain
ADAMTS proteins are initially synthesized as pre-proenzymes with a signal peptide 
and prodomain, which is generally to maintain enzyme latency, accurate protein folding 
and secretion (Milla et al., 1999, Cao et al., 2000). Firstly, the ADAMTSs undergo an 
N-terminal processing to remove the signal peptide on the endoplasmic reticulum 
membrane. Removal of the prodomain has also thought to occur in the trans Golgi. This 
process in the ADAMTSs is catalysed by furin, also called proprotein convertase (PC), 
at the furin recognition site between the prodomain and the catalytic motifs. Furin is a 
calcium-dependent serine protease that is known to cleave precursor proteins. Furin has 
been shown to interact with the pro-form of ADAMTS-4 and to co-localize within the 
trans-Golgi network (Wang et al., 2004). Removal of the prodomain has also been 
reported for ADAMTS-1 (Kuno et al., 1999).
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The prodomain of human and mouse ADAMTS-5 contains three potential furin
• 'ico 9f^ 9recognition sites (Hurskainen et al., 1999) within a multi basic sequence RRRRR at 
the activation site. Although the predicted activating cleavage site at R - S has been 
detected in an in vitro expression system (Zeng et al., 2006), cleavage at this site has not 
been confirmed in vivo. Whether proprotein convertases other than furin can activate 
ADAMTS-5 and whether removal of the prodomain is required for its secretion has yet 
to be resolved (Wang et al., 2004).
1.5.2.2 The Metalloproteinase Domain (Catalytic Domain)
All ADAMTSs have a Zn-binding peptidase consensus HEXXH, catalytic domain 
which contains a zinc-binding active site similar to that in the ADAMs, which 
distinguishes the ADAMs and ADAMTSs from other metalloproteinases (reviewed in 
Porter et al., 2005).
1.5.2.3 The Disintegrin-Iike Domain
This domain in ADAMs and ADAMTSs has some primary sequence similarity (25 to 
45%) to that of the snake venom disintegrins. The snake venom disintegrins have an 
integrin recognition sequence RGD (Arg-Gly-Asp) and bind to integrins. ADAMTSs 
lack this RGD sequence and do not appear to interact with integrins (Perutelli, 1995).
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Figure 1.7: Domain structure of ADAMTS proteins Reproduced with permission, 
from S. Porter, I.M. Clark, L. Kevorkian and D.R. Edwards, (2005), The ADAMTS 
metalloproteinases, (386), (15-27).© the Biochemical Society.
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1.5.2.4 The Cysteine-rich Domain (CRD)
This domain is a cysteine rich sequence containing ten cysteine residues. Little is 
known of the function of this domain. However, the expression of various domain- 
deletion constructs of murine ADAMTS-1 showed that the CRD-spacer sequence is a 
functional ECM-binding domain (Kuno and Matsushima, 1998).
1.5.2.5 The Spacer Domain
There are no common structural features in this region and it is variable in length. 
ADAMTSs may undergo an extracellular C-terminal processing in this domain, which 
may have a significant effect on enzyme activity, localization and substrate specificity. 
ADAMTS-4 undergoes a C-terminal truncation to generate two isoforms with a distinct 
reduction in affinity of binding to their substrate (Flannery et al., 2002). Efficient 
aggrecanase activity requires the presence of GAGs attached to the aggrecan core 
protein. Flannery et al, (2002) demonstrated that full-length ADAMTS-4 (~ 68 kDa) 
undergoes autocatalytic C-terminal truncation to generate two distinct isoforms ( -5 3  
kDa and 40 kDa), which showed a clear reduction in affinity of binding to sulphated 
GAGs. ADAMTS-4 without the spacer region was 53 kDa (Gendron et al., 2007).The 
C-terminal spacer domains also affect binding of full-length ADAMTS-4 to sulphated 
GAGs (Flannery et al., 2002).
Kashiwagi et al, (2004) found the full-length ADAMTS-4 of 70 kDa was the most 
effective aggrecanase, but shows less activity against the Glu373-Ala374 bond, the site 
originally characterised as the target for aggrecanase activity. However, it cleaved the 
Glul480-Glyl481 bond in the chondroitin sulphate-rich region of aggrecan. There were 
considerable changes in substrate specificity upon deletion of the spacer domain. 
ADAMTS-4 with the C-terminal spacer domain deletion cleaved more effectively both 
the Glu373-Ala374 and Glul480-Glyl481 bonds. Processed forms (53 kDa and 40 
kDa) cleaved non-PG substrates, decorin and fibromodulin, in addition to the 
chondroitin sulphate-rich region of aggrecan (Kashiwagi et al., 2004).
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1.5.2.6 The Thrombospondin (TSP) - Repeats
The major difference between ADAMTSs, MMPs and ADAMs is the ability of 
ADAMTSs to bind to the ECM (Kuno and Matsushima, 1998, Somerville et al., 2003, 
Kashiwagi et al., 2004). They possess a well conserved thrombospondin (TSP)-repeat, 
homologous to the type I repeat of thrombospondins 1 and 2. The anti-angiogenic 
activity of ADAMTS-1 and -8 is thought to be mediated through their TSP-repeats 
(Porter et a l , 2005). It has been found that ADAMTS-4 cannot cleave GAG-free 
aggrecan. Kuno and Matsushima, (1998) demonstrated that ECM binding was mediated 
through the central and C-terminal TSP-repeats and the spacer region, and that 
sulphated GAGs were probably binding sites (Kuno and Matsushima, 1998).
With the exception of ADAMTS-4, which has no C-terminal TSP-repeats, all 
ADAMTSs have between 1 and 14 TSP-repeats, C-terminal to the spacer region (Figure 
1.7). C-terminal TSP-repeats are more variable in sequence than the central TSP-repeats. 
For murine ADAMTS-1 it was demonstrated that C-terminal TSP-repeats had a 
significant role in binding to heparin (Kuno and Matsushima, 1998). The TSP-repeats of 
the C-terminus are arranged in groups separated by a short linked sequence between the 
groups such as in ADAMTS-9 and ADAMTS-20 or a mucin-like domain as in 
ADAMTS-7 and ADAMTS-12 (Somerville et al, 2004). Other types of domains may 
be C-terminal to the TSP-repeats groups; ADAMTS-9 and -20 contain gon-1 domains, 
containing ten conserved cysteine residues (Somerville et al., 2003). ADAMTS-6, -7, - 
10,-12,-16,-17,-18 and -19 contain a protease and lacunin domain with six conserved 
cysteine residues (Nardi et a l , 1999). Additional C-terminal domains are present in 
ADAMTS-13 which contains two cubilin domains, (Zheng et al., 2001) (Figure 1.7).
1.5.3 ADAMTS-1, -4 and -5 and Brain ECM Breakdown
A subgroup of ADAMTSs, ADAMTS-1, -4, -5, -8, -9 and -15 are GEPs, cleaving 
peptide bonds at the carboxyl end of the glutamate residues.
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Figure 1.8: Schematic representation of the domain structure of ADAMs and ADAMTSs. A 
typical ADAM and ADAMTS-1 are similar in structure but most ADAMs have a transmembrane 
domain that incorporates them into the cell membrane, which ADAMTSs lack and instead have 
central TSP-repeats with variable numbers at the C-teminus. Most ADAMs and ADAMTS 
zymogens are processed and converted into a mature form at a furin recognition site by furin 
proprotein convertase enzymes (red arrow).
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They also have been demonstrated to cleave the major cartilage proteoglycan aggrecan, 
and have been termed ‘aggrecanases’ (Porter et al., 2005). ADAMTS-1, -4 and -5 also 
cleave other lectican family members and have other functions as shown in Table 1.1. 
ADAMTS-1 can cleave both aggrecan and versican. Kuno et al, (2000) showed that 
ADAMTS-1 cleaves aggrecan in vitro and that the spacer region is necessary for this. 
N-terminal sequence analysis of the cleavage product revealed that the chondroitin 
sulphate attachment domain of aggrecan was cleaved (Kuno et al., 2000).
ADAMTS-4 and -5 are the most extensively studied of the aggrecanases. Previous 
studies have shown that both enzymes can cleave aggrecan (Ilic et al., 2000) but 
ADAMTS-4 can also cleave brevican and versican. The main aggrecanase cleavage site 
of ADAMTS-4 and -5 is Glu373-Ala374 but there are also four other sites in the GAG 
attachment regions at Glul480-Glyl481, Glul667-Glyl668, Glul771-Alal772 and 
Glul871-Leul872 (Sugimoto et al., 1999, Tortorella et al., 2000) (Figure 1.9). In 
addition, ADAMTS-5 exhibited an additional site of cleavage in the region spanning 
residues Glyl481 and Glul667, representing a unique cleavage of ADAMTS-5 
(Tortorella et al., 2002). Nakamura et al, (2000) demonstrated that ADAMTS-4 cleaves 
brevican at only one site Glu395-Ser396. Furthermore, Nakada et al (2005) showed that 
glioblastoma cells transfected with ADAMTS-4 and -5 produced brevican cleavage 
products, whereas ADAMTS-1 and un-transfected cells displayed no cleavage (Nakada 
et al., 2005).
Brain proteoglycans aggrecan, brevican, neurocan, phosphocan, appican and versican 
components are important in normal homeostasis of the brain (Bandtlow and 
Zimmermann, 2000, Novak and Kaye, 2000). Alterations in synthesis or breakdown of 
the ECM may contribute to disease processes. In MS, ECM and BBB breakdown 
enables inflammatory mediators to migrate to sites of destruction i.e. myelin. Also, it is 
thought that ADAMTS-1, -4 and -5 mediated degradation of CSPGs may increase 
access of inflammatory cells that release proinflamatory cytokines TNF and IL-1 
(Figure 1.10) promoting axonal damage. Alternatively, ADAMTS-1, -4 and -5 may be 
beneficial in MS by breaking down CSPGs which accumulate at the edge of MS lesion 
and which normally have an inhibitory effect on axonal outgrowth and prevent axonal 
regeneration.
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Table 1.1: ADAMTS-1, -4 and -5 functions
ADAMTS-1 METH-1/
Aggrecanase-3
Inflammatory response, anti-angiogenic 
activity, organ morphogenesis, aggrecan 
and versican cleavage.
ADAMTS-4 Aggrecanase-1
Aggrecan, brevican, versican cleavage 
also cleaves fibromodulin, decorin, 
carboxymethylated transferrin and anti- 
angiogenic activity
ADAMTS-5 Aggrecanase-2/ 
ADAMTS 11
Aggrecan cleavage
(Porter el al., 2005, Hsu et al., 2012).
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Figure 1.9: Aggrecan cleavage sites. The cleavage sites are located within the G1/G2 
interglobular (IGD) domain. The Asn341-Phe342 is the main MMP cleavage site, 
whereas the Glu373-Ala374 is cleaved by aggrecanases. There are also four cleavage 
sites within the chondroitin sulphate-rich region of aggrecan for ADAMTS-4 and 
ADAMTS-5, arrows indicate cleavage sites (Reproduced by permission from Biochem J. 
from Porter et al., 2005).
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Figure 1.10: A schematic representation of the brain ECM in normal and degraded ECM. It is 
suggested that lecticans play a central role in assembling a well organised ECM in the adult brain. 
Lecticans bind the hyaluronan and tenascin-R to form a complex (A). It is thought when degradation 
of lecticans by ADAMTSs occurs after injury or in MS the ECM is disrupted, the matrix becomes 
loosened. (B) Such a loose matrix may provide constructive surroundings for cell migration and the 
infiltration of inflammatory cells and the secretion of cytokines such as IL-lf3 and TNF and may 
contribute to the disease (Adapted and redrawn from Viapiano and Matthew, 2006).
38
1.5.4 Studies of ADAMTS-1, -4 and -5 in MS
Previous studies have shown that MMPs contribute in CNS inflammatory disorders 
(Yong et al., 1998, Yong, 1999). However, more recent studies have shown that other 
peptidases such as ADAMTSs are expressed by CNS tissue and modulated in 
inflammatory CNS disorders (Cross et al., 2006b, Haddock et al., 2006). MS is an 
inflammatory demyelinating disorder of the CNS and is thought to involve cytokines 
and proteases. Only a limited number of studies have demonstrated that ADAMTS-1, -4 
and -5 are expressed in the CNS. These ADAMTSs are thought to have a significant 
role in the CNS during the disease process due to their ability to cleave CSPGs, which 
are essential molecules in the CNS ECM.
Previous studies, performed in our laboratory, demonstrated that in primary human 
astrocytes in vitro, TNF can upregulate ADAMTS-4 expression at both the mRNA and 
protein level (Cross et al., 2006a). In EAE, differential changes of ADAMTS-1, -4, -5 
and TIMP-3 were identified during different stages of CNS inflammation which may 
contribute to ECM degradation in disease progression (Cross et al., 2006b). In addition, 
ADAMTS-1, -4 and -5 (mRNA and protein) were expressed in post mortem MS brain 
tissue. However, immunohistochemical studies demonstrated that ADAMTS-4 protein 
was increased in post mortem MS brain tissue and it was associated predominantly with 
astrocytes (Haddock et al., 2006). ADAMTS-4 immunoreactivity was co-localised with 
brevican in rat brain as shown in Figure 1.11 (Haddock et al., 2007).
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Figure 1.11: Immunohistochemical confocal microscope image of rat CNS tissue 
following transient middle cerebral artery occlusion (tMCAo). (A) ADAMTS-4, (B) 
brevican and (C) co-localisation is represented in white in the merged image (Haddock et
1.6 Tissue Inhibitors of Metalloproteinases (TIMPs)
Metalloproteinase activity is regulated by a group of physiological inhibitors (TIMP-1, - 
2, -3 and -4), the tissue inhibitors of metalloproteinases (TIMPs) (Amour et al., 1998, 
Yu et al., 2000, Borland et al., 1999). TIMPs are proteins of between 21 and 34 kDa, 
with twelve conserved cysteine residues. The proteins are folded into two domains, with 
all the TIMPs containing a conserved binding site for proteinases, in the domain 
responsible for the inhibitory activity, the N-terminal domain (Lambert et al, 2004). 
TIMP-3 has been shown to be the only member of the TIMP family able to effectively 
inhibit the actions of ADAM-17 (Amour et al., 1998). It is also known as the main 
inhibitor of ADAMTSs, although TIMP-1 and TIMP-2 are inhibitory at higher 
concentrations (Hashimoto et al, 2001). TIMP-3 is the only TIMP known to bind to the 
ECM (via GAGs) (Yu et al., 2000), suggesting it has the potential to inhibit ADAMTSs 
in cartilage or brain.
Hashimoto et al (2001) suggests that TIMP-3 can inhibit aggrecanase activity of 
ADAMTS-4 in vivo (Hashimoto et al., 2001). While Kashiwagi et al (2001) 
demonstrated that TIMP-3 blocked ADAMTS-4 and -5 cleavage of aggrecan in vitro. In 
contrast, TIMP-1 and TIMP-2 had no effect on aggrecanase activity of both ADAMTSs. 
35% inhibition of ADAMTS-4 was shown with TIMP-4 in high concentrations but 
there was no inhibition of ADAMTS-5 (Kashiwagi et al., 2001).
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1.7 The Aims and Objectives of this Study
Hypothesis
• Neuronal ADAMTS-1, -4 and -5 expression is modulated in response to 
proinflammatory cytokines in MS.
• Increased ADAMTS activity in the brain causes breakdown of ECM 
components in MS
Aim
The main aim of this project was to elucidate a role for neuronal ADAMTS-1, -4 and -5 
in the pathogenesis of multiple sclerosis. Their presence has been shown previously in 
MS and normal CNS tissue but their production by neuronal cell lines has received little 
attention and no studies have looked at neoepitopes versican (V0 /V2 ) produced by these 
ADAMTSs in the CNS as a result of their specific GEP activity. This study may 
indicate the role of these enzymes in MS. To achieve this aim, the objectives were:
■ In vitro investigations of the ADAMTS-1, -4, and -5 gene expression and their 
modulation by cytokines IL-1 and TNF. These cytokines have been implicated in 
the pathogenesis of MS, as it is highly likely ADAMTSs are induced by cytokines 
during the pathogenesis of the disease. This was achieved by using the human 
neuroblastoma cell lines SHSY-5Y and SK-N-DZ with and without retinoic acid 
differentiation as neuronal models.
■ Studies of the expression ADAMTS-1 at the protein level. ADAMTS-1 was the 
most highly expressed ADAMTS at the mRNA level. ADAMTS-1 has been 
previously shown to be increased at the mRNA level in rat hypoglossal motor 
neurons following nerve injury (Sasaki et al., 2001). Knockdown of ADAMTS-1 
and peptide blocking experiments were performed to confirm the identity of 
ADAMTS-1 on western blotting and verify the specificity of the antibody used.
■ Studies of CSPG breakdown in normal and MS CNS post mortem tissue by 
ADAMTS. This was investigated via a study of neoepitopes of ECM component 
versican, as a potential measure of ADAMTS activity in normal and MS CNS tissue
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using immunohistochemistry. The accumulation of CSPGs around lesions forms a 
barrier which inhibits neurite outgrowth and prevents axonal regeneration (Sobel 
and Ahmed, 2001). Breakdown of CSPGs by ADAMTSs may enable axonal 
outgrowth and repair. Conversely, it may increase the access of inflammatory cells 
and the secretion of cytokines such as IL-ip and TNF and may promote axonal 
damage.
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Chapter 2 
Materials and Methods
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2.1 Materials
Materials used in this study and their details i.e. catalogue number, supplier and the 
methodology used are shown in Table 2.1.
2.2 Cell Culture
2.2.1. Human neuroblastoma SHSY-5Y and SK-N-DZ cell lines
All cell culture procedures were carried out under sterile conditions in a HERA safe 
class II laminar flow cabinet. Two human neuroblastoma cell lines (SHSY-5Y cell line 
and SK-N-DZ) were used in this study and their details are shown in Table 2.2. These 
cell lines have an adherent mode of growth with neuronal cell morphology. Cells were 
maintained at 37°C in 5% C0 2 /9 5 % air in a Hera Cell incubator (Heraeus Instruments, 
Kandro Laboratories Products, and Germany). Complete media was changed every 3 
days until they became 80-90% confluent.
When cells were 80-90% confluent, media were discarded and cells rinsed in 5-10 ml 
phosphate buffer saline (PBS (GIBCO®) without Ca2+ and Mg2+). 1.5 or 3 ml of 
trypsin-ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin and 0.53 mM EDTA 
(GIBCO® (TE)) was added to a culture flask (25 cm2 or 75 cm2 respectively) to detach 
the cells from the substratum. The flask was gently rocked back and forth to ensure all 
the cells were covered with the TE. The cells were incubated at 37°C for 2 minutes or 
until the cells began to detach. The flask was removed from the incubator and the cells 
were monitored under the microscope to ensure the majority of cells were detached. 
They were removed from the flask into a sterile falcon tube and the flask was rinsed 
with a volume of media equal to that of the TE used and these were pooled.
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Table 2.1 (continued): Materials utilised in this study
1HC
IHC
Cryo-sectioning IHC
Cell preservation
Cell culture
Cell cuture
cDNA synthesis
Histology
cDNA synthesis, WB
Cell culture
Cell culture
Cell culture
WB
IHC
RNA extraction
RNA/ Protein extractions
ICC
Fisher Scientific, UK
TAAB laboratories Equipments, UK
Cell Path Ltd
Sigma-Aldrich, UK
Fisher Scientific, UK
Fisher Scientific, UK
Invitrogen, UK
Sigma-Aldrich, UK
Grant Instrument (Cambridge) Ltd
Invitrogen, UK
Invitrogen, UK
Invitrogen, UK
GE Healthcare LTD, UK
Sigma-Aldrich, UK
Sigma-Aldrich
Sigma-Aldrich
Fisher Scientific, UK
FB58661
C028
KNA-0173-00A
D4540
05-539-12
05-539-8
Bio39026
44581
QBD2
31965-023
14200-067
14190-094
RPN2132
HT110116
Z666548
E7023
M/4450/17
Coverslip glasses 22 X 50 mm
Cryo M-bed
Cryo spray freezer spray 175g
Dimethyl sulfoxide (DMSO) 100 ml
Disposable centrifuge tube, sterile, polypropylene, 
15 ml, 50/bag
Disposable centrifuge tube, sterile, polypropylene, 
50 ml, 50/bag o£=LooXcuHXT3
DPX mountant for histology
Dry block heating system
Dulbecco's modified eagle medium DMEM + 
GlutaMAX IX
Dulbecco's phosphate buffer saline (D-PBS) 10X 
GIBCO®500 ml
Dulbecco's phosphate buffer saline (D-PBS) IX 
GIBCO® 500 ml
ECL Plus western blotting detection reagents 
ECL Plus western blotting detection reagents
Eosin Y solution 500 ml
Eppendorf LoBind microcentifuge tubes 
DNA/RNA, volume 1.5 ml, pack of 250
Ethanol for molecular biology, 500 ml
Ethanol, 2.5 litre
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Cells were centrifuged in a Sorvall RT7 plus centrifuge (Kendro Laboratory Products, 
Newtown, USA), at 200 x g  for 10 minutes and the supernatant discarded. The cell 
pellet was resuspended in 1 ml of complete culture media and mixed gently by pipetting 
up and down. Cells were counted using a haemocytometer and the number of cells in 
the central and four corner squares of the middle square (25 small squares) of the 
counting area were counted. Then the number of cells per ml was calculated using the 
following equation:
Cell per ml = Total cell count in 5 squares x 5 x 104.
The counted cells were further diluted to the densities required for experimental 
procedures.
2.2.2. Cryopreservation of Neuroblastoma Cells
Harvested cells were resuspended and mixed gently in HIFCS by pipetting and prior to 
making aliquots. A cryopreservative, dimethyl sulfoxide (DMSO, Sigma Aldrich, and 
Poole, UK) was added to a final concentration 10%, which prevents ice crystal 
formation in the cells when freezing them. 1 x 1 0 6 cells/ml were put in cryovials, which 
were then placed in a Cryo 1°C freezing container (Nalgene, Hereford, UK) containing 
isopropanol (-80°C overnight) in order to gradually lower the temperature by 
l°C/minute for maximal cell preservation. Cryovials were stored in a Dewar (Forma 
Scientific Inc., Ohio) containing liquid nitrogen. When cryovials of cells were removed 
from the liquid nitrogen storage for culture they were immediately taken to be thawed 
by placing the vials in a 37°C water bath. 1 ml of pre-warmed complete medium was 
added to the cells, mixed and then they were quickly transferred to cell culture flasks 
(75 cm ) containing 15 ml pre-warmed complete culture media. The flasks were gently 
agitated to distribute the cells evenly and then incubated at 37°C in 5% C0 2 /9 5 % air 
until they became 80-90% confluent.
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Table 2.2: The details of neuroblastoma cell lines and media composition used in this study
SHSY-5Y/
94030304
European Cell 
Culture Collection 
(ECACC)
Bone marrow of female
-Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 
glutamax
-10% v/v heat-inactivated 
foetal calf serum (HIFCS)
- 1% v/v penicillin (100 U/ml) 
and streptomycin (100 pg/ml).
SK-N-DZ/
94092305
European Cell 
Culture Collection 
(ECACC)
Bone marrow of a female
-Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 
glutamax
- 10% v/v heat-inactivated 
foetal calf serum (HIFCS)
- 1% v/v penicillin (100 U/ml) 
and streptomycin (100 pg/ml)
1 % non essential amino acids
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2.3 Characterisation of SHSY-5Y and SK-N-DZ Neuroblastoma Cell 
Lines with a Neuronal Marker Neurofilament L (NF L)
Neurofilaments are 10 nm intermediate filament proteins found specifically in neurons, 
which are the main structural elements of neuronal axons and dendrites. They are 
composed predominantly of three major proteins called neurofilaments L, M and H; 
named according to the apparent molecular size of the mammalian subunits on Sodium 
Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). The light or 
lowest, NF L, runs at 68-70 kDa, the medium or middle NF M runs at 145-160 kDa and 
heaviest or highest (NF H) runs at 200-220 kDa. NF L was used as a neuronal marker to 
characterise both neuroblastoma cell lines (SHSY-5Y and SK-N-DZ) in this study, 
which is the light or low molecular weight polypeptide with about 6 8  kDa on SDS- 
PAGE gels according to the manufacturer’s instructions.
Cells were plated out into 8 -well chamber slides at a density of 5 x 104 cells /500 pL 
media/well) and were allowed to adhere for 24 hours. Immunocytochemistry (ICC) was 
performed as follows: slides were fixed in 4% (w/v) paraformaldehyde (PFA) for 15 
minutes. After 2 x 5  minutes washes with PBS, the cells were placed in ice-cold 
methanol for 4 minutes followed by ice-cold acetone for 2 minutes. Slides were then 
blocked with blocking buffer (1 0 % normal rabbit serum of the animal in which the 
secondary antibody was produced), (Sigma-Aldrich, UK) in PBS for 30 minutes to 
prevent non-specific binding of the secondary antibody. Primary antibody against NF L 
(mouse monoclonal antibody, Abeam) was diluted (1:500) in PBS (according to 
manufacturer's instructions). PBS without primary antibody was used as a negative 
control. Incubation with antibody was performed overnight at 4°C in a humidified 
chamber. Slides were then washed for 3 x 5 minutes in PBS. The secondary antibody 
was a rabbit anti-mouse IgG (H+L)-fluorescein isothiocyanate (FITC) (Invitrogen, UK) 
1:50 diluted with PBS containing 10% normal rabbit serum, according to manufacturer's 
suggestions. The secondary antibody was applied for 2 hours at room temperature 
before washing 3 x 5  minutes in PBS. The nuclei of the cells were counterstained with 
propidium iodide (Sigma-Aldrich, UK) by diluting the 1 mg/ml stock solution (1:5000) 
in PBS. 300 pi was added to each well to cover the cells and slides were incubated, for
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15 minutes at room temperature in the dark to stain the nuclei orange to red. Then cells 
were washed 2 x 5  minutes each with PBS to remove unbound dye. Chambers were 
removed at this step and slides were mounted in citifluor glycerol solution. Cells were 
viewed and immunofluorescent images were captured using an Olympus BX60 
fluorescence microscope with Cool Snap Pro an integrated solution colour digital 
camera (Olympus Media Cybernetics, Silver Spring, USA). Images were analysed by 
LabWorks Image Acquisition and Analysis Software.
2.4 Treatment with Cytokines
Cells were passaged into 24-well plates at a density of 1 x 105/well in 1 ml medium and 
allowed to adhere for 24 hour in a cell incubator. Then the media was aspirated from the 
wells and cells were washed with PBS to remove any serum that could interfere with the 
experiment. Cells were then treated with either IL-ip or TNF (recombinant cytokines; 
Peprotech, UK) in triplicate at 0, 1, 10 or 100 ng/ml for 24 hours in 1 ml serum-free 
media. Media were removed then 333 pi of Tri-reagent (Sigma-Aldrich, UK) was added 
per well for RNA and protein extractions. Each experiment was repeated 3 times.
2.5 SHSY-5Y and SK-N- DZ Cell Differentiation with Retinoic Acid
Retinoic acid (RetA), vitamin A can control the expression of genes in the CNS 
(Clagett-Dame et al., 2005). RetA treatment has been shown to increase extension of 
neurite outgrowths producing a more neuronal phenotype comparable to in vivo
neurones (Encinas et al., 2000). Both SHSY-5Y and SK-ND-Z cells were treated for 7
•  •  « 0days with RetA (Sigma Aldrich, UK). A 10' M RetA stock solution was prepared in
100% molecular grade ethanol. Cells were cultured, as described in section 2.2.1 and 
were seeded in 24 well plates at 1 x 105 cells/well density for the experimental 
treatments. RetA was added 24 hours after plating at a final concentration of 10’5 M in 
DMEM with 10% HIFCS. After 7 days in the presence of RetA, cells were treated with 
cytokines in serum free medium for a 24 hour incubation period at 37°C and 5% C02. 
These neuroblastoma cell lines were examined for cellular differentiation under the 
contrast light microscope (Leica Microsystems, Wetzlar, Germany) xlOO or x200 and
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images were captured with the USB 2.0 camera/XLi-Cap software (XL Imaging Ltd. 
Swansea, UK).
2.6 RNA and Protein Extraction
2.6.1 Sample Preparation
In accordance with the manufacturer's protocol (Sigma-Aldrich, UK), RNA and protein 
were extracted from SHSY-5Y or SK-N-DZ cells by lysis in Tri-reagent. For 24 well 
plates, treatments were carried out in triplicate and 333 pi of Tri-reagent added to each 
well. For 25 cm culture flasks of cells, 2 ml of Tri-reagent was added to lyse the cells 
followed by repeated pipetting. Extracts were placed in microcentrifiige tubes (1 ml in 
each) and stored at -20°C.
2.6.2 RNA Extraction
Samples were left in Tri-reagent for 5 minutes at room temperature to dissociate 
nucleoprotein complexes. Upon addition of 0.2 ml chloroform/ml Tri-reagent and 
centrifugation at 12,000 x g  for 15 minutes at 4°C, the mixture separated into three 
phases: a lower pink organic phase containing the protein, a white interphase containing 
DNA and upper clear phase containing RNA. At this step the interphase and the organic 
phase were stored at -20°C for later protein isolation. RNA was isolated by transferring 
the upper aqueous phase into a clean microcentrifiige tube and 0.5 ml of isopropanol 
was added to each tube and centrifuged at 12,000 x g  for 10 minutes. The RNA was 
precipitated in pellet form on the side/bottom of the tube. The microcentrifiige tubes 
were placed in the centrifuge, with the top hinges facing the outside of the rotor to 
enable the location of the (usually) tiny pellet.
The supernatant was carefully removed and discarded then 1 ml of 75% ethanol added 
to each pellet. Tubes were vortexed and centrifuged at 8000 x g  for 5 minutes. The 
supernatant was discarded and the RNA pellets were briefly air dried for 5-10 minutes 
and resuspended in nuclease free water (20-30 pi) depending on the size of the pellet. 
The RNA samples were stored at -20 °C prior to use.
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2.6.3 Protein Extraction
Following lysis of cells with Tri-reagent and subsequent removal of the RNA and DNA 
containing phases, the pink layer containing the protein was divided into two 1.5 ml 
microcentrifuge tubes. 750 pL of isopropanol was added to each tube, mixed and left to 
stand for 10 minutes at room temperature. Tubes were centrifuged at 12,000 x g  for 10 
minutes at 4°C and the supernatant was discarded. 1 ml of 0.3M guanidine 
hydrochloride in 95% ethanol was added to each tube and allowed to stand for 20 
minutes and then centrifuged 8,000 x g  for 5 minutes. The 1 ml of 0.3M guanidine 
hydrochloride in 95% ethanol and wash steps were repeated two more times. Then the 
pellet was finally washed in 1 ml of 1 0 0 % ethanol, vortexed and allowed to stand for 2 0  
minutes at room temperature. This was followed by centrifugation at 8,000 x g  for 5 
minutes and the supernatant was discarded. Protein samples were resuspended in 100 
pL 1% SDS and stored at -20°C until used.
2.7 Agarose Gel Electrophoresis of RNA
The quality of intact RNA was determined by the presence of two bands representing 
18S rRNA and 28S rRNA subunits on 1% agarose gel after electrophoresis. The basic 
principle of this method is that nucleic acids are separated by applying an electric 
current to move the negatively charged molecules through an agarose matrix. Agarose 
(1%) was dissolved in Tris-boric acid-EDTA (TBE) buffer (89 mM Tris, 89 mM boric 
acid, 2 mM EDTA, pH 8.3) by heating prior to addition of 5 pL ethidium bromide 
(EtBr). EtBr fluoresces under UV light when bound to DNA/RNA and allows their 
visualisation. RNA samples (1 pL) were mixed with 4 pL H2O and 1 pL of 6  x loading 
buffer (40% sucrose, 0.01% bromophenol blue, lx  TBE) prior to loading in agarose 
wells. Electrophoresis was carried out at 100 volts for 30 minutes. Images were 
captured by UVP Bio-imaging System, USA and analysed with Lab Works Image 
Acquisition and Analysis Software (UVP, USA) and RNA/DNA gel programme.
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2.8 Bicinchoninic Acid (BCA) Protein Assay
The bicinchoninic acid (BCA) (Sigma-Aldrich, UK) protein assay was performed to 
determine the loading concentration of protein/well for the sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE). The principle of this test is that 
protein reduces Cu ions to Cu and interacts with the BCA reagent forming a violet- 
coloured product. Protein concentrations were calculated by plotting a standard curve in 
Microsoft® Office Excel 2007 of known protein concentrations of bovine serum 
albumin (BSA) as following 4, 2, 1, 0.8, 0.6, 0.4, 0.2 and 0.1 mg/ml and the unknown 
samples were read off. The volumes (pi) of unknown protein samples for loading were 
calculated by the following equation: amount required for loading (6  pg) / the 
concentration of the unknown sample then multiplied by 2  as the sample was already 
diluted 1:1 with sample buffer. Dilutions for the standard curve were prepared using 
20% BSA stock in 1% sodium dodecyl sulphate (SDS) diluent to yield the 
concentrations of the previously mentioned standards. Protein samples (in duplicates), 
standards (0-4 mg/ml) and blank (20 pL) (in triplicate) were added to 96-well plates. 
BCA reagent was prepared by adding 0.5 ml 4% [w/v] copper [II] sulphate (CUSO4) to 
24.5 ml BCA reagent (Sigma-Aldrich, UK). 200 pL was added to each well containing 
protein samples and incubated for 30 minutes at room temperature. Then absorbance at 
570 nm was measured using a Wallac Victor plate reader (PerkinElmer, USA).
2.9 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
2.9.1 Introduction
PCR technology was first developed in 1983 to amplify minute amounts of DNA. It 
uses the ability of a thermo-stable DNA polymerase enzyme (Taq polymerase) to extend 
a pair of oligonucleotide primers. The primers are designed to be complementary to 
each of the DNA fragments to be amplified during repeated cycles of denaturation 
(~95°C), primer annealing (~55°C) and primer extension (~72°C).
qRT-PCR was developed by Higuchi et al (1992) and has become a common technique, 
where a RNA strand is reverse transcribed into its DNA complement (cDNA) using the
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enzyme reverse transcriptase, and the resulting cDNA is amplified using PCR (Orlando 
et al., 1998, Bustin, 2000). Benefits of this procedure over conventional methods its 
sensitivity and accurate quantification. To achieve this, however, appropriate 
normalisation strategies are required to control for experimental error introduced during 
the multistage process required.
qRT-PCR has the same basic principles as the classical PCR but the monitoring of 
accumulating amplicon has been made possible by using fluorescent molecules to label 
probes. The change in signal which occurs when these labels directly interact with or 
hybridise to the amplicon is proportional to the amount of amplicon present during each 
cycle (Wong & Medrano, 2005).
2.9.2 The Amplification Plot
Amplification plots consist of two phases; an exponential phase and a plateau phase 
(cycle 28—40) Figure 2.1. The amount of product (amplicon) is doubling in each cycle 
of PCR, resulting in an exponential increase in fluorescence throughout the 
amplification reaction. However, as the reaction progresses the reactants are being 
consumed and the reaction slows and at an endpoint the reaction stops (plateau phase). 
qRT-PCR allows accurate and precise quantification of product during the exponential 
phase. Therefore, results are more sensitive than conventional PCR, in which products 
are measured during the plateau phase, where differences in target levels are not 
proportional.
2.9.3 Cycle Threshold (CT)
A number of cycles of the qRT-PCR show a background level prior to significant
accumulation of the target (cycle 1-18) in Figure 2.1. The cycle number at which the
fluorescence generated crosses the threshold known as the cycle threshold (Ct) and is
taken into account and used for qRT-PCR results analysis. The Ct values or the number
of amplification cycles depends on the amount of target, the larger the amount of
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template in the reaction the fewer amplification cycles to form a significant fluorescent 
signal. In contrast a small amount of the target will require more amplification cycles 
for the fluorescent signal to generate a detectable fluorescence signal. Thus, the reaction 
will have a high, or late, Ct.
Relative mRNA levels of the genes in this study were determined using the cycle 
threshold (Ct) and the 2-AACt  method (Livak and Schmittgen, 2 0 0 1 ), where AACt is 
calculated using the following formulae: Ct (target gene) -  Ct (housekeeping gene e.g. 
RNA Polymerase-II) = ACt, and ACt (treated sample) -  ACt (control sample) =AACt.
62
Plateau Phase
0.3
0.2
ExponentialCt value
Phase
0.1
Threshold
40200 10 30
Cycles
Figure 2.1: qRT-PCR amplification plot. This plot shows the exponential and 
plateau phases of qRT-PCR amplification. The PCR cycle number is shown on the x- 
axis, and the change in fluorescence from the amplification, which is proportional to 
the amount of the amplified product, is shown on the y-axis.
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2.9.4 TaqMan Probes
In this study the relative qRT-PCR technique was used with primers and TaqMan 
probes. TaqMan probes are also called double-dye oligonucleotide or dual labeled 
probes and are the most widely used type of probes. The principle of the TaqMan probe 
action is based on the 5’-3’ nuclease activity of Taq polymerase to cleave a dual-labeled 
probe during hybridization to the complementary target sequence and fluorophore-base 
detection (Figure 2.2). The TaqMan probe consists of single stranded probe sequence 
that is complementary to one strand of the template DNA. A fluorophore called 6- 
carboxy fluorescein (FAM) is attached to the 5' end and the quencher, 
tetramethylrhodamine (TAMRA) is attached to other 3' end. While the probe is intact 
and is attached or unattached to the template DNA and prior to the polymerase actions, 
the quencher (Q) (TAMRA) reduces the fluorescence from the fluorophore (F).When 
the Taq polymerase extends from the primer it displace the 5' end of the probe, which is 
then degraded by the 5'-3' exonuclease activity of the Taq polymerase. The end result of 
this process is to separate the fluorophore from the quencher. This leads to an increase 
in the fluorescence.
64
Forward Primer
Anneal
Extend
Fluorescence
TaqMan Probe
Fluorophore Q  Quencher
* Reverse Primer
*
F
Probe cleavage1
t
AT '
Figure 2.2 TaqMan Probes Action Adapted and redrawn from Walter FI. Koch 
Nature Reviews Drug Discovery 3, 749-761 (2004)
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2.9.5 cDNA Synthesis and qRT-PCR
RNA, extracted as described in section 2.6.2, was reverse transcribed using the 
Superscript™ II Reverse Transcriptase (RT). All reagents were from Invitrogen, unless 
otherwise specified. Filter tips (Starlab, UK) and clear-view snap-cap microtubes, size 
0.6 ml were used throughout the preparation of cDNA. The master mix for each RNA 
consisted of 4 pi 5x first strand buffer, 2 pi dithiothrietol (DTT), 0.5 pi RNAseOut 
ribonuclease inhibitor, 0.5 pL random primers and 1 pi deoxynucleotide triphosphates 
(dNTPs), which carry the bases adenine (dATP), cytosine (dCTP), guanine (dGTP) and 
thymine (dTTP) (Bioline, London, UK) and 9 pi nuclease-free water. 1 pi RNA was 
mixed with mastermix and 1 pi RT was added to all samples in an RNase-free PCR tube 
on ice. The primers in the mix bind to the RNA randomly, and the RT inserts dNTPs 
into the gaps to complete the cDNA strand, which represents all the transcribed RNA. 
Negative controls were performed for each experiment by using samples set up as above 
but with either no RT or without RNA. The reaction mix was placed in a heating block 
set at 42°C for 1 hour and followed by 95°C for 5 minutes to inactivate the RT enzyme. 
Synthesised cDNA was cooled to 4°C and then stored at -20°C until required.
Synthesised cDNA is used as a template for qRT-PCR and was diluted 1:1 in nuclease- 
free water. All PCR experiments were prepared on ice. Amplification was carried out in 
an ABI PRISM 7900HT sequence detection system (Applied Biosystems, Warrington, 
UK) at The University of Sheffield (Genetics Core Facilities, the School of Medicine 
and Biomedical Science) and Sheffield Hallam University, the Biomedical Research 
Centre (BMRC) with the following thermo-cycler programme: 2 minutes at 50°C, 10 
minutes at 95°C, 40 cycles of 15 seconds at 95°C, then 1 minute at 60°C.
Primers and FAM labelled probes were used for determination of ADAMTS-1, -4, -5, 
ADAM-17 and TIMP-3, (Applied Biosystems, Warrington, UK) assay numbers: 
Hs00199608_ml, Hs00192708_ml and Hs00199841_ml Hs00234224_ml and 
Hs00165949_ml respectively). Expression of ADAM-17, TIMP-3 and ADAMTS-1, -4, 
-5 was normalised against expression of the housekeeping gene RNA polymerase-II
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(assay number: Hs00992801_ml). According to the manufacturer's information primer 
efficiencies of the targets and reference genes were approximately 100%. These were by 
Applied Biosystems Assays-On-Demand, gene-specific TaqMan® probes (TaqMan® 
Gene Expression Assays, Applied Biosystems). All information that could be provided 
from Applied Biosystems is shown in Table 2.3.
2.9.6 Housekeeping Genes for qRT-PCR Validation
Variations due to different amounts of RNA can be excluded by normalization to one 
housekeeping gene. However, it is important to make sure that the house keeping gene 
is expressed at constant level throughout the experiment and between the samples. 
Housekeeping genes that were used in the SHSY-5Y neuroblastoma cell line qRT-PCR 
experiments were optimised from the following three genes: glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH), cyclophilin-A and RNA polymerase-II (RNAP-II), 
which were analysed for stability as normalisers for qRT-PCR. RNAP-II showed the 
least variation among the housekeeping genes used in this study, therefore this gene was 
used in subsequent experiments.
Table 2.3: The details of gene expression assays used in this study
ADAMTS-1 NM 006988 .3 1-2 68
ADAMTS-4 NM 00509 9 .4 4-5 63
ADAMTS-5 NM 007038 .3 3-4 65
ADAM-17 NM 003183 .4 1-2 111
TIMP-3 NM 0003 62 .4 1-2 59
* Sequences: Assays-on-Demand (Applied Biosystems)
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2.10 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Western Blotting
2.10.1 General Principle
SDS-PAGE is a commonly used technique for separating proteins in an electric field on 
the basis of molecular weight. Proteins migrate through a polyacrylamide gel as a 
support medium. The common electrophoresis technique cannot be used to measure the 
molecular weight of the biological molecules in biological samples because the mobility 
of the molecules in the matrix is influenced by both charge and size. The SDS gel 
electrophoresis, samples are treated with SDS so that proteins have an even negative 
charge. The molecular weight (MW) of proteins may be estimated if they are subjected 
to electrophoresis in the presence of the detergent SDS and a reducing agent. SDS 
disrupts the secondary, tertiary and quaternary structure of the protein and coats it with 
a negative charge uniformly. Negatively charged SDS coated proteins migrate in the gel 
relative to their size only and not to their charge. A marker containing proteins of 
known molecular weights is run in parallel to enable determination of molecular 
weights of proteins in the test sample.
Proteins from polyacrylamide gels can be transferred electrophoretically to 
nitrocellulose membranes by western blotting. The presence of the target protein within 
a sample can be detected on the blot using a specific primary antibody raised against the 
target antigen. Then it will form an antigen-primary antibody complex. Enzyme-labelled 
secondary antibodies can then bind to the primary antibodies prior to the detection of 
the antigen-antibody complex with an appropriate enzyme substrate as shown in Figure 
2.3.
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2.10.2 SDS-PAGE and Western Blotting Procedure to Determine 
ADAMTS-1 Protein Expression in SHSY-5Y
All reagents and materials were from Invitrogen, Paisley, UK, unless otherwise 
mentioned. The extracted proteins from the SHSY-5Y cells (100 pi) were denatured to 
their primary structures by dilution in 50 pi (4x concentrate) NuPAGE lithium dodecyl 
sulphate (LDS) sample buffer (pH 8.4), which allows maximal activity of the reducing 
agent and 20 pi (5x concentrate) reducing agent dithiothreitol (DTT) and 30 pi H2O. The 
denaturation process involves the breaking of S-S bonds by DTT. The process occurs 
most efficiently at 60°C for 30 minute as described in Cross et al, (2006a).
SDS-PAGE was performed in Novex Minicell tanks with pre-cast gels, 10% NuPAGE 
Novex Bis-Tris gels (pH 7.0) used in this study, 1 mm thick with 10 wells, in the 
presence of NuPAGE lx  3-(N-Morpholino) propanesulfonic acid (MOPS) SDS running 
buffer (pH 7.7). Protein was loaded per well and gels run for 1 hour at 100 volt (300 
mA) as described (Cross et al., 2006a) in detecting ADAMTS-1. Protein samples were 
run concurrently with 7 pL SeeBlue Plus2 pre-stained marker which contained protein 
standards of known molecular weight. Protein was transferred to Hybond-C 
nitrocellulose membranes (GE Healthcare, UK) at 150 volt for 1 hour in the presence of 
IX NuPAGE transfer buffer with 10% methanol and 0.1% NuPAGE antioxidant. 
Following transfer, blots were immediately placed in blocking solution, 5 % non-fat 
dried milk (NFDM) in Tris-buffered saline (TBS; 20mM Tris, pH 7.4/0.9% NaCl; 
containing 0.05% Tween 20 (Sigma-Aldrich, UK) (TBST).
2.10.2.1 Optimisation of Abeam and Triple Point Antibodies to Detect 
ADAMTS-1 Protein by Western Blotting in Human Neuroblastoma 
Cell Lines
Western blot optimisation for ADAMTS-1 was carried out using various polyclonal 
antibodies (see Table 2.4) raised against the C-terminus of the human protein to confirm 
the identity of ADAMTS-1. Briefly, protein was separated by electrophoresis on 10%
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NuPAGE precast gels (Invitrogen, Paisley, UK) under reducing conditions. The proteins 
in the gel were electroblotted onto a nitrocellulose membrane (Hybond-C, Amersham, 
UK) at 150 volts for 1 hour. Blots were blocked with NFDM in Tris-buffered saline (20 
mM Tris, 0.9% [w/v] NaCl, pH 7.4) (TBS) (Sigma-Aldrich, UK) containing 0.05% 
Tween 20 (Sigma-Aldrich, UK) (TBST) for 90 minutes prior to 3 x 10 minute washes 
with TBST. Blocking the membrane prevents non-specific background binding of the 
primary and/or secondary antibodies to the membrane (which has a high capacity at 
binding proteins and therefore antibodies). The ADAMTS-1 primary antibodies (Abeam, 
Triple Point Biologies) were added at a 1:100 and 1:500 dilutions in TBST (see Table 2.4). 
The blots were incubated overnight at 4°C and unbound antibody was washed off with 
TBST ( 3 x 1 0  minute washes) prior to incubation with secondary antibody [goat anti­
rabbit IgG with horseradish peroxidase (HRP) conjugate (1:80,000 in 0.05% NFDM in 
TBST)] (see Table 2.4) for 2 hours with gentle shaking. Further 3 x 5  minute washes in 
TBST were followed by 3 x 5 minute washes in TBS to remove excess Tween 20. Blots 
were developed with the enhanced chemiluminescence (ECL) PlusWestem Blotting 
detection reagent chemiluminescence substrate (GE Healthcare, UK) and 
diaminobenzidine (DAB) detection methods in accordance with the manufacturer's 
protocol. Detection of actin using an anti-actin antibody (Sigma-Aldrich, UK) was 
included as a loading control on blots. Details of the control, primary and secondary 
antibodies mentioned are shown in Table 2.4.
2.10.2.2 Optimisation of Santa Cruz Biotechnology Antibody to Detect 
ADAMTS-1 Protein by Western Blotting in Human Neuroblastoma 
Cell Lines
Protein samples were extracted from both SHSY-5Y and SK-N-DZ neuroblastoma cell 
lines (section 2.6.3) and protein determined (section 2.8) in order to load 15 pg/well in 
precast gels, which was according to the supplier's recommendations. The western 
blotting protocol was as previously described in section 2.10.2. A few modifications to 
the procedure were made to optimise the ADAMTS-1 Santa Cruz Biotechnology (sc- 
31080) goat polyclonal antibody. Its epitope is about 15-25 amino acids long and maps
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within the last 50 C-terminal amino acids of the human ADAMTS-1 protein. Details of 
the primary and secondary antibodies are shown in Table 2.4. Briefly blots were 
blocked with 5% NFDM in TBST for 1.5 hour prior to 3 x 10 minute washes with 
TBST. The primary antibody was added (1:500) in TBST and incubated overnight at 
4°C. The blots were then washed 3 x 1 0  minutes in TBST and incubated with secondary 
antibody donkey anti-goat IgG with HRP conjugate (Santa Cruz Biotechnology), 
1:50,000 in 2.5% NFDM TBST on an orbital shaker at room temperature for 2 hours. 
This was followed by 2 x 5 minute washes in TBST with the excess Tween 20 removed 
by a further 2 x 5  minute washes in TBS with gentle agitation. Recombinant human 
ADAMTS-1 (rhADAMTS-1) was used as positive control.
The detection method was with the ECL Plus Western Blotting Detection Reagent 
chemiluminescence substrate (GE Healthcare, UK). Images were captured and analysed 
using a UVP bioimaging system (Biorad, Hertfordshire, UK).
2.10.2.3 Antibody Detection (Enhanced Chemiluminescence (ECL) and 
SIGMAFAST 3,3' Diaminobenzidine (DAB)) Tablets
ECL detection reagent (Amersham Biosciences, UK) was prepared by mixing 2 ml 
reagent solution A with 50 pi reagent solution B. The excess washing buffer was 
drained from membranes and blots were placed, protein side up, on a plastic wallet 
spread on the bench. 2 ml ECL reagent was applied directly to the blot and incubated 
for 5 minute at room temperature. Excess detection reagent was drained off by holding 
the membrane gently in forceps and touching the edge against a tissue. In a similar 
manner the DAB detection method was performed with DAB SIGMAFAST tablets 
(Sigma-Aldrich, UK), which were developed for use in immune-blotting as a 
precipitating substrate for the localization of peroxidase activity. Tablets were dissolved 
in 15 ml deionized water to produce a buffered solution containing DAB and urea 
hydrogen peroxide. The membranes that the substrates were added to were transferred 
to the inside of new clear plastic wallets and placed protein side up. HRP-conjugated 
antibodies were detected by using a UVP bioimaging system (Biorad, Hertfordshire, 
UK). The camera detects the chemiluminescence emanating from the membrane,
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transforming the signal into a digital image for rapid analysis UVP bioimaging software. 
The programme was setup for each 15 minutes developing time. i.e. 3 images were 
captured every 5 minutes for each blot to obtain the best exposure time. A diagram 
illustrating protein detection on western blots is shown in Figure 2.3. Semi-quantitative 
analysis of protein expression by measuring the integrated optical density (IOD) of each 
band (densitometry) used Labworks4 software. Normalization was performed by using 
this equation:
Relative IOD = IOD of protein of interest / IOD of internal control protein.
2.10.2.4 Measurement of the Molecular Weight
In this study, measuring the MW was done by running a set of standard proteins of 
known MW to one well in the gel. These are called molecular weight markers, which 
come pre-stained in a range of colours (e.g. rainbow markers). SeeBlue Plus2 pre­
stained markers (Invitrogen, Paisley, UK) was used. The relative migration from the top 
in centimetres of each of the marker proteins was plotted against logio MW to form a 
standard curve. The MW of unknown protein could then be calculated from migration of 
that protein.
2.10.2.5 Stripping for Re-probing Western Blots
Stripping was performed to eliminate the primary and secondary antibodies from the 
membrane (Restore Plus western blot). Membranes were rinsed with TBST and the 
stripping buffer was added on the blots for 15 minutes on orbital shaker, and then 
washed for 10 minutes in TBST. The advantage of re-probing a single membrane for 
more than one protein is saving samples, materials, time and it is easier to compare 
immunoreactivity on the blots as the loading is identical.
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2.11 Small Interfering RNA (siRNA) Mediated Gene Silencing for 
ADAMTS-1 Knockdown in SHSY-5Y Cells
2.11.1 General Principle
RNA interference (RNAi) was first discovered by Hamilton and Baulcombe (1999) as 
part of post-transcriptional gene silencing (PTGS) in plants. It is a regulatory 
mechanism of most eukaryotic cells that uses small double stranded RNA (dsRNA) 
molecules in cellular anti-viral mechanisms and post-transcriptional regulation 
(Hutvagner and Zamore, 2002, Hannon, 2002, Zamore, 2001, McManus et a l , 2002). 
RNAi silencing is initiated when dsRNA is processed into small interfering RNA 
(siRNA) between 19-25 base pairs in length with a characteristic 2 nt 3' overhang that 
allows them to be recognized by an RNase-III enzyme called Dicer. These siRNAs are 
subsequently incorporated into RNA-induced silencing complexes (RISC) which leads 
to the degradation of the target mRNA (Figure 2.4). SHSY-5Y cells were transfected 
with siRNA pre-designed for ADAMTS1 On-TARGET plus SMART pool (Perbio 
Science, UK) to knockdown human ADAMTS-1 at its mRNA and therefore protein 
levels. The procedure was performed according to the manufacturer's instructions.
2.11.2 Cell Plating
SHSY-5Y cells were seeded into a 24-well plate at a density of 5 x 104 cells per well 
(mRNA determination) in 500 pi complete culture media without antibiotics. For the 
protein determination a 6-well plate at 2 x 105 cells in 2000 pl/well in complete culture 
media free of antibiotics was set up. Cells were allowed to adhere for 24 hours in an 
incubator. The media were then aspirated and cells were washed twice with PBS before 
adding siRNA and transfection reagents.
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Figure 2.4: Principle of siRNA method. This technique is based on the RNA interference 
pathway, which is triggered by double-stranded RNA (dsRNA) molecules that share 
sequence-specific homology for target mRNA. The appearance of these dsRNAs induces 
a cytoplasmic RNAase Ill-like protein called Dicer and RNA induced silencing complex 
(RISC). The Dicer digests the long dsRNA into siRNA duplexes (19-25 base pairs). The 
siRNAs are incorporated into RISC. RISC is then activated and binds the complementary 
mRNA. Upon identifying the specific region of complementarity, RISC mediates the 
mRNA cleavage and consequently gene inhibition.
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2.11.3 Transfection
ADAMTS-1 gene knockdown was performed by the use of lipid-mediated siRNA 
transfection (Perbio Science, UK Ltd) of SHSY-5Y cells which required optimisation.
2.11.3.1 Optimisation of Transfection
The first step of the optimisation of the siRNA knockdown was determining the most 
efficient transfection reagent for the SHSY-5Y cells, because this cell line had not been 
optimised for DharmaFECT transfection reagents. Four DharmaFECT transfection 
reagents, 1, 2, 3 and 4, were tested for their efficiency for siRNA delivery into the 
SHSY-5Y cells and the most efficient was selected.
siGLO transfection indicator (red) is a fluorescent oligonucleotide, suitable for delivery 
into mammalian cells by lipid mediated transfection and localises to the nucleus. This 
was used to determine the optimal siRNA transfection conditions. Cells were plated out 
in chamber slides at a density of 2 x 104 cells per well. After 24 hours they were 
transfected with siGLO and ADAMTS-1 siRNA using each of the four DharmaFECT 
transfection reagents. ADAMTS-1 siRNA (12.5 pi) was added to siGLO (12.5 pi), 
mixed and diluted 1:1 in SFM (25 pi) in 4 tubes (tubel). 1.5 pi of each transfection 
reagent 1, 2, 3 and 4 separately was mixed with 48.5 pi SFM in another tube (tube 2). 
Tubes were incubated at room temperature for 5 minutes. Each diluted transfection 
reagent tube 2 was mixed with tube 1 to form the transfection medium and incubated for 
20 minutes at room temperature. Cells were washed IX with PBS, then the transfection 
medium was added. 400 pi of antibiotic free media was added to each well to make a 
total volume of medium of 500 pi. After 24 hours of transfection, the optimum time for 
signal development according to the manufacturer's recommendation, cells were washed 
once with PBS. Then they were fixed with 4% PFA, which has no effect on the signal 
and the nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich, UK) (blue 
stain). 10 pi aliquots (10 mg/ml) of Hoechst 33342 were stored at -20 C and diluted 
1:1000 in dH2 0  (10 pg/ml) for final use.
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2.11.3.2 Transfection of SHSY-5Y Cells
Cells were transfected in triplicate wells, with siRNA targeting GAPDH as positive 
control (ON-TARGETplus GAPDH control pool), siRNA for the target gene (ON- 
TARGETplus ADAMTS-1 SMART pool), negative control or ON-TARGETplus non­
targeting pool a scrambled siRNA sequence, used to determine any non specific effects. 
Untreated control samples containing culture medium, without antibiotics and foetal 
calf serum were used to compare or measure the variations in the experiment.
Transfection of samples was performed in triplicate wells. In a 24 well plate, for each 
siRNA reaction 25 pi siRNA solution (2 pM siRNA solution), which was prepared in 
IX siRNA buffer (100 mM KC1, 30 mM HEPES-pH 7.5, 1.0 mM MgCk), was added to 
25 pi antibiotic and serum free culture medium and mixed gently (tube 1) and the 
appropriate DharmaFECT reagent (1.5 pi) with serum free medium (SFM) 48.5 pi 
added to tube 2. The cells were transfected with Dharmafect 1 reagent because in 
preliminary experiments it showed the best transfection efficiency of the four 
DharmaFECT transfection reagents 1, 2, 3 and 4 (Perbio Science, UK) as determined 
using siGlO (red), transfect indicator fluorescent oligonucleotide (Perbio Science, UK). 
The content of each tube was mixed gently by carefully pipetting up and down and 
incubated for 5 minutes at room temperature. Contents of tube 1 (siRNA) was added to 
tube 2 (transfection reagent 1) and mixed by gently pipetting up and down forming the 
transfection medium and was incubated for 20 minutes at room temperature. 400 pi of 
medium free of antibiotics and serum was then added to the transfection medium. The 
transfection medium was then added to cells after the removal of culture medium from 
the wells. They were incubated at 37°C in a CO2 incubator for 24 or 96 hours for mRNA 
and protein determination by qRT-PCR and western blotting respectively.
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2.12 Subjects for study
2.12.1 Human Brain Tissue
Snap-frozen CNS tissues were obtained from the UK Multiple Sclerosis Tissue Bank, 
Division of Neuroscience and Mental Health, Imperial College London (REC reference 
number 08/MRE09/31) (see appendix IV). Tissue blocks were from people with MS, 
including blocks containing normal appearing white matter (NAWM). The normal 
controls blocks were from donors with no history of MS and were from similar brain 
regions as blocks from MS donors. The UK Multiple Sclerosis Tissue Bank prepared 
the tissue blocks using a coronal slicing method. Briefly, a single coronal cut through 
the mamillary bodies was used to separate the brain into anterior (A) and posterior (P) 
halves (Figure 2.5 A). It was then cut into 2 cm thick slices, the first anterior to the 
mamillary bodies is A l, the next is A2 etc. The first slice posterior to mamillary bodies 
is PI, the next is P2 etc (Figure 2.5 B). Each slice was then divided into 2X2 cm blocks, 
with letters for the rows, and numbers for the columns given after the anterior or 
posterior slice number e.g. MS58 P1D3: MS58 indicates the case number, PI (P) is the 
posterior portion of the brain and (1) is the number of slice, 1 is nearest the mamillary 
bodies. D3 indicates the portion of the brain in row D of that slice and column (3) as 
described above (see Figure 2.5). Each block was frozen by immersing in isopentane, 
pre-cooled on a bed of dry ice. Then all tissue blocks were stored at -80°C.
2.13 Scoring of MS Lesions
2.13.1 Haematoxylin and Eosin (H&E) / Oil-Red O Staining (ORO)
In this study H&E/ORO staining was performed on MS, NAWM and control human 
brain tissue to re-characterise it for histology and grade lesion inflammation. Grading 
was carried out by two independent observers.
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MS58 P1D3
Figure 2.5: Human brain tissues cut into 2X2 cm blocks (Adapted from the UK Multiple Sclerosis 
Tissue Bank).
8 1
Ten-micrometre thick cryosections were cut using a cryostat, mounted on polysine- 
coated glass slides and stored at -80°C until required. These sections were stained with 
H&E/ORO and graded by using a four-point scale to determine the extent of 
inflammation and demyelination (Plumb et al., 2005, Plumb et al., 2006, Haddock et al., 
2006). Negative grade in H&E/ORO corresponded to no staining. H&E sections were 
scored + a small amount of cellular infiltrate in the perivascular region, ++ moderate 
cellular infiltrate and grade +++ an abundant number of cellular infiltrates in 
perivascular region. H&E is a stain that uses the basic dye haematoxylin to detect 
basophilic structures within a tissue section. Basophilic structures; such as the nucleus, 
ribosomes, and RNA-rich cytoplasmic regions produce a blue or purple colour. The 
acidic dye, eosin stains eosinophilic structures, generally proteins which can be 
extracellular or intracellular e.g. cytoplasm, connective tissues, and collagen which are 
stained pink.
ORO was scored + in the presence of few ORO positive cells, ++ moderate number of 
ORO positive cells in a MS lesion and grade +++ an abundant number of ORO positive 
cells. ORO is a neutral lipid dye which indicates areas of myelin breakdown and 
demyelination by staining myelin debris engulfed by macrophages.
H&E staining was performed in Coplin jars. Tissue sections (MS, NAWM and controls) 
were removed from -80°C and fixed in 4% PFA for 5 minutes. Sections were immersed 
in filtered Harris' haematoxylin (Sigma-Aldrich, UK) for 1 minute followed by a rinse 
with tap water. Then sections were stained with eosin (Sigma-Aldrich, UK) for 2 
minutes and rinsed with water again. Slides were then dehydrated with 50, 70, 80, 95 
and 100% (v/v) ethanol for 2 minutes each. Sections were placed in xylene (Sigma- 
Aldrich, UK) for 4 minutes and then mounted with DPX (mountant for the histology, 
Sigma-Aldrich, UK).
The ORO stain was prepared by adding lg  ORO powder to 100 ml 60% triethyl 
phosphate (TEP) and heated to 100°C for 5 minutes whilst stirring continuously. Then 
the ORO solution was filtered (warm), left for 1 hour and then filtered again when 
cooled. ORO staining was also performed in Coplin jars and sections were fixed with 
4% PFA for 15 minutes at room temperature. Sections were washed in tap water and
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immersed in 60% TEP for 2 minutes. Then the slides were incubated in filtered ORO 
stain for 30 minutes at room temperature. Slides were rinsed again with tap water. The 
nuclei of the tissue was counterstained with 20% Harris haematoxylin for 2 minutes and 
rinsed in tap water prior to mounting with aqueous mountant glycerol gelatin (stored at 
4°C Sigma-Aldrich, UK) which was heated in water bath at 60°C to melt prior its use. 
H&E/ORO stained sections were visualised under an Olympus BX60 light microscope, 
scored with the 4 point scale (-, +, ++, +++) method and images were captured with a 
Cool Snap Pro (Cybernetics) colour digital camera and analysed by LabWorks Image 
Acquisition and Analysis Software.
2.14 Immunohistochemistry for Versican (V0/V2) Neoepitopes in MS 
and Normal CNS Tissue
2.14.1 Immunofluorescence for Versican (V0/V2) Neoepitopes
The rabbit anti-human versican (V0/V2) neoepitopes polyclonal antibody (Perbio 
Science, UK) was used in this study, which was previously verified for its specificity by 
Westling et al (2004). Determination of the versican neopitopes was performed to 
identify ADAMTS-mediated versican cleavage via their glutamyl peptidase activity. 
According to Westling et al (2004), the cleavage of versican (V0/V2) by ADAMTSs in 
human brain in vivo is similar to the cleavage of aggrecan in cartilage and spinal cord by 
ADAMTSs in that it occurs at a specific site after a glutamate residue (Rodriguez- 
Manzaneque et al., 2002, Lemons et al., 2001).
Sections were allowed to reach room temperature. Around the tissue a border circle was 
drawn with a wax pen (ImmEdge hydrophobic barrier pen) (Vector laboratories, UK) to 
define the tissue area. A deglycosylation step was required for versican (V0/V2) 
ADAMTS-generated neoepitope detection to unmask the antigen. Sections were treated 
with chondroitinase ABC (0.25 IU/ml) for 90 minutes at 37°C. They were washed twice 
with PBS for 5 minutes, blocked with 0.5% normal goat serum in PBS buffer for 30 
minutes at room temperature then the primary antibody (versican V0/V2 neoepitopes 
antibody) 200 pL (1:100), was added and incubated on sections overnight at 4°C in a
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moist chamber. Following 3 x 5  minute PBS washes, secondary antibody (1:800) was 
applied in PBS as shown in Table 2.5 and was incubated for 2 hours at room 
temperature in a moist humid chamber in the dark. Slides were washed 3 times with 
PBS and a Sudan Black B (SBB) staining step was carried out.
All slides were stained with SBB. 1% SSB is used to reduce or eliminate lipofuscin 
auto-fluorescence in the brain. Tissue lipofuscin is a fluorescent pigment that 
accumulates with age in the cytoplasm of cells in the CNS (Goddard et al., 2001). SBB 
stain was prepared by dissolving lg of SBB powder in 100 ml 70% ethanol, with 
stirring for 2 hours in the dark in the fume hood followed by filtration (Schnell et al., 
1999). Slides were stained with SBB for 5 minutes in the dark and slides then rinsed 6-8 
times with PBS. Sections were then mounted with Vectashield mounting media (Vector 
Laboratories, Inc, Burlingame, USA), containing 4'-6-Diamidino-2-phenylindole 
(DAPI), which forms fluorescent complexes with dsDNA, enabling nuclei visualisation.
Sections were graded on a 4-point scale. Devoid of versican (V0/V2) neoepitopes 
immunoreactivity were graded -, sections showing versican (VON2) neoepitopes only 
associated with the blood vessels were graded +, sections with blood vessel and ECM 
staining versican (V0/V2) neoepitopes expression were graded ++ and sections with an 
abundance of extracellular staining versican (V0/V2) neoepitopes expression were 
graded +++. Grading was carried out blind by two observers.
2.14.2 Immunofluorescence for Markers von Willebrand factor (vWF), 
Human Leucocyte Antigen DR (HLA-DR) and Myelin 
Oligodendrocyte Glycoprotein (MOG) in Human Brain Tissue
Tissues were characterised using markers for the detection of endothelial cells of the 
blood vessels (vWF) and activated macrophage/microglial cells (HLA-DR), indicative 
of active lesions. MOG was also immunostained to determine regions of demyelination, 
indicative of MS lesions. These markers were immunostained with different antibody 
dilutions or incubation durations as shown in Table 2.5.
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Briefly, sections were fixed with ice-cold acetone for 10 minutes at room temperature. 
Slides were air dried and a border line drawn around the tissue as previously described 
in section 2.14.1. Slides were incubated with 10% normal rabbit serum in PBS as 
blocking buffer for 30 minutes at room temperature. Then the primary antibody a mouse 
anti-human (vWF, HLA-DR and MOG) was applied. Details of the antibodies and their 
optimal dilutions are shown in Table 2.5. The primary antibodies were washed 3 times 
for 5 minutes each with PBS, followed by applying the secondary antibody with optimal 
dilutions and incubation times (Table 2.5). This was followed by washes ( 3 x 5  minutes 
in PBS) and then staining with SBB and mounting as previously described in section 
2.14.1.
2.14.3 Dual Immunofluorescence
Dual-label immunofluorescence was performed to determine if there is any co­
localisation of versican (V0/V2) neoepitopes produced by ADAMTS-mediated versican 
cleavage with other markers. Dual staining was based a sequential detection method 
with monoclonal antibody to either the endothelial marker (vWF) or indication of 
deymelination (MOG) with the polyclonal antibody to versican (V0/V2) neoepitopes. 
Sections were treated with chondroitinase ABC (deglycosylation) and the monoclonal 
mouse anti-vWF or monoclonal mouse anti-MOG were added to the slides according to 
the optimal dilution and incubation time required for each marker as shown in Table 2.5. 
This was followed by secondary detection antibody donkey anti-mouse alexa fluor 488 
(Invitrogen, Molecular probes, 1:500 in PBS) for 2 hour in the dark at room temperature. 
This was followed by 3 x washes 5 minute in PBS and the versican (V0/V2) 
neoepitopes antibody with staining as previously described for the single-labelled 
immunoflourescence staining in section 2.14.1. Secondary antibodies were washed off 
in the same manner as primary antibodies, treated with SBB and mounted with DAPI as 
described in section 2.14.1.
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2.15 Expression of ADAMTS-1 Protein in Human Brain Tissue by 
Western Blotting
Briefly, 15 |ng/ lane of the protein samples were loaded into pre-cast gels and after 
transferring the protein samples to the membrane, the optimal blocking buffer 2% 
NFDM in TBST was added to the blots on an orbital shaker for 1 hour. Blots were 
washed 3 X 5  minutes each with TBST, and then the primary ADAMTS-1 antibody 
(Santa Cruz Biotechnology) was applied (1:100) and incubated at 4°C overnight. Blots 
were washed 3 X for 5 minutes each in TBST, then the secondary antibody was added 
(1:2000) in TBST and incubated for 2 hours at room temperature. The blots were 
washed with TBST 3 X for 5 minutes each with a final wash 1 X 5  minutes with TBS to 
remove excess Tween. Bands were detected as previously described in section 2.10.2.3 
using the ECL detection method.
2.16 Expression of Versican (V0/V2) Neoepitopes in Human Brain 
Tissue by Western Blotting
An additional step was required for the versican (V0/V2) neoepitopes detection in 
human brain tissue by western blotting. This was an enzymatic deglycosylation step to 
enable the proteoglycan to run as a discrete band(s) on SDS-PAGE. Because the 
glycosaminoglycan chains are susceptible to chondroitinase ABC, the samples were 
treated with chondroitinase ABC to digest the GAGs, allowing samples run as discrete 
bands and the antibody to more easily recognise epitopes. The chondroitinase ABC 
(Sigma-Aldrich, UK) treatment used in study was as previously described by (Gerard et 
al., 1993). Briefly, 12 IU/ml stock of the chondroitinase ABC in 0.1 M Tris/HCL 
containing 0.5 M sodium acetate was prepared. This was further diluted to get a 
concentration of 1 mlU/ml of chondroitinase ABC containing 10% protease inhibitor 
cocktail (P2714, Sigma-Aldrich, UK). This chondroitinase preparation was diluted 1:1 
with protein sample (in 1% SDS). Incubation was at 37°C for 4 hours for
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deglycosylation. The deglycosylated protein samples were denatured by the boiling at 
95°C for 5 minutes then run on SDS-PAGE. The western blot was performed as 
previously described in section 2.10.2.2.
2.17 Statistical Analysis
To ascertain whether the difference in relative ADAMTS-1, -4 and -5 mRNA 
expression levels (2 'ACt)  between RetA differentiated and undifferentiated SHSY-5Y 
cells, the Mann-Whitney U test was performed. The Mann-Whitney test is a non- 
parametric unpaired T-test used to assess the differences between two means. The 
Mann-Whitney test was also used to determine the difference between mRNA levels of 
ADAMTS-1, -4 and -5 in the RetA differentiated SK-N-DZ neuroblastoma cell line.
The Kruskal-Wallis test was used to determine any statistically significant differences in 
the stability of housekeeping genes and also of relative fold increases/decreases ( 2 ' A A C t )  
in ADAMTS-1, -4, -5, ADAM-17 and TIMP-3 mRNA expressions between untreated 
or cytokine treated cells. The Kruskal-Wallis test is a non parametric test equivalent to 
parametricto one way analysis of variance, used for comparing three or more means of 
independent experiments. Kruskal-Wallis gives an overall P value. This was followed 
by Dunnetfs post hoc test in this study to calculate a P value for each particular 
cytokine treatment relative to the control sample (untreated sample) to ascertain whether 
differences were statistically significant. Both Mann-Whitney U and Kruskal-Wallis 
tests were performed using GraphPad Prism Inc.
Results were expressed as +/- standard error of the mean (SEM), for three independent 
experiments. Statistically significant differences were represented in Figures by * = 
p<0.05, ** =p<0.01 and *** =p<0.001.
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Chapter 3
ADAMTS-1, -4 and -5 Expression 
and Modulation in Neuroblastoma
Cell Lines
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3.1 Introduction
It has been suggested that ADAMTS degradation of CSPGs may increase access of 
inflammatory cells promoting axonal damage. Alternatively, breakdown of CSPGs, by 
ADAMTSs may enable axonal regeneration and neurite outgrowth which is inhibited by 
CSPGs. Previously it has been demonstrated in our laboratory that ADAMTS-1, -4 and 
-5 are expressed by astrocytic cell lines (U373-MG and U87-MG) primary astrocytes 
and CHME3 microglial cells (Cross et al., 2006a). Also Sasaki et al, (2001) showed that 
ADAMTS-1 was expressed by N1E-115; a neuroblastoma cell line (Sasaki et a l, 2001). 
ADAMTSs, especially ADAMTS-1, -4, -5, and -9, are expressed in brain (Hurskainen 
et a l, 1999, Jungers et al., 2005) and it is interesting that each of these proteases is 
active in cleaving PGs. Several of the ADAMTSs have been shown to be elevated in 
human neurodegenerative disease and animal models of brain injury. ADAMTS-1, but 
not ADAMTS-5, appears to be up-regulated in Down’s syndrome, Pick’s disease and 
Alzheimer’s disease (Miguel et al., 2005).
IL-lp is elevated in the CSF of MS patients and in lesions in the animal model of MS, 
EAE (Wang and Shuaib, 2002). TNF also has been shown to be elevated in CSF and 
serum in MS patients with a correlation to disease severity (Munoz-Femandez and 
Fresno, 1998). The expression of ADAMTS-4 and ADAMTS-1 mRNA was markedly 
elevated in the hippocampus of rats in response to kainate-induced excitotoxic lesion 
(Yuan et al., 2002). An increase in ADAMTS-1 mRNA has also been demonstrated by 
Sasaki et al. (2001) who found that ADAMTS-1 was expressed at very low levels by rat 
hypoglossal motor neurons but following nerve injury, mRNA levels were rapidly 
increased, indicating that these proteases may be increased in response to injury or 
during an inflammatory response. However, research into whether neurons express 
ADAMTSs with aggrecanase activity has received little attention. ADAMTS-1, -4 and - 
5 have not been studied in neuronal cells in relation to the pathogenesis of MS. 
Therefore, an analysis of ADAMTS-1, -4 and -5 mRNA expression levels in SHSY-5Y 
and SK-N-DZ human neuroblastoma cells was performed using qRT-PCR.
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3.1.1 Objectives
• To characterise the two neuroblastoma cell lines (SHSY-5Y and SK-N-DZ) used
in this study, by detecting a neuronal marker neurofilament L (NF L).
• To determine the morphological effect of RetA on both neuroblastoma cells
utilised in this study.
• To validate and optimise the qRT-PCR method for the detection of ADAMTS-1,
-4 and -5 and TIMP-3 gene expression
• To determine the modulation of ADAMTS-1, -4, -5, ADAM-17 and TIMP-3
mRNA expression in undifferentiated or differentiated SHSY-5Y and SK-N- 
DZ by proinflamatory cytokines.
3.2 Results
3.2.1 Characterisation of the Neuroblastoma Cell Lines
The SHSY-5Y and SK-ND-Z neuroblastoma cell lines used in this study were 
spontaneously transformed cells from a female patient with neuroblastoma as shown in 
Table 2.2. Both cell lines propagate via mitosis and can be differentiated to extend 
neurites to the surrounding area. The cells grow as neuroblastic cells with epithelial like 
morphology with multiple, short, fine cell processes (neurites). To determine whether 
the human neuroblastoma cells that were used in this study had neuronal features, ICC 
was performed with a NF L antibody as described in section 2.3. NF L, is one of the 
neurofilament subunits present in neurons, neuronal processes, and peripheral nerves 
and is a specific neuronal cell marker.
Neuroblastoma cell lines (SHSY-5Y and SK-N-DZ) were plated into 8-well chamber
slides at a density of 5 x 104/500 pi media/well and allowed to adhere for 24 hours.
They were incubated with primary antibody against NF L followed by rabbit anti-mouse
IgG-FITC secondary antibody (green). Nuclei were counterstained using propidium
iodide (orange). Both SHSY-5Y and SK-N-DZ cells stained for NF L indicating a
neuronal phenotype (Figures 3.1 A and C). No staining was observed when NF L
antibody was omitted (replaced by PBS) from the protocol as a negative control for
non-specific binding of the secondary antibody (Figures 3.1 B and D).
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Figure 3.1: Characterisation of the neuroblastoma cell lines (SHSY-5Y and SK-N-DZ) without 
RetA used in this study. A) SHSY-5Y cells staining (green) with anti-NF L antibody. B) No 
primary antibody (SHSY-5Y cells), as a negative control. C) SK-N-DZ cells staining (green) 
with anti-NF-L antibody and D) omission of the primary antibody (SK-N-DZ) as negative 
control. Nuclei of the cells were counterstained using propidium iodide (orange). Images were 
captured with an Olympus BX60 fluorescence microscope with Cool Snap Pro an integrated 
solution colour digital camera (Olympus Media Cybernetics, Silver Spring, USA) (x200).
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3.2.2. Neuroblastoma Cell Lines Differentiation with Retinoic Acid 
(RetA)
Cells were cultured as previously described in section 2.2.1 and treated with RetA as 
described in section 2.5. Figure 3.2 shows the differences in cell morphology between A) 
untreated and B) RetA (lO'5 M) treatment of the SHSY-5Y cells and C) untreated and D) 
RetA treatment of the SK-N-DZ cells. Cell images were taken on day seven of culturing 
with RetA. Cells treated with RetA appeared to have decreased proliferation compared 
to untreated cells in that they were observed to grow more slowly than untreated cells. 
The morphology of RetA treated cells has also changed. Arrows indicate that RetA can 
enhance or elongate the neurite out growth processes, suggestive of differentiation to a 
more neuronal phenotype.
3.3 Expression of ADAMTS-1, - 4 and -5 mRNA in SHSY-5Y Cells
In this study, the expression and modulation of ADAMTS-1, -4, -5 and TIMP-3 mRNA 
after proinflammatory cytokine (24 hour) treatment (described in section 2.4) was 
analysed in SHSY-5Y human neuroblastoma cell line by qRT-PCR (described in 
section 2.9.5). These cells were also treated with RetA as previously described, to 
induce neuronal differentiation, to assess whether ADAMTS-1, -4 and -5 mRNA 
expression levels are affected by RetA treatment.
3.3.1 Sample Preparation for qRT-PCR
After proinflammatory cytokine treatment with IL-1 p or TNF (0-100 ng/ml) as 
described in section 2.4, total RNA was extracted from SHSY-5Y cells. Then the 
samples were separated by agarose gel electrophoresis (described in section 2.7). Figure
3.3 shows a representative SHSY-5Y extracted RNA gel with intact and good quality 
RNA as determined by the presence of discrete bands for 28S and 18S rRNA subunits.
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Figure 3.2: Morphological affect of RetA on neuroblastoma cell lines. SHSY-5Y cell 
morphology A) untreated B) treated with RetA. SK-N-DZ morphology C) untreated D) 
treated with RetA. RetA treatment was for 7 days. Images were captured on a light 
microscope (Leica) (x200).
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Figure 3.3: RNA extraction from SHSY-5Y cells. Cells treated with IL-1 
P (A) or TNF (B) for 24 hour treatment. Upper band shows 28S rRNA and 
lower bands show 18S rRNA.
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3.3.2 qRT-PCR Validation, Normalisation and Housekeeping Genes
It is essential to rule out variations between samples when detecting mRNA expression. 
These variations can be introduced at a number of stages throughout the experimental 
protocol (RNA extraction as described in section 2.6.2 and reverse transcription into 
cDNA as described in section 2.9.5). A widely used approach is to normalize mRNA 
levels of the target to an internal reference or housekeeping gene.
The strategy here in this study to validate the qRT-PCR was by comparing the mRNA 
expression of three housekeeping genes GAPDH, cyclophilin-A and RNAP-II in the 
SHSY-5Y neuroblastoma cell line under the same conditions i.e. proinflammatory 
cytokine treatment of cells with IL-1 p at 1, 10 and 100 ng/ml concentrations as 
described in 2.4. Results showed that RNAP-II was the most stable housekeeping gene 
as its relative mRNA expression was constant either used as reference or as a target 
compared to the untreated sample (control) (Figure 3.4 A and C). When using GAPDH 
and cyclophilin-A (Figure 3.4 B) changes were observed on the cytokine treatment (IL- 
ip at 1 ng/ml). However, no statistical significance was seen with these housekeeping 
genes. Statistics were performed by Kruskal-Wallis non parametric test, followed by 
Dunnetf s test using the Graph Pad Prism software.
3.3.3 Comparison of ADAMTS-1, -4 and -5 mRNA Expression in 
SHSY-5Y Cells with and without RetA Differentiation
qRT-PCR analysis of relative expression levels (2 'ACt)  demonstrated that the SHSY-5Y 
cell line expressed ADAMTS-1, -4 and -5 mRNA levels with and without RetA 
differentiation in this study (Figure 3.5). Results were expressed as +/- standard error of 
the mean (SEM), for three independent experiments. Representative amplification plots 
are shown in appendix I.
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Figure 3.4: Validation of housekeeping genes (qRT-PCR) for normalising mRNA 
expression in SHSY-5Y cells. A) Cyclophilin A vs RNAP-II, B) GAPDH vs cyclophilin 
A and C) RNAP-II vs GAPDH. Results showed that RNAP-II was the most stable 
housekeeping gene as its relative mRNA expression was constant either used as reference 
or as a target. Results expressed are relative to untreated control sample (grey bar) (A, B 
and C). When using GAPDH and cyclophilin-A (B) changes were observed on the 
cytokine treatment (IL-1 p at 1 ng/ml). However, no statistical significance was seen with 
these housekeeping genes. Results are expressed as means ± SEM (n=3 independent 
experiments).
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A statistically significant increase was observed in differentiated cells compared with 
undifferentiated cells in terms of ADAMTS-1 mRNA expression (p<0.05, Mann- 
Whitney). There was an increase in ADAMTS-4 expression in differentiated cells 
compared to undifferentiated cells, but this was not statistically significant. There was 
low expression of ADAMTS-5 mRNA in both treated and untreated cells (Figure 3.5).
3.3.4 Effect of Pro-inflammmatory Cytokines on ADAMTS-1, -4, and - 
5 , ADAM-17 and TIMP-3 mRNA Expression Levels in SHSY-5Y Cells
To detect the modulation of ADAMTS-1, -4 and -5 and ADAM-17 expression in the 
SHSY-5Y cells, they were treated with pro-inflammatory cytokines (IL-ip or TNF), 
which are implicated in the pathogenesis of MS. Relative quantification of mRNA 
levels of ADAMTS-1, -4 and -5 from cytokine stimulated cells compared to untreated 
cells was calculated by the comparative cycle threshold C t  method ( 2 ' AACt )  (see section 
2.9.3).
Figures 3.6 (A, B and C) show no statistically significant effects (p>0.05) on 
ADAMTS-1, -4 and -5 mRNA expression in SHSY-5Y cells differentiated with RetA 
(+RetA) or undifferentiated (-RetA), following 0-100 ng/mL treatment with IL-1 or 
TNF. Furthermore, there was no effect of the cytokines on ADAM-17 or TIMP-3 
mRNA expression (Figure 3.6 D and E respectively) in the SHSY-5Y cells with and 
without RetA. Results shown are the combined results of three independent experiments.
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ADAMTS-5ADAMTS-1 ADAMTS-4
Figure 3.5: ADAMTS-1, -4 and -5 mRNA expressions in SHSY-5Y cells. Comparison 
of ADAMTS-1, -4 and -5 mRNA expression in SHSY-5Y cells with RetA differentiation 
(10°M) compared to control (undifferentiated cells), the signal is normalised to the 
reference gene (RNAP-II). Results are expressed as mean ± SEM of three independent 
experiments (*P<0.05, Mann-Whitney test n=3).
1 0 0
Figure 3.6: ADAMTS-1, -4 and -5 mRNA expression in SHSY-5Y cells following 
cytokine treatment. ADAMTS-1, -4 and-5 mRNA expression in SHSY-5Y cells with 
and without RetA differentiation following 24 hours of treatment with IL-1 or TNF (1- 
100 ng/ml). The signal is normalised to the reference gene (RNAP-II) and relative to 
the untreated control sample. Results are expressed as mean ± SEM, n= 3 independent 
experiments.
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Figure 3.6 (continued): ADAM-17 and TIMP-3 mRNA expression in SHSY- 
5Y cells following cytokine treatment. D) ADAM-17 (+RetA and -RetA) and E) 
TIMP-3 (-RetA only) mRNA expression in SHSY-5Y cells following 24 hours 
of treatment with IL-1 or TNF (1-100 ng/ml). The signal is normalised to the 
reference gene (RNAP-II) and relative to the untreated control sample. (n=3 
independent experiments).
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3.3.5 Comparison of ADAMTS-1, -4, -5 and TIMP-3 mRNA 
Expression in Cytokine Treated SK-N-DZ Cells with RetA 
Differentiation
SK-N-DZ cells were used as another example of a neuroblastoma cell line, used as a 
neuronal model, to compare with the SHSY-5Y neuroblastoma cell line. The SK-N-DZ 
cells were characterised with neuronal marker NF L, differentiated with retinoic acid 
and treated with proinflamatory cytokines. RNA was extracted, cDNA was synthesised 
and used as a template for the qRT-PCR, as described in Chapter 2.
qRT-PCR analysis of relative expression levels (2 'ACt) demonstrated that the SK-N-DZ 
cell line constitutively expressed ADAMTS-1, -4, -5 mRNA levels with RetA 
differentiation with no detectable TIMP-3 expression (Figure 3.7). Representative 
amplification plots are shown in appendix II.
3.3.6 Effect of Pro-Inflammmatory Cytokines on ADAMTS-1, -4, -5 
and TIMP-3 mRNA expression levels (qRT-PCR) in Differentiated 
(+RetA) SK-N-DZ Cells
To detect the expression and modulation of ADAMTS-1, -4 and -5 in differentiated SK- 
N-DZ cells, they were treated with pro-inflammatory cytokines (IL-ip or TNF) as 
described in section 2.4. The analysis of relative gene expression data using qRT-PCR 
was performed using the 2 'AACt method (Livak and Schmittgen, 2001).
Figure 3.8 A shows a statistically significant increase (p<0.05) in ADAMTS-1 mRNA 
expression in differentiated SK-N-DZ cells with IL-1 P (10 ng/ml). Furthermore, 
ADAMTS-4 mRNA expression level were significantly increased with 10 ng/ml and 
100 ng/ml TNF treatment (Figure 3.8 B). However, ADAMTS-5 mRNA expression 
levels showed no statistically significant changes following either IL-1 or TNF 
treatment (Figure 3.8 C).
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Figure 3.7: ADAMTS-1, -4, -5 and TIMP-3 mRNA expression in SK-N-DZ cells 
differentiated with RetA. The signal is normalised to the reference gene (RNAP-II). There 
was no TIMP-3 expression and results are expressed as +/- standard error of the mean 
(SEM), for three independent experiments. A statistically significant difference was 
observed in the ADAMTS-1 mRNA expression compared to ADAMTS-4 and -5 (*P<0.05, 
Mann-Whitney test).
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Figure 3.8: ADAMTS-1, -4 and -5 mRNA expression in RetA differentiated SK-N-DZ cells 
following 24 hours of IL-1 or TNF treatment (0-100 ng/ml). The signal is normalised to the 
reference gene (RNAP-II) and relative to the untreated control sample. Results are expressed 
as +/- standard error of the mean (SEM), for three independent experiments. A) ADAMTS- 
1, B) ADAMTS-4 and C) ADAMTS-5 * P<0.05, **P<0.01, ** *<0.00 l(Kruksal-Wallis 
followed by Dunnet's post test).
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3.4 Discussion
3.4.1 ADAMTS-1,-4, -5 and TIMP-3 Expression in Neuroblastoma Cell 
lines
The objectives of these studies were to determine whether ADAMTS-1,-4, -5 and their 
endogenous inhibitor TIMP-3 are expressed in SHSY-5Y and SK-N-DZ neuroblastoma 
cell lines. Production of ADAMTSs and TIMP-3 by neuronal cells may be important in 
the pathogenesis of MS. Increased ADAMTS production by neurons may enable neurite 
outgrowth into regions of axonal damage or loss, via breakdown of CSPG rich ECM, to 
enable repair. The enzyme-inhibitor balance may be important in this process. These 
cell lines were used as a model for neuronal cells in this study. Previous studies have 
demonstrated that neuroblastoma cells can constitute a useful neuronal model system 
for in vitro study. They show one of the highest rates of induction to differentiation into 
more neuronal CNS cells of all cancer cells (Thiele, 1998).
The SHSY-5Y cell line has been widely used as a model of neurons since the early 
1980s as these cells possess many biochemical and functional properties of neurons. It 
shows neuronal marker enzyme activity (tyrosine and dopamine-P-hydroxylases), 
specific uptake of norepinephrine and expresses neurofilament proteins and nerve 
growth factor receptors. In addition, SHSY-5Y cells can proliferate in culture for long 
periods maintaining their phenotype, a requirement for the development of an in vitro 
cell model. SHSY-5Y cells have the potential to differentiate upon treatment with RetA 
leading to production of cells with neuronal morphology (Encinas et al., 2000). The cell 
lines are the nearest alternative to primary cells which would be difficult if not 
impossible to obtain from humans and of reduced relevance if obtained from animals.
In vitro studies with cytokine treatment such as IL-1 p and TNF, which are involved in
the pathogenesis of MS could induce ADAMTSs. Under basal conditions, the SHSY-
5Y and SK-N-DZ cells express ADAMTS-1, -4 and -5 mRNA. Previous studies in our
laboratory revealed that U373-MG, U87-MG, primary astrocytes and CHME3
microglial cells expressed ADAMTS-1, -4 and -5 (Cross et al., 2006a). Sasaki et al,
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(2001) reported that ADAMTS-1 is expressed in N1E-115 neuroblastoma cell line 
(Sasaki et al., 2001). This suggests that CNS cells may express ADAMTS-1, -4 and -5.
ADAMTS-1 is the predominant GEP of the ADAMTSs expressed by both SHSY-5Y 
and SK-N-DZ cells, whereas ADAMTS-5 mRNA is expressed at low levels in both cell 
lines. RetA is an active metabolite of vitamin A, involved in development and 
differentiation of the nervous system. The RetA has an essential role during 
development and maturation of the CNS, mainly in the generation of neurons by the 
increase of neurite outgrowth (axons and dendrites) (Clagett-Dame et al, 2005). 
Culturing SHSY-5Y cells in the presence of RetA demonstrated an impact on the 
morphology of the cells, which agrees with Encinas et al., (2000). Microscopic images 
of the cells in this study showed apparent differentiation with extension of cells to 
produce neurite-like outgrowths.
Differentiated SHSY-5Y cells (RetA) showed a statistically significant (p<0.05) 
increase in ADAMTS-1 expression when compared to cells cultured without RetA. The 
increase of ADAMTS-1 in differentiated cells could lead to the breakdown of CSPGs 
and allow the neurite outgrowth as CSPGs are normally inhibitory. There was no 
difference in mRNA expression for ADAMTS-4 and -5 in both treated and untreated 
cells with RetA. A study done by East et al (2007), showed an increase in ADAMTS-5 
mRNA in cartilage explants with RetA treatment for only three days, whereas in our 
study differentiated SHSY-5Y cells were cultured for 7 days and there were no 
differences in ADAMTS-5 mRNA expression levels. It may indicate differential 
ADAMTS -5 expression between different cell types.
ADAMTS expression could be regulated at different stages including, pre- 
transcriptional (e.g. cytokine modulation of expression) post-transcriptional (e.g. 
alternative splicing) and post-translational (e.g. prodomain or C-terminal cleavage) 
regulation. Stability of the ADAMTS expression levels in normal physiology avoids the 
alterations that could result in neurodegenerative diseases.
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There was no modulation of ADAMTS-1, -4 and -5 or ADAM-17 mRNA expression 
found in the SHSY-5Y neuroblastoma cell line with either IL-ip or TNF, at the 
concentrations used in this study, compared to controls. However, ADAMTS-1 mRNA 
expression in differentiated SK-N-DZ on treatment with IL-lp at the 10 ng/ml, showed 
a significant increase (~ 8 fold change). A higher concentration (100 ng/ml) seemed to 
be inhibitory. There is also a significant increase in ADAMTS-4 mRNA expression 
with TNF treatment (10, 100 ng/ml). However, ADAMTS-5 showed no statistically 
significant change after proinflammatory cytokine treatments. In a previous study in 
glial cells, a gradual increase in ADAMTS-4 mRNA and protein expression in response 
to TNF treatment was demonstrated. In the same study, IL-lp did not significantly alter 
expression of ADAMTS-4 mRNA and protein levels by astrocytes and only increased 
ADAMTS-4 mRNA expression at 1 ng/ml (Cross et ah, 2006a). TIMP-3 mRNA 
expression in SHSY-5Y cells indicated that there was no modulation on cytokine 
treatment and in the SK-N-DZ cell line there was no TIMP-3 expression. The 
differences in the expression and modulation of ADAMTSs in both neuronal cell lines 
used in this study could be due to differences in their selected phenotypes and cell 
populations. The SK-N-SH is the parent cell line for both SHSY-5Y and the SK-N-DZ 
contains cells with three different phenotypes: neuronal (N type), Schwannian (S type), 
and intermediary (I type). The SHSY-5Y cell line is a comparatively homogeneous 
neuroblast-like cell line (N type) (Joshi et al., 2006).
In this study there was no modulation of ADAM-17 mRNA expression levels with 
proinflammatory cytokines in both differentiated and undifferentiated SHSY-5Y cells. 
This in vitro investigation indicates that neuronal ADAM-17 may not play a role in the 
pathogenesis of MS. It has been previously demonstrated that there is upregulation of 
ADAM-17 in MS lesions and that endothelial cells; parenchymal astrocytes and 
activated macrophages or microglia are responsible for the expression of ADAM-17 
within MS brain tissue (Plumb et a l , 2006).
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Chapter 4 
Expression of ADAMTS-1 Protein
111
4.1 Introduction
The data in chapter 3 indicates that ADAMTS-1 mRNA was the most highly expressed, 
compared with ADAMTS-4 and -5 by both the SHSY-5Y and SK-N-DZ neuroblastoma 
cells. Furthermore, ADAMTS-1 has been previously observed to be expressed in the 
N1E-115 neuroblastoma cell line (Sasaki et al., 2001). ADAMTS-1 gene was first 
identified as inflammation and cancer cachexia-related (Kuno et al., 1997). It appears to 
be necessary for normal growth, fertility, and organ morphology and function (Shindo 
et al., 2000). Kuno et al, (1997) indicated that ADAMTS-1 gene expression is induced 
in the kidney and heart of mice treated with lipopolysaccharides. Moreover, ADAMTS- 
1 mRNA could be induced by stimulating colon 26 cells, an adenocarcinoma cell line, 
with an inflammatory cytokine, interleukin-1 in vitro, suggesting a possible role of 
ADAMTS-1 in various inflammatory processes (Kuno et al., 1997).
Cross et al (2006) demonstrated that ADAMTS-1, -4 and -5 are constitutively expressed 
in normal and EAE spinal cord and showed changes in expression of mRNA and 
protein levels during different stages of EAE. ADAMTS-1 had the lowest level of 
expression of the ADAMTSs, although it was the only ADAMTS with increased 
mRNA levels in animals with EAE (pre-disease) compared to normal controls (Cross et 
al., 2006b). Sasaki et al (2001) found that ADAMTS-1 was expressed at very low levels 
by rat hypoglossal motor neurons but following nerve injury, mRNA levels were rapidly 
increased (Sasaki et al., 2001).
Therefore, a study was performed to analyse ADAMTS-1 protein levels, by western 
blotting, in SHSY-5Y cells. In order to study the expression of ADAMTS-1 at the 
protein level, three commercially available antibodies were tested from Abeam 
(ab391940), Triple Point Biologies (RP1-ADAMTS 1) and Santa Cruz Biotechnology 
(sc-31080).
The aim of the study was to optimise an ADAMTS-1 antibody (or antibodies) for the 
detection of ADAMTS-1 by western blotting and verify its specificity. This antibody 
could then be used in further experiments.
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This aim was achieved by the following objectives.
4.1.1 Objectives
• To test the specificity of ADAMTS-1 antibody by the pre-incubation with 
immunising blocking peptide.
• To knockdown ADAMTS-1 in SHSY-5Y cells using an siRNA method and 
detect any reduction of ADAMTS-1 at mRNA (qRT-PCR) and protein (western 
blotting) levels.
4.2. Results
4.2.1 Optimisation of Abeam and Triple Point Biologies Antibodies to 
Detect ADAMTS-1 Protein by Western Blotting
Western blot optimisation is an important procedure to verify the immuno-detection of 
target protein and to eliminate non specific bands. Protein samples were extracted from 
SHSY-5Y cells (section 2.6.3) and their protein levels determined as previously 
described in section 2.8. The western blotting protocol used was as described in sections
2.10.2. and 2.10.2.1. Bands of approximately 51 kDa and 87 kDa were obtained with 
the Abeam and Triple Point Biologies ADAMTS-1 antibodies respectively (Figure 4.1 
A and B). The ADAMTS-1 87 kDa band could represent the full length active form and 
the 51 kDa band a product of C-terminal proteolytic processing (Cross et al., 2006a, 
Haddock et al., 2006). However, with both of these antibodies the zymogen, with a 
molecular weight of 105 (according to the manufacturer’s information) was not present. 
The immunogen for both of these antibodies is a synthetic peptide based on the 
carboxyl end of the human ADAMTS-1 that recognizes the last 28 amino acids of the 
protein. Anti-P actin was detected by P actin immunoblotting (42 kDa) as a reference 
protein (Figure 4.1 C). The Abeam and Triple Point Biologies ADAMTS-1 antibodies 
gave results which were not reproducible.
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ADAMTS-1 P actin
Figure 4.1: ADAMTS-1 protein optimisation by western blotting in SHSY-5Y 
cells. (A) Abeam (1:100) in TBST, (B) Triple Point Biologies (1:500) in TBST, (C) 
anti- (3 actin (1:1,000) in 5% TBST. Lane: 1, 3, 5 -  molecular weight markers, Lane: 
2, 4, 6 - protein samples.
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4.2.2 Optimisation of Santa Cruz Biotechnology Antibody to Detect 
ADAMTS-1 Protein by Western Blotting in Human Neuroblastoma 
Cell Lines
Optimisation of Santa Cruz Biotechnology antibody to detect ADAMTS-1 protein by 
Western Blotting in human neuroblastoma cell lines was performed as described in 
section 2.10.2.2. The antibody showed a band of ~ 37 kDa for ADAMTS-1 which may 
represent a degraded or processed form of ADAMTS-1. ADAMTS-1 zymogen (110 
kDa) was not present or the active mature form (85 kDa) which are detectable with this 
antibody, according to manufacturers information (Figure 4.2 A). Recombinant human 
ADAMTS-1 (rhADAMTS-1) was used as positive control. Figure 4.2 B shows an 
approximately 63 kDa molecular band which is around the predicted molecular mass of 
rhADAMTS-1 according to the manufacturer’s instructions.
4.2.3 Determination of ADAMTS-1 Santa Cruz Biotechnology 
Antibody Specificity
The Santa Cruz Biotechnology antibody was tested for its specificity because it was the 
only antibody producing reproducible results in this study and a blocking peptide was 
available.
4.2.3.1 ADAMTS-1 Santa Cruz Biotechnology Antibody and Blocking 
Peptide
Peptide blocking of the Santa Cruz ADAMTS-1 antibody was performed according to 
the manufacturer’s instructions using its commercially available peptide. This enabled 
determination of the ADAMTS-1 specific band. The western blotting method was 
performed as described in section 2.10.2.2. Samples were run from SHSY-5Y protein 
extracts. Again the antibody showed a band of ~ 37 kDa for ADAMTS-1 (Figure 4.3
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A). Also demonstrated was almost a complete removal of this band following 
incubation of the primary antibody (0.4 pg/ml) with 2 pg/ml of ADAMTS-1 
immunising peptide for 2 hours at room temperature (Figure 4.3 B).
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A ADAMTS-1 rhADAMTS-1
Figure 4.2: Detection of ADAMTS-1 by western blotting. (A) ADAMTS-1 detected in 
SIISY-5Y and SK-N-DZ cells using Santa Cruz Biotechnology antibody (1:500) in 
SHSY-5Y (lane 2) and SK-N-DZ (lane 3) cells showed ~ 37 kDa ADAMTS-1 bands. 
(B) Shows that ADAMTS-1 Santa Cruz Biotechnology antibody with rhADAMTS-1 
protein detects a ~ 63 kDa band (lane 4), which is around the predicted molecular 
weight of the protein according the manufacturer’s information, 66 kDa (R&D systems) 
under reducing conditions. Lane 1 indicates the molecular weight markers in both blots 
A and B.
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SHSY-5Y Protein for ADAMTS-1 and Blocking Peptide
A) ADAMTS-1
kDa 1 2
B) Peptide Blocking
Figure 4.3: Western blot analysis of ADAMTS-1 antibody specificity using blocking 
peptides (Santa Cruz Biotechnology). A) The antibody demonstrated a reactive band ~ 37 
kDa (lane 2). Blocking antibody by pre-incubation with the immunising peptide lowered 
the intensity of the 37 kDa immunoreactive band (lane 3). Lane 1: molecular weight 
markers (A and B) (n=l).
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4.2.4 ADAMTS-1 siRNA Knockdown in the SHSY-5Y Neuroblastoma 
Cell Line
An ADAMTS-1 siRNA knockdown experiment was performed, as described in section
2.11.2, to confirm ADAMTS-1 mRNA expression in SHSY-5Y cells by qRT-PCR and 
to verify the specificity of the Santa Cruz Biotechnology ADAMTS-1 antibody.
4.2.4.1 Optimisation of Transfection
Optimisation of transfection was previously described in sections 2.11.3.1 and 2.11.3.2. 
Slides of transfected cells were examined under the microscope at 400 x magnification 
and the assessment of nuclear fluorescence was by counting the cells with a bright, red 
nuclear fluorescence, a signal of transfection success. The number of fluorescent cells 
out of 100 cells was counted. This allows easy optimisation of conditions that resulted 
in efficient siRNA delivery into cells because the siGLO transfection indicators are 
specially designed for nuclear localisation. Figure 4.4 shows the transfection reagents 1, 
2, 3 and 4 efficiencies of optimisation. The most efficient transfection reagent for the 
SHSY-5Y cells was the transfect 1 reagent as it showed the highest rate of successful 
transfection (78.5%) red nuclear signal or siGLO uptake positive transfected cells, 
compared to the transfection reagents 2, 3 and 4 (Table 4.1).
4.2.4.2 ADAMTS-1 siRNA Knockdown in the SHSY-5Y 
Neuroblastoma Cell Line Determined at the mRNA (qRT-PCR) and 
Protein (Western Blotting) Levels
The ADAMTS-1 in SHSY-5Y cells was knocked down using the siRNA method which 
was performed as described in section 2.11.2. In section 3.3.3 ADAMTS-1 showed the 
most abundant mRNA expression levels and a significant up-regulation with RetA 
differentiation in SHSY-5Y cells. To confirm the ADAMTS-1 mRNA expression in 
SHSY-5Y cells by qRT-PCR, the SHSY-5Y cells were transfected for 24 hour with 
siRNA for ADAMTS-1 and GAPDH as a positive control. The mRNA levels for
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ADAMTS-1 and GAPDH were determined by qRT-PCR as previously described in 
chapter 2. Results showed that ADAMTS-1 was knocked down ~ 66% and GAPDH 
was by -98% at the mRNA level compared to the untreated sample (no treatment) 
(Figure 4.5).
The SHSY-5Y cells were transfected with ADAMTS-1 siRNA for 96 hour to determine 
the specificity of the Santa Cruz Biotechnology antibody. At the protein level, by 
densitometric analysis, ADAMTS-1 showed ~ 67% knockdown of the 37 kDa band 
(Figure 4.7 A). Western blotting was performed with detection of GAPDH using anti- 
GAPDH antibody as a positive control. All samples constitutively expressed GAPDH 
protein (40 kDa) with a clear reduction in the intensity of the GAPDH knockdown 
sample, compared to the untreated (cells without transfection medium) and non target 
samples (scrambled siRNA), which were used as negative controls. Western blotting 
was performed for P actin to verify equal loading levels (15 pg/ lane) (Figure 4.6 A). 
Non specific immune-reactivity was determined by omission of the primary antibody to 
detect any non specific reaction of the secondary antibody and as a negative control 
(Figure 4.6 B). Densitometric semi-quantitation of the bands as integrated optical 
density (IOD) was performed as previously described (Cross et al., 2006) (Figure 4.7).
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igure 4.4: Transfection reagent efficiencies optimisation. Red nuclear staining (white arrows) is indicative of positive siGLO red uptake: TransFECT 1 (, 
ransFECT 2 (B), TransFECT 3 (C) and TransFECT 4 (D). The lower plates indicate the nuclei staining with Hoechst 33342.
Table 4.1: Transfection reagents efficiencies in the siRNA experiment
in SHSY-5Y (mean of two determinations).
DharmaFECT 1 78.5
DharmaFECT 2 33.0 ;
DharmaFECT 3 45.0
DharmaFECT 4 25.0
1 2 2
U ntrea ted ADAMTS-1 GAPDH
Figure 4.5: qRT-PCR of the ADAMTS-1 and GAPDH after siRNA knockdown 
in SHSY-5Y cells, GAPDH siRNA was used as a positive control. GAPDH 
showed a 98% reduction in the mRNA and ADAMTS-1 66% knockdown in 
mRNA level compared to untreated SHSY-5Y cells (no treatment) (n=l).
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SHSY-5Y Protein for ADAMTS-1 siRNA
Knockdown
A) ADAMTS-1 and GAPDH B) Negative Control 
Immunoprobe
M U N A  M U N A
kDa
3 7 ------ ►
GAPDH 4 0 ----- ►
P actin 42 -------► w
Figure 4.6: Western blotting of ADAMTS-1 and GAPDH after 96 hour siRNA transfection 
in SHSY-5Y cells (A) shows ADAMTS-1 detected by Santa Cruz Biotechnology antibody 
(1:500 in TBST), GAPDH as positive control and (3-actin to verify the equal loading of 
protein samples (15pig/ lane). The ADAMTS-1 band at ~37 kDa was reduced in the 
ADAMTS-1 siRNA sample (A) compared to untreated (U) and non target (N) siRNA protein 
samples. The GAPDH antibody showed a band at the predicted molecular size o f GAPDH 
(40 kDa) in all samples (GAPDH siRNA (G), U and N, which was reduced in the GAPDH 
siRNA (G) sample compared to the untreated and non target samples, p actin antibody 
showed comparable bands (42 kDa) P actin protein in all samples. (B) Omitting the primary 
antibody as a negative control (n=2).
(A)
Untreated ADAMTS-1 siRNA
Oo
8x10
6x10
4x10
2x10
2x10b
18x10 _
16x10
14x10
12x10
10x10
Untreated Non target GAPDH siRNA
Figure 4.7: IOD of the ADAMTS-1 and GAPDH in SHSY-5Y cells. (A) Shows that 
ADAMTS-1 protein siRNA sample was approximately one third compared to the non 
target sample and approximately half to untreated SHSY-5Y cells after siRNA 
knockdown. (B) GAPDH (positive control) was reduced after siRNA knockdown 
compared to untreated and non target sample. Y-axis represents the densitometric 
results (IOD).
125
4.3 Discussion
4.3.1 The Optimisation of Antibodies and the Detection of ADAMTS-1
In chapter 3 using qRT-PCR, human neuroblastoma cell lines in vitro were 
demonstrated to constitutively express ADAMTS-1, -4 and -5 mRNA. ADAMTS-1 
mRNA appeared to show the highest expression levels, ADAMTS-4 and ADAMTS-5 
mRNA were lower. There is little known about neuronal ADAMTS expression. The 
SHSY-5Y cells, used as a neuronal cell model in this study, showed on siRNA 
knockdown ~ 66% reduction of ADAMTS-1 mRNA, which is consistent with previous 
results in chapter 3 that SHSY-5Y cells express ADAMTS-1 mRNA. Therefore, the 
main objective of this study was to detect ADAMTS-1 protein in the SHSY-5Y 
neuroblastoma cell line and determine the specificity of an ADAMTS-1 antibody to 
verify it for further uses. Initially, ADAMTS-1 immunoprobed blots with antibodies 
from three different sources showed immunoreactive bands with dissimilar sizes. The 
Abeam ADAMTS-1 antibody showed ~ 51 kDa band, which could represent a form 
produced by proteolytic cleavage similar to one previously described by Cross et al. 
(2006). However, the difference was that the previous study by Cross et al. (2006) used 
a polyclonal carboxyterminal Santa Cruz Biotechnology ADAMTS-1 antibody for the 
detection of the protein in primary astrocytes (Cross et al., 2006a). Also, a 50 kDa 
ADAMTS-1 form has been demonstrated previously by Haddock et al., 2006 in human 
brain tissue by using a Triple Point Biologies antibody.
The other antibody used in this study (Triple Point Biologies) has shown a ~87 kDa
band which could represent the full length active form. Abeam and Triple Point
Biologies antibodies, being directed against the C-terminus, can recognise processed
forms of ADAMTSs (Haddock et al., 2006). The Abeam and Triple Point Biologies
antibodies were unsuitable to be used in further studies because they produced
unreproducible results (repeated 5 times) and did not have available blocking peptides
of the immunizing peptides to test specificity. Therefore, the antibody that was used
further in this study was from the Santa Cruz Biotechnology. Using the Santa Cruz
Biotechnology antibody, western blots showed a ~ 37 kDa ADAMTS-1 band. It is
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unknown whether these three antibodies to ADAMTS-1 from Abeam, Triple Point 
Biologies and Santa Cruz Biotechnology recognised similar or overlapping epitopes 
though all were directed to the C- terminus of ADAMTS-1. No information was 
available from the suppliers regarding exact binding regions of the antibodies in terms 
of epitopes or domains. A previous study by Miguel et al (2005), using a Santa Cruz 
Biotechnology antibody to ADAMTS-1 showed 37 kDa and 50 kDa ADAMTS-1 bands. 
Interestingly, both bands were fivefold over-expressed in neurodegenerative diseases 
(Miguel et al., 2005). Also another company (Sigma-Aldrich, UK) reports that 
ADAMTS-1 C-terminal antibody (A 4476) detects bands at 34 kDa and 50 kDa, which 
represent ADAMTS-1 fragments, helping to confirm that ADAMTS-1 could be present 
as a fragment at -37 kDa.
The 37 kDa ADAMTS-1 protein band was reduced on ADAMTS-1 siRNA knockdown 
and blocked on pre-absorption of the antibody with the immunizing peptide. The 37 
kDa band could represent a form produced by C-terminal proteolytic processing or may 
represent protein polymorphisms or splicing variants (Miguel et al., 2005). The peptide 
blocking and the siRNA knockdown experiments were able to confirm the specificity of 
the antibody to ADAMTS-1. According to the data in this chapter the most suitable 
antibody for ADAMTS-1 protein detection is from Santa Cruz Biotechnology and could 
be used in further investigations because it the only antibody that produced reproducible 
results and had an available blocking peptide.
These data suggest that neuronal cells may express ADAMTS-1 at both mRNA and 
protein levels. Data obtained from a previous study (Miguel et al., 2005) and from this 
one showing that the neuronal model produces a -  37 kDa ADAMTS-1 band.
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Chapter 5
Versican (V0/V2) Neoepitopes in 
Normal and MS Human Brain
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5.1 Introduction
Key components of CNS ECM are proteoglycans of the lectican family, also known as 
or hyalectans as they bind to hyaluronan (Figure 1.3). They include CSPGs aggrecan, 
brevican, neurocan, phosphacan, appican and versican. Their role is to provide 
structural support as well as influencing cell behaviour through a wide variety of 
physiological brain processes e.g. development, repair, proliferation, cell signalling and 
interaction with other ECM components (Bellail et al., 2004).
There are four versican isoforms (VO, VI, V2 and V3) which result from alternative 
splicing. Versican VO contains the two GAG-attachment domains, GAGa and P, 
whereas versican VI and V2 contain only GAG-p and GAG-a respectively. Versican 
V3, the smallest lectican, lacks both of these alternatively spliced elements and 
consequently carries no GAGs as shown in Figure 1.4. The V2 isoform is largely 
present in the CNS. Its cellular origin in the CNS is most likely oligodendrocytes 
(Schmalfeldt et al., 2000).
In healthy adult tissue, protein synthesis, modification, and degradation is a continuous 
feature of the physiological system (controlled and balanced) in the body. In many 
pathological conditions, this stable equilibrium is unbalanced leading to an increased 
rate of protein breakdown. Modulations in synthesis and degradation of the CSPGs may 
contribute to pathological processes. In damaged CNS, accumulated CSPGs may inhibit 
neurite outgrowth and prevent axonal regeneration (Asher et al., 2000). CSPG could 
form barriers to the regenerating nerve fibres in the central and peripheral nervous 
system (Bronner-Fraser, 1994, Landolt et al., 1995, Fitch and Silver, 1997). CSPGs 
neurocan (Friedlander et al., 1994), brevican (Yamada et al., 1997) and phosphacan 
(Milev et al., 1994) demonstrated in vitro neurite outgrowth inhibiting activities. 
Conversely, the removal of chondroitin sulphate promotes neuronal regeneration 
(Bradbury et al., 2002, Moon et al., 2001).
It has also been shown that in vitro, the V2 splice variant inhibits axonal outgrowth and 
migration (Fidler et al., 1999, Niederost et al., 1999, Schmalfeldt et al., 2000). This
inhibiting activity of versican can be reduced, but not eliminated, by removing 
chondroitin sulfate chains, indicating that multiple domains of versican are involved in 
controlling axon regeneration.
ADAMTSs are proteins synthesised on the ER. They undergo N-terminal processing, 
resulting in the removal of the signal peptide in the ER and a subsequent removal of the 
prodomain, often in the trans Golgi. The prodomain is generally considered to preserve 
enzyme latency and is also important for correct protein folding and secretion (Cao et 
al., 2000). With the exception of ADAMTS-10 and ADAMTS-12, all currently known 
ADAMTSs contain a proprotein convertase cleavage site containing furin recognition 
sequences. Pro-protein processing has been demonstrated for ADAMTS-1 (Rodriguez- 
Manzaneque et al., 2000), ADAMTS-7 (Somerville et al., 2004), ADAMTS-9 and 
ADAMTS-12 (Cal et al., 2001). It has also been observed that intracellularly, pro- 
ADAMTS-4 co-localises with furin (Wang et al., 2004). Additional proteolytic 
processing or cleavage occurs within the ancillary C-terminal domains of the 
ADAMTSs. This C-terminal processing affects both substrate specificity and 
localisation of these enzymes (Kashiwagi et al., 2004).
ADAMTS-1, -4 and -5 are known for their aggrecanase activity. Also it is known that 
ADAMTS-1 and -4 can cleave versican, and ADAMTS-4 can cleave brevican. 
Therefore, these enzymes could play a significant role in brain ECM turnover. 
ADAMTSs are endopeptidases, cleaving substrate proteins into smaller polypeptide 
fragments. The result of protein cleavage is the generation of new N- and C-termini. 
These termini form neoepitopes as they are antigenically different from the sequence of 
the intact protein. The cleavage of the core protein of CSPGs generates neoepitopes. 
Antibodies that recognise the cleavage specific sites, neoepitopes, generated by 
proteolysis of the aggrecan and versican by glutamyl endopeptidases such as 
ADAMTS-1, -4 and -5, neoepitope antibodies, are now commercially available. They 
are important products in determining the enzymes responsible for tissue turnover and 
breakdown (Mort and Buttle, 1999).
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Sandy et al, 2001 demonstrated that mature human aorta contains a 70-kDa versican 
fragment, which reacts with a neoepitope antibody to the C-terminal peptide sequence 
DPEAAE. This protein could correspond to the G1 domain of versican VI (Gl- 
DPEAAE441), which has been generated in vivo by proteolytic cleavage by one or more 
members of the ADAMTSs at the Glu441-Ala442 bond, within the sequence 
DPEAAE441-A442RRGQ (Sandy et al., 2001). The V2 isoform, which is a 
predominant brain proteoglycan, is composed of the G1 domain, GAG-a domain, and 
the G3 domain. Westling et al., 2004 demonstrated that versican V2 protein core is 
cleaved by ADAMTS-4 at the Glu405-Gln406 bond in the GAG-cc domain which 
generates a 64 kDa glial hyaluronate binding protein (GHAP) fragment (Westling et al., 
2004). The same study suggests that it is possible that a small amount of this neoepitope 
is generated in the human brain by cleavage of V0 versican at the same cleavage site 
(Glu405-Gln406). V0 versican also contains the GAG-a domain, so this would also 
generate the 64 kDa fragment. An antibody produced using the same neoepitope peptide 
by Westling et al (2004) (JSCNIV) was used in this study to detect neoepitopes 
produced by ADAMTS cleavage of versican.
5.1.1 Versican (V0/V2) Neoepitopes in Human Brain Tissues
Versican is a proteoglycan known to be expressed during embryonic development 
(Landolt et al., 1995, Stigson et al., 1997, Perissinotto et al., 2000) and found during 
adult life in most of the connective and nervous tissues (Yamagata et al., 2003, 
Schmalfeldt et al., 1998, Asher et al., 2002). It was isolated and characterized from 
bovine aorta and chick embryo fibroblasts (Oegema et al., 1979, Kimata et al., 1986, 
Shinomura et al., 1990) and cloned and sequenced in cultured chick and human cells 
(Shinomura et al., 1993). Several studies recognized that there are three isoforms, VI, 
V2, and V3 which could be generated by alternative splicing from V0 transcript (Dours- 
Zimmermann and Zimmermann, 1994, Zako et al., 1995).
In normal adults, versican appears to be largely in vascular constitutions. Versican is 
abundantly expressed by vascular smooth muscle cells (Lemire et al., 1999, Lee et al.,
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2001). Furthermore, previous studies on normal and diseased blood vessels in vivo have 
suggested that versican could represent a major constitutive ECM component of the 
adult endothelium (Riessen et al., 1994, Bode-Lesniewska et al., 1996). Cattaruzza et al
(2002) demonstrated that versican isoforms can be expressed by the human brain as 
shown in Table 5.1. They also showed expression patterns of V0-V2 splice variants in 
different human organs (Cattaruzza et al., 2002).
Table 5.1: Transcriptional versican isoforms in normal human tissues
T issu e /o rg a n
VO
V ersica n  iso  form  
VI V2 V3
1. S p lee n + + — 4-
2 , S to m a ch ■f + - +
3 . M am m ary  g la n d a. 4- \ I
4 . L iv er •* + -
5 . B rain •t- 4- 4
6 . H eart + •l 1 •I
1. T estis .. ••
8 , T h y m u s - - i —
9 . P la cen ta -T •!- — 4
10. S a liv a ry  g land 4-
1 1 . K id n ey -I * 4
"This was originally published in Journal of Biological Chemistry. Cattaruzza S, 
Schiappacassi M, Ljungberg-Rose A Spessotto P, Perissinotto P, Morgelin M, 
Mucignat M T, Colombatti A, Perris R. Distribution of PG-M/Versican Variants in 
Human Tissues and de Novo Expression of Isoform V3 upon Endothelial Cell 
Activation, Migration, and Neoangiogenesis in Vitro. J. Biol. Chem. 2002; 277: 
47626-47635. © the American Society for Biochemistry and Molecular Biology."
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The aim of this work was to determine the versican cleavage by ADAMTS GEP activity 
in normal and MS CNS tissue as an index of enzyme activity and their role in MS 
pathogenesis. This was done by detecting neoepitopes of versican V2 using an antibody 
specific for the new C-terminal at the sequence NIVSFE405 which is a product of 
cleavage of versican VO or V2 at the Glu405-Gln406 bond generated on ADAMTS 
cleavage as shown in Figure 5.1 (Westling et al., 2004). This aim was achieved by the 
following objectives.
5.1.1 Objectives
• To study CSPG breakdown by ADAMTSs in post-mortem tissue via the 
production of versican (V0/V2) neoepitopes of ECM components in brain tissue. 
These neoepitopes were detected using a commercial antibody (Perbio Science, 
UK Ltd) by both immunohistochemistry and western blotting.
• To determine whether the expression levels of the versican (V0/V2) neoepitopes 
showed any differences in MS post mortem tissues compared to normal control 
brain tissue.
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Figure 5.1: A schematic diagram of the versican (V0/V2) core glycoprotein species. 
There are a number of possible enzyme cleavage sites of versican (V0/V2) producing 
species detected in the human brain. The versican (V0/V2) neoepitopes antibody used 
in this study detects a C-terminus neoepitope at 64 kDa, produced by ADAMTS 
cleavage, by western blotting (species 7) (Adapted from Westling et al., 2004).
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5.2 Results
As previously described (section 2.12.1), tissues were obtained from the UK Multiple 
Sclerosis Tissue Bank, Division of Neuroscience and Mental Health, Imperial College 
London. Tissue blocks were from people with MS, including blocks containing NAWM 
and normal controls, people with no history of MS. White matter blocks containing MS 
lesions were from 3 females and 2 males with a mean age 55.2 years (range 37-71 yr). 
NAWM blocks were from 6 females and 1 male with a mean age of 62.6 years (range 
46-86 yr). The tissue had a mean time from death to freezing of 17.9 h (range 5-33 h). 
11 of the people with MS were diagnosed with secondary progressive MS and 1 with 
primary progressive MS. Five normal control brain tissue blocks were obtained from 
people with no history of MS, 3 female and 2 males with a mean age 61.2 (range 35-78 
yr) see Table 5.2. Patient's details used in this study are summarised in Table 5.3. Tissue 
blocks were re-characterised in house using H&E and ORO as previously described in 
section 2.13.1.
5.2.1 Re-characterisation of the Human Brain Tissues (Blocks)
Ten-micrometre thick cryosections were cut, mounted on polysine-coated glass slides 
and stored at -80°C until required. The H&E or the ORO screening was performed on 
the tissue sections for lesion grading using a four point scale (negative - ,  +, ++, +++) as 
previously described in section 2.13.1 (Sanders et al., 1993, Plumb et al., 2002, Kirk et 
al., 2003). This was performed to re-characterise the tissue used in this study. Tissue 
blocks with no inflammatory or ORO positive cells were scored negative. H&E, grade + 
contained a small number of cells in the perivascular region, grade ++ moderate cellular 
infiltrate and grade +++ had an abundant number of cells in the perivascular region. 
Figure 5.2 A shows an MS plaque x40, B shows +++ H&E staining for an MS lesion 
with perivascular cellular infiltrate. ORO, was scored + for a few scattered ORO 
positive cells, ++ frequent ORO positive cells in a MS lesion and grade +++ had an 
abundant number of ORO positive cells. Figure 5.2 E shows an ORO positive (grade 
+++) (demyelination) lesion in an MS patient x40. At higher magnification x200 the
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presence of myelin breakdown in the activated lipid-laden macrophages with ORO 
positive (red) is evident (Figure 5.2 F). Figure 5.2 for normal control brain showed a 
negative score (C and G) as did NAWM (D and H) for H&E and ORO. ORO positive 
and perivascular cellular infiltrates were classified as lesional MS; those with ORO 
negative were classified as chronic plaques. A few of the NAWM blocks that were 
obtained from the UK Multiple Sclerosis Tissue Bank, when they were re-characterised, 
showed inflammation. The microscope settings were kept consistent when comparing 
images.
Table 5.2: Case Material
55.2 yr ±12.7 
(37-71 yr) 3 :2 19.6 ±5.0 10
62.6 yr ±14.2 
(46-86 yr) 6: 1 12.6 ±8.3 12
61.2 yr ±16.1 
(35-78 yr) 3 :2 23.8 ±8.9 9
DAI, death autopsy interval; NC, normal control; NAWM, normal appearing white matter.
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T a b l e  5.3: Summary of case details in this study
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Immunofluorescence for versican neoepitopes was performed as previously described in 
section 2.14.1. Sections were graded on a 4-point scale as previously described 
(Haddock et al., 2006, Plumb et al., 2006). Figure 5.3 shows negative controls A, 
omission of primary antibody and B, IgG class to detect the non specific background. 
Both showed red fluorescence background nuclear-like staining in the tissue but no 
staining resembled staining of the ECM with versican (V0/V2) neoepitopes in the 
tissues. Sections that showed no versican (V0/V2) neoepitopes staining 
(immunoreactivity) were graded -, those which showed versican (V0/V2) neoepitopes 
only associated with the blood vessels were graded +, sections with blood vessel and 
ECM staining of versican (V0/V2) neoepitopes expression were graded ++ and those 
with an abundance of ECM staining were graded +++. Figure 5.4 summarises results 
from the 31 human brain tissues (blocks) studied of which 10 were MS lesion blocks, 
12 were NAWM and 9 were normal control blocks. 9 of the MS blocks showed ++/+++ 
immunoreactivity out of 10. All normal control blocks were within - or + grading. 
NAWM showed variable immunoreactivity results (Figure 5.4). Within a lesional MS 
tissue, (MS58 P1D3), versican (V0/V2) neoepitope expression was increased (+++) 
with an abundance of ECM staining (Figure 5.3 C). In comparison, a normal control 
brain shows the absence of the versican (V0/V2) neoepitope staining in the ECM 
(Figure 5.3 D). As shown in Figure 5.5, in control tissues (C025 P1B2 (B) and C025 
P1C2 (C)), shows versican (V0/V2) neoepitopes localised to blood vessels (determined 
using vWF as a marker for the blood vessels (Figure 5.5 A)), but were absent in the 
ECM (Figure 5.5 B and C).
Versican (V0/V2) immunostaining was heterogeneous in its distribution between 
sections. Four blocks out of nine of the normal control brain tissues demonstrated low 
(Grade +) versican (V0/V2) neoepitope expression whilst the remaining showed 
undetectable levels of expression and none of the normal control samples showed a 
++/+++ grading. Higher expression levels of the versican (V0/V2) neoepitopes 
immunoreactivity were observed in lesional MS tissue (grading ++/+++) showing nine 
MS blocks out of ten, which is higher compared to normal control brain tissues and 
could indicate more activity of ADAMTSs in MS compared to normal control brain 
tissues (Figure 5.4).
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Figure 5.4: Versican (V0/V2) neoepitopes scoring in human brain tissue. The 
majority of MS cases were scored ++/+++, normal control brain tissue blocks 
showed only -  or + scoring and NAWM showed variable scoring results -  to ++.
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5.2.3 Human Brain Tissues Classification According to HLA-DR 
Immunostaining
HLA-DR is a transmembrane human MHC class II family member and consists of a 34 
kDa (alpha) and 28 kDa (beta) subunits. It is expressed primarily on cells on which it 
presents antigenic peptides for recognition by the T cell receptor on CD4+ T cells. 
Undetectable or low expression levels of MHC class II antigen expression in normal 
brain has been previously observed; in response to inflammatory stimuli in MS, 
microglia become activated and up regulate MHC class II antigen expression (Hayes et 
al., 1987). A number of lesional MS cases that had shown positive versican (V0/V2) 
staining were further characterised to determine the presence of active lesions by 
detection of HLA-DR using an HLA-DR mouse monoclonal antibody (Table 5.4). 
Immunohistochemistry was performed as described in section 2.14.2. The HLA-DR 
antibody optimal concentration used in this study is shown in Table 2.5 and was 
according to the manufacturer's recommendations. An isotype control (IgG2b) was used 
as a negative control, replacing the primary antibody to detect the non specific 
background staining. Non-specific staining could result from the binding of the primary 
antibody to the Fc-receptors on cells.
Cellular activation (HLA-DR) was graded using a four-point scale (negative, + ,  + + , 
+++ ) as previously described (Sanders et al, 1993; van der Valk et al, 2000; Plumb et 
al, 2002; Kirk J et al, 2003), according to the abundance of HLA-DR positive cells and 
the intensity of the staining. Figure 5.6 A shows a negative control when replacing 
HLA-DR antibody with its isotype control (IgG2b), showing no reactivity with the 
tissue. Figure 5.7 A and B show images of an active MS lesion (MS58 P1C3 and MS80 
P1A4 respectively) with HLA-DR staining which is compared to a normal control brain 
tissue (C025 P1B2) where expression levels of HLA-DR were undetectable (Figure 5.7 
C).
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5.2.3.1 Expression of HLA-DR and Versican (V0/V2) Neoepitopes in 
Human Brain Tissues
Immunohistochemical examination of HLA-DR and versican (V0/V2) neoepitopes was 
carried out on serial sections from a tissue block as previously described in section 2.14. 
Figure 5.8 A) shows HLA-DR staining in a lesional MS section with corresponding 
DAPI staining of cell nuclei (Figure 5.8 D).
An increase in versican (V0/V2) neoepitopes expression was found associated with an 
increase in HLA-DR in MS (Figure 5.8 B and E). Normal control brain tissue showed 
low expression for HLA-DR (Figure 5.8 C and F).
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Figure 5.6: Negative controls. Isotype control (IC) IgG2b used instead of primary antibody 
anti HLA-DR at the same concentration (A), isotype control (IgGl) to detect the non specific 
binding of the anti-vWF primary antibody (B). Lower plates show nuclei counterstained with 
DAPI in blue.
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5.2.4 vWF and Versican (V0/V2) Neoepitopes in Human Brain Tissues
The antibody used in this study detects both VO and V2 splice variant neoepitopes. 
These splice variants could be expressed by endothelial blood vessels as reported by 
(Cattaruzza et al., 2002). Both VO and V2 have an a-GAG region in their core protein, 
which is cleaved by ADAMTSs. The new C-terminal produced on cleavage is 
recognised by this commercial antibody. Neoepitope expression could therefore also be 
associated with blood vessels. vWF is a marker for endothelial cells in blood vessels.
Single immunostaining was performed as previously described in section 2.14.3 using 
the mouse monclonal anti-vWF antibody at a 1:25 dilution, according to the 
manufacturer's recommendation. Immunostaining of the vWF marker was initially 
optimised in normal control brain tissue as shown in Figure 5.5 (A) and compared to 
control brain tissues stained with versican (V0/V2) neoepitopes (Figure 5.5 B and C). In 
addition, dual staining for vWF marker and versican (V0/V2) neoepitopes was 
performed (section 2.14.3) to investigate the localisation of the versican (V0/V2) 
neoepitopes with blood vessels and to investigate whether their expression is within the 
perivascular areas in MS tissue. Figure 5.9 shows co-localisation of versican (V0/V2) 
neoepitope with a blood vessel. It also shows positive staining of the versican (V0/V2) 
neoepitopes in the ECM.
Figure 5.9 continued (E and H) also shows representative images of blood vessels with 
vWF in MS sections, F and I also demonstrate perivascular and blood vessel versican 
(V0/V2) neoepitopes expression in the MS lesional blocks. Their co-localisation is 
shown in Figure 5.9 continued in G and J. Normal control brain tissue showed no 
versican (V0/V2) neoepitopes in a perivascular region but with some staining in the 
blood vessel (Figure 5.10 A) vWF (green), B) versican (V0/V2 neoepitopes (red) and 
DAPI C)). Negative controls for the dual staining were carried out by omitting the 
primary antibodies (Figure 5.3 (E and F).
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Figure 5.9: Expression of versican (V0/V2) neoepitopes in a perivascular region in 
lesional MS tissue (MS58 P1D3). vWF expression (blood vessel) (green) (A), versican 
(V0/V2) neoepitopes (+++) in the ECM (perivascular region) (red) (B), their co­
localisation (yellow) (C) and vWF, versican (V0/V2) neoepitopes (white arrows) and 
nuclei of cells counterstained with DAPI in blue (D) x400.
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Figure 5.10: Expression of versican (V0/V2) neoepitopes in normal control brain tissue 
(C028 P1C3) in the perivascular region. vWF expression in a blood vessel (green) (A), 
negative staining for versican (V0/V2) neoepitopes in the ECM and some staining is 
only in the blood vessels (perivascular region) (B), nuclei counterstained with DAPI (C) 
and their co-localisation with vWF x400(D).
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5.2.5 Expression of MOG and Versican (V0/V2) Neoepitopes in Human 
Brain Tissues
MOG is a membrane myelin glycoprotein expressed on the cell surface of 
oligodendrocytes and the outermost surface of myelin sheaths. Due to its localisation, it 
is a primary target antigen involved in immune-mediated demyelination (Reder and 
Oger, 2004).
In this study the expression of MOG in human brain tissue was to determine the extent 
of demyelination. An anti-MOG antibody, provided as a gift by Dr. S. McQuaid, was 
used at his recommended dilution (Table 2.5). Figure 5.11 (A) shows a normal control 
tissue (C022 P1C3) with a uniform pattern of expression of MOG and Figure 5.11 (B), 
lesional MS tissue (MS58 P1C3), shows loss and disruption of MOG. Following dual 
staining, as previously described in section 2.14.3., loss of myelin was found in areas 
where there was increased expression of versican (V0/V2) neoepitopes, indicative of 
increased ADAMTS activity in lesional MS tissue (Figure 5.12 A and B). Control and 
NAWM tissues showed an evenly distributed expression of MOG respectively (Figure
5.12 D and G).
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B100 pm
100 pm
Figure 5.11: Expression of MOG in normal control and lesional MS tissues to determine the 
extent of demyelination. Normal control tissue (C022 P1C3) showed an evenly distributed 
expression of MOG (A). Lesional MS (MS58 P1C3) (B) showed disrupted MOG, with 
areas of complete loss (asterisk). Nuclei counterstained with DAPI in blue (C and D x400).
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5.3 Expression of ADAMTS-1 and Versican (V0/V2) Neoepitopes in 
Human Brain Tissues by Western blotting
5.3.1 Protein Extracts from Human Brain Tissues
Serial cryostat sections (5 X 30 pm) of 2X2 cm human brain tissue blocks were 
collected in microcentrifuge tubes from 5 MS, 2 NAWM and 5 normal control tissue 
blocks as previously described in Plumb et a l (2006) and Haddock et a l (2006). The 
protein was extracted using Tri-reagent following the manufacturer’s protocol and as 
described in sections 2.6.3. Protein concentrations were determined by the bicinchoninic 
acid assay as described in section 2.8. The western blotting method was performed as 
previously described in section 2.15 for ADAMTS-1 and section 2.16 for versican 
(V0/V2) neoepitope detection. ADAMTS-1 western blotting was performed on tissue 
from 3 MS cases and 4 normal controls using an ADAMTS-1 antibody from Santa Cruz 
Biotechnology. This antibody had been verified for its specificity as is previously 
described in chapter 4. In addition, pre-absorption of the antibody with its immunising 
peptide was performed as previously described in section 4.2.3.1 to confirm specificity 
of ADAMTS-1 antibody in western blots of protein extracts from CNS tissue (Figure
5.13 A, B).
The results demonstrated that ADAMTS-1 protein was present in both normal controls 
and in MS human brain tissues at full length (-107 kDa) and in two proteolytically 
cleaved forms -50 and 49 kDa (Figure 5.13 A), which was verified by peptide blocking 
(Figure 5.13 B).
A band -  18 kDa was detected, which was not removed after pre-absorbing the antibody 
with its immunising peptide (Figure 5.13 B) indicating that it was non-specific. The p 
actin (42 kDa) was used to verify the equal loading of the samples (Figure 5.13 C). 
From Figure 5.14 it is difficult to make any conclusions. ADAMTS-1 expression is 
variable in normal controls and MS brains. More samples are needed to confirm any 
differences.
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Figure 5.14: Densitometry of the ADAMTS-1 (all bands except the 18 kDa 
band) in protein extracts from human brain tissue samples. Integrated optical 
density (IOD) ratio is the IOD of protein of interest / IOD of internal control 
protein.
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5.3.2 Expression of Versican (V0/V2) Neoepitopes in Human Brain 
Tissue by Western Blotting
Figure 5.15 shows the optimised western blot with A) negative control (no primary 
antibody) B) and C), the versican (V0/V2) neoepitopes detected by both the ECL and 
DAB immunodetection methods in human brain (NC and MS). Western blotting for the 
detection of versican (V0/V2) neoepitopes was carried out on 5 MS, 5 NC and 2 
NAWM tissue samples as shown in Table 5.4. All the MS samples contained lesions 
and one NAWM sample showed inflammation according to the re-characterisation 
carried out as part of this work.
This study was to determine whether lesional MS differs from NAWM and NC tissues 
in their ADAMTS activity as determined by the presence of versican (V0/V2) 
neoepitopes by western blotting. Figure 5.15 shows that the expected 64 kDa versican 
(V0/V2) neoepitope fragment (Westling et al., 2004) is present. All human brain tissue 
samples studied, whether from control or MS tissue showed the 64 kDa versican 
(V0/V2) neoepitope (Figure 5.16).
The intensities of the 64 kDa band in all samples, when analysed by densitometry, 
showed variable results when comparing MS and NC brain tissues. One o f the 5 MS 
samples analysed here showed a greater intensity of the 64 kDa band compared to NC 
control samples. Surprisingly NAWM showed an increase in both blocks compared to 
controls (Figure 5.17). Because NAWM could be close to white matter lesions, axonal 
pathology and microglial activation may explain changes in so-called NAWM or it may 
be only artifactual. More samples need to be studied to determine if  there are any 
consistent trends. Other bands were detected in these studied cases, which could 
represent other cleaved sites in the core protein for the versican VO and V2 by other 
enzymes in addition to ADAMTSs. Bands o f less than 64 kDa may represent additional 
cleavage o f the 64 kDa species by AD AMTSs or other enzymes. Bands higher than 64 
kDa e.g. 86 kDa band, may result from incomplete deglycosylation o f the proteins.
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Optimisation of the Versican (V0/V2) Neoepitopes in Human Brain 
Tissues (MS/NC) by Western Blotting
A) Negative Control B) ECL Detection C) DAB Detection
kDa M MS NC
6 4 ---- ►
M MS NC M MS NC
MKJKINtk
1 
; 
'
---- -----------|
D) 42 kDa —► P actin
Figure 5.15: Western blot optimisation of detection of versican (V0/V2) neoepitopes in 
human brain, generated by ADAMTS cleavage. Negative control (omitting the primary 
antibody) (A). Red arrow indicates the position of the versicanase-generated 64 kDa 
fragment visualized in blot (B) ECL and DAB (C) detections. Positions of the molecular 
weight markers (M) are indicated at the left of each blot. The p actin control was to 
verify equal loading of protein samples (D)
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Figure 5.17: Densitometry o f the 64 kDa versican neoepitope band in protein 
extracts from human brain tissue samples. IOD ratio is the IOD of protein of 
interest / IOD of internal control protein.
165
5.4 Discussion
The objective in this chapter was to study ADAMTS-1 protein expression and CSPG 
breakdown by AD AMTSs in post mortem tissue via the production o f versican (V0/V2) 
neoepitopes in brain tissue. This was done by immunohistochemistry and western 
blotting. Also to show any differences in MS, MS tissues were compared to normal 
control brain tissue in terms of versican (V0/V2) neoepitopes expression.
The results demonstrated that ADAMTS-1 protein was present in both normal controls 
and in MS human brain tissues at full length (-107 kDa) and in two proteolytically 
cleaved forms ~50 and 49 kDa (Figure 5.13 A), which was verified by peptide blocking 
(Figure 5.13 B). A band ~ 18 kDa was detected, which was not removed after pre­
absorbing the antibody with its immunising peptide (Figure 5.13 B) indicating that it 
was non-specific. Unfortunately, using this ADAMTS-1 antibody (Santa Cruz 
Biotechnology) for immunohistochemistry on human brain tissue gave no consistent 
results. Previous studies by Haddock et al, (2006), using western blotting, showed 
ADAMTS-1 bands at 62 kDa and a doublet at 53 and 50 kDa, which correspond to the 
mature active form and two forms produced by proteolytic cleavage at the carboxyl end, 
respectively. These were detected for all the normal and MS tissue samples run, no 
differences were observed (Haddock et al, 2006). These results showed some similarity 
with those of this study. The only difference is that the previous study used a C-terminal 
antibody that detected the mature form at 62 kDa whereas this study showed a band, 
possibly the zymogen form, at -107 kDa. More samples should be analysed to 
determine if  there are any differences between MS and normal control brain tissues with 
respect to ADAMTS-1 protein expression.
The versican V2 isoform has been proposed to be abundant in adult human, bovine and 
rat brains (Perides et al., 1992; Schmalfeldt et al., 1998; Sandy et al., 2001). In this 
study, it was demonstrated that versican (V0/V2) neoepitopes were expressed in normal 
and MS brain, which has not previously been reported in MS or normal brain tissue 
immunohistologically. From a previous study using the same versican neoepitope
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antibody a 64 kDa band indicated the presence of this neoepitope in human brain tissue 
(Westling et al., 2004). Versican (V0/V2) neoepitope expression was increased, as 
observed by immunohistochemistry, in lesional tissue relative to normal control tissue, 
suggesting that changes in versican matrix degradation may result from changes in 
ADAMTS activity levels. It has been previously demonstrated that ADAMTS-4 is 
expressed in the CNS and shows an increased expression in MS compared to normal 
control tissues (Haddock et al, 2006). Also a previous study showed that TIMP-3, 
which is an endogenous inhibitor for these AD AMTSs, is decreased in MS (Haddock et 
al, 2006) and EAE (Plumb et al, 2005). This increase in the ADAMTS activity could 
indicate a role for the ADAMTS in lesion development and ECM turnover in MS.
Sobel and Ahmed demonstrated that in active MS lesions, versican was decreased in 
the ECM (Sobel and Ahmed, 2001). The decrease in intact versican in MS lesions is in 
keeping with the observation of increased versican neoepitope expression in lesional 
MS in this study. The versican neoepitopes produced are characteristic o f ADAMTS 
glutamyl peptidase cleavage suggesting an increase o f their activity in MS lesions.
Generally, western blotting could be a further confirmatory test for the IHC method 
because western blotting can test the expression of a protein qualitatively or 
quantitatively. However, in this study western blotting for versican (V0/V2) 
neoepitopes detection in MS compared to normal controls and NAWM produced 
different results from the immunohistochemical method. Western blotting is used to 
investigate the expression of a protein of interest derived from a whole tissue sample 
and may include normal and lesional tissue, possibly diluting out differences. 
Immunofluorescence allows specific areas to be investigated, lesional and non-lesional, 
allowing a better evaluation as to whether neoepitope expression is increased or not. 
There were no clear differences between V0/V2 neopepitopes detected from MS or 
normal control tissues by western blotting. Further work is required to examine more 
samples.
Other bands in addition to the 64 kDa band were observed. Those < 64 kDa may have 
resulted from further cleavage of 64 kDa species by ADAMTSs or other enzymes.
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Bands > 64 kDa were seen in this study and by Westling et al, (2004) with the similar 
antibody though their origin was not discussed. An 86 kDa species could arise from the 
cleavage of the versican (V0/V2) core protein (see Figure 5.1) (Westling et al, (2004) 
but this is unlikely to be detected by this antibody. These higher molecular weight bands 
may arise as a result o f incomplete deglycosylation. Co-localisation o f the versican 
(V0/V2) neoepitopes with the endothelial marker, vWF, following dual labelled 
immunofluorescence indicates the localisation of these neoepitopes with blood vessels 
in both MS and control brain. However MS cases showed also an increased neoepitope 
in ECM relative to normal control brain. The co-localisation of versican (V0/V2) 
neoepitope with the blood vessel agrees with an earlier study on versican isoform 
expression by endothelial cells that showed that isolated endothelial cells express all 
versican isoforms except the V3. The same study demonstrates that both versican VO 
and V2 isoform transcripts are expressed by the healthy human brain tissue (Cattaruzza 
et al., 2002).
Recently it has been indicated that TLRs are expressed by a variety of peripheral 
immune cells and resident cells o f the CNS. They have a significant role in modulating 
MS, as well as EAE (Racke and Drew, 2009). In addition to lymphocytes that control 
adaptive immune responses, dendritic cells and tissue macrophages that regulate innate 
immune responses also play a role in controlling MS disease pathogenesis. These cells 
express TLRs that recognize pathogen-associated molecular patterns (PAMPs) present 
on the surface of pathogens. Following ligand binding to TLRs, innate immune cells 
produce proinflamatory cytokines and can serve as APCs to prime naive T cells to 
recognize antigens (Takeda and Akira, 2005, Hacker et al., 2006). Thus, TLRs play an 
important role in linking the innate to the adaptive immune response (Bell et al. 2005).
TLRs may be activated by fragments o f the ECM molecules generated by proteolytic 
cleavage. The 64 kDa fragment could be a candidate for this. Other ECM molecules 
may have this effect e.g. short hyaluronan fragments also versican (Piccinini and 
Midwood, 2010).
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Activation of TLRs induces the expression o f proinflammtory cytokines such as IL-1, 
TNF, chemokines and adhesion molecules. TLRs have been found in MS tissues and are 
thought to be involved in the pathogenesis of MS (Piccinini and Midwood, 2010). 
Versican breakdown products could be involved in the perpetuation of inflammation in 
MS.
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Chapter 6 
General Discussion
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Though, it has been demonstrated that ADAMTS expression may be modulated by a 
number of mediators in a number of different cell systems (Yamanishi et al., 2002, 
Bevitt et al., 2003, Tsuzaki et al., 2003, Cross et al., 2005), studies o f ADAMTSs in 
neuronal cells are very limited (Sasaki et al., 2001). ADAMTS-1 and -4 expression in 
astrocytes and neurons has been reported following physical or toxic injury to the CNS 
and it was suggested that this expression at the site of injury may support neurite 
outgrowth (Satoh et al., 2000, Lemons et al., 2001, Sasaki et al., 2001, Yuan et al., 
2002).
ADAMTS-1, -4 and -5 are known to be expressed in normal adult and MS CNS and 
have the ability to cleave CSPGs that are present in the brain ECM. ADAMTS-1, -4 and 
-5 possess aggrecanase activity (Somerville et al., 2003, Vankemmelbeke et al., 2003), 
ADAMTS-1 and -4 are capable o f cleaving versican (Sandy et al., 2001, Somerville et 
al., 2003, Westling et al., 2004), and brevican is cleaved by ADAMTS-4 (Matthews et 
al., 2000). It is therefore proposed that these enzymes are intimately involved in brain 
ECM turnover. ECM alteration due to the activity o f the ADAMTSs has not been 
studied in MS tissue. The aim of this study was to investigate ADAMTS-1, -4 and -5 in 
neuronal cells and to determine the ADAMTS activity in MS tissue via their versican 
(V0/V2) cleavage to produce neoepitopes.
6.1 In Vitro Studies
6.1.1 Expression and Modulation of ADAMTS-1, -4 and -5 in Human 
Neuroblastoma Cell Lines
The data in chapter 3 demonstrated that ADAMTS-1, -4 and -5 mRNA are expressed 
under basal conditions by human neuroblastoma cell lines in vitro. The ADAMTS-1 
mRNA showed the highest expression levels by both the human neuroblastoma cell 
lines used in this study SHSY-5Y and SK-N-DZ compared to ADAMTS-4 and 
ADAMTS-5. Previously, work in our laboratory has shown that these ADAMTSs are
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constitutively expressed by human astrocytes and that ADAMTS-1 appeared to show 
the highest expression level, by ICC, compared to ADAMTS-4 and -5 staining which 
were much lower (Cross et al., 2006a), in agreement with our finding in the neuronal 
cells. In this study ADAMTS-1 mRNA showed an upregulation with RetA treatment in 
SHSY-5Y cell line. RetA plays an essential role in nervous system development, 
including neuronal survival and neurite outgrowth. It serves as a main regulator o f gene 
expression. RetA exerts its effects on gene transcription by binding to nuclear retinoic 
acid receptors (RARs) (Clagett-Dame et al., 2006). It has been shown that human 
neuroblastoma cells decrease their proliferation and exhibit enhanced extension with 
neurite processes in response to 10‘5M treatment o f RetA (Encinas et al., 2000).
In this study, no modulations in the expression of ADAMTS mRNA were observed in 
SHSY-5Y cells with proinflammatory cytokines. However, the SK-N-DZ cell line 
showed an increase in ADAMTS-1 mRNA with IL-ip (10 ng/ml) and ADAMTS-4 
mRNA with TNF (10 and 100 ng/ml). A previous in vitro study showed modulation of 
ADAMTS-1 and -4 mRNA expression by TNF in astrocytes (Cross et al., 2006a). This 
study also showed that IL-lp treatment did not significantly alter mRNA expression 
levels of ADAMTS-1, -5 and TIMP-3 in astrocytes, although there was a significant 
increase in ADAMTS-4 at the low concentration of 1 ng/ml IL-ip. In the same study, 
no changes were seen, on IL-lp treatment, in ADAMTS-1, -4, -5 or TIMP-3 protein 
levels compared with control. However, IL-ip has been shown to increase ADAMTS-1 
expression in other systems (Kuno et al., 1997). ADAMTS-5 mRNA is expressed at 
low levels in both neuronal cell lines in this study, which concurs with the study of 
Haddock et al, (2006) which showed ADAMTS-5 mRNA expression to be low in brain 
tissue (Haddock et al., 2006). Modulation o f ADAMTSs with proinflammatory 
cytokines in neuronal cells and astrocytic cells (Cross et al., 2006a, Haddock et al., 
2006) is summarized in Figure 6.1.
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6.1.2 Expression and Modulation of ADAM-17 and TIMP-3 in Human 
Neuroblastoma Cell Lines
ADAM-17 is an ADAM metalloproteinase, a well known sheddase which is involved in 
releasing soluble TNF (17 kDa extracellular domain) from its membrane-bound 
precursor (pro-TNF) (Moss et al., 1997, Black et al., 1997). ADAM-17 is also 
responsible for the cleavage of a wide variety o f substrates involved in inflammation 
including transforming growth factor-alpha, L-selectin, p75 (Peschon et al., 1998) and 
p55 TNF receptors (Reddy et al., 2000), the chemokine (fractalkine) (Garton et al., 
2001) and amyloid precursor protein (Garton et al., 2001). TNF is involved in the 
adaptive immune response to injury or infection and is upregulated after ischaemic 
events (Cardenas et al., 2002).
ADAM-17 expression has been shown in the CNS (Goddard et al., 2001). Plumb et al 
(2006) observed expression of ADAM-17 in activated macrophage/microglia and 
astrocytes in MS white matter (Plumb et al., 2005, Plumb et al., 2006). Its expression is 
upregulated in active MS lesions (Plumb et al., 2006). It has also been studied in spinal 
cords o f rats with EAE where there was an upregulation of ADAM-17 mRNA 
expression with a decrease in mRNA levels o f its inhibitor TIMP-3, suggesting a role 
for ADAM-17 in EAE pathogenesis (Plumb et al., 2005, Plumb et al., 2006).
As previous findings indicate, ADAM-17 can be implicated in the pathogenesis of MS. 
Neuronal ADAM-17 has been investigated in this study to further elucidate its role in 
MS. This in vitro study showed no modulation in the expression levels o f neuronal 
ADAM-17 with proinflammatory cytokines in both differentiated and undifferentiated 
SHSY-5Y cells. It suggests any involvement o f ADAM-17 in MS pathogenesis may be 
via other cell types.
TIMP-3 has been shown to be the only member o f the TIMP family able to effectively 
inhibit the actions of ADAM-17 (Amour et al., 1998). It is also known as the main
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inhibitor of ADAMTSs. This study showed no modulation in TIMP-3 expression in 
vitro in SHSY-5Y cells. SK-N-DZ cells did not express TIMP-3 at the mRNA level. 
This contrasts with previous studies which demonstrated a significant decrease in 
TIMP-3 mRNA in MS human brain tissue compared to controls (Haddock et al., 2006) 
and in EAE (Plumb et al., 2005).
6.2 Antibody Optimisation and ADAMTS-1 Expression (Western 
Blotting)
The aim of chapter 4 was to verify the specificity of the commercial ADAMTS-1
antibody for further use in this study. Data in chapter 4 demonstrated, using a number of
commercial antibodies from different sources (Triple Point Biologies, Abeam and Santa
Cruz Biotechnology), that the most suitable antibody for ADAMTS-1 protein detection
was from Santa Cruz Biotechnology. This was used in further investigations. It was the
only antibody that produced reproducible results from SHSY-5Y extracts and had an
available blocking peptide. It produced a 37 kDa band which indicates the expression of
a fragment of ADAMTS-1 and was reduced in intensity on ADAMTS-1 siRNA
knockdown and blocked on pre-absorption of the antibody with the immunizing peptide.
The peptide blocking and the siRNA knockdown methods were able to confirm the
specificity o f the antibody to ADAMTS-1 in this study. It is suggested that the 37 kDa
band could represent a fragment o f ADAMTS-1 produced by C-terminal proteolytic
processing or may represent protein splicing variants. Miguel et al, (2005) observed a
similar sized band in other neurodegenerative diseases in agreement with the present
work. Furthermore, Miguel et al (2005), showed another band at 50 kDa band.
Interestingly, both bands were fivefold over-expressed in neurodegenerative diseases
(Miguel et al., 2005). The findings of Miguel et al (2005), suggest that this fragment
could be involved in neurodegenerative disease. Further studies on ADAMTS-1 are
needed to determine the functional role o f this fragment in processes occurring MS.
This Santa Cruz Biotechnology ADAMTS-1 antibody used here has been used
previously by Pockert et al, (2009) in a study of intervertebral disc degeneration.
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ADAMTS-1 was detected immunohistochemically in degenerative discs compared with 
non degenerative discs. Also their results showed that ADAMTS-1, -4, -5, and -15 at 
the gene level were significantly increased in degenerated tissue compared with 
nondegenerated tissue. However, the immunostaining of ADAMTS -4, -5, -9, and -15 
were significantly increased in degenerated tissue compared with nondegenerated tissue.
Other workers, in studies o f ADAMTS-1 protein by western blotting, have observed 
species with different molecular sizes depending on the antibody source and the source 
of cell or tissue extract. In a study o f CNS tissue after induction o f experimental 
cerebral ischaemia by transient middle cerebral artery occlusion in the rat, using western 
blotting, ADAMTS-1 protein produced a band at 97 kDa. In the same study a band for 
ADAMTS-1 was also observed at 51 kDa in protein extracts from primary human 
astrocytes (Cross et al., 2006a). Other studies demonstrated bands for ADAMTS-1 at 64 
kDa and 50 kDa in EAE (Cross et al., 2006b) and in human brain tissue, ADAMTS-1 
bands were seen at 62 kDa and a doublet at 53 and 50 kDa which corresponds to the 
mature active form and two proteolytic cleaved forms, respectively. This suggests these 
antibodies detect different processed forms of ADAMTS-1 depending on the cell or 
tissue type.
6.3 Post mortem Studies
6.3.1 Versican (V0/V2) Neoepitopes in Normal and MS Human Brain 
Tissue
The CSPGs are widely expressed throughout the developing and adult CNS and have a
role in guiding or limiting neurite outgrowth and cell migration. Alterations in the
synthesis or breakdown of the ECM may contribute to disease processes (Jones et al.,
2003, Medina-Flores et al., 2004, Miguel et al., 2005, Haddock et al., 2006). Thus,
ADAMTS-mediated cleavage of lecticans, aggrecan, versican and brevican in the CNS
ECM, via their GEP activity, could have a potential role in normal ECM turnover and
ECM breakdown in MS. To support this hypothesis this study demonstrated CSPG
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breakdown by ADAMTSs via the production of versican (V0/V2) neoepitopes as an 
indicator o f enzyme activity. This provides evidence for a potential role o f these 
ADAMTSs in MS pathogenesis.
Detection o f neoepitopes of versican (V0/V2) used an antibody specific for the new C- 
terminal sequence (NIVSFE405) generated by cleavage o f versican VO or V2 at the 
Glu405-Gln406 bond by ADAMTS glutamyl endopeptidase activity. IHC results 
showed increased versican (V0/V2) neoepitopes in lesional MS compared to normal 
controls. Western blotting results showed bands for versican (V0/V2) neoepitopes in 
both normal and MS samples at 64 kDa. This is in agreement with Westling et al, (2004) 
who observed a similar sized fragment with this antibody on versican V0/V2 cleavage 
by ADAMTSs. The V2 isoform of versican is the predominant form in the brain. It is 
composed of the G1 domain, GAG-alpha domain, and the G3 domain. Westling et al, 
2004 found that the cleavage o f versican V2 at the Glu405-Gln406 bond generates a 
versican (64 kDa) fragment on ADAMTS-4 cleavage (Westling et al., 2004).
In contrast to the IHC method western blotting did not show an increase in neoepitopes 
in MS human brain tissues. Western blot procedure is often conducted to complement 
and support IHC studies. Inconsistent results between western blot and IHC studies may 
reflect differences in the experimental conditions. IHC can distinguish lesional and 
non-lesional tissue so can determine more specifically the increase o f versican (V0/V2) 
neoepitopes in MS lesions. For western blotting sections (5 X 30 pm) o f human brain 
tissue were collected to obtain a sufficient amount of protein for western blotting. This 
tissue contains lesions and NAWM in the same sections and may cause ‘diluting out’ of 
any differences making them more difficult to determine. This is particularly so if  the 
lesion constitutes a small proportion of the tissue extracted for western blotting. 
Selection of tissue from more specific regions, lesion or NAWM would be required to 
obtain more meaningful results.
It has been reported that ADAMTS-4 may be involved in the loss o f ECM by cleaving 
proteoglycans, as demonstrated in other tissues (Matthews et al., 2000, Sandy et al., 
2001, Tortorella et al., 2002, Vankemmelbeke et al., 2003). Sobel and Ahmed
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demonstrated that in active plaque centres and active lesions, versican, aggrecan and 
neurocan were decreased in the ECM (Sobel and Ahmed, 2001). The present study is 
consistent with this and suggests that the decrease o f versican in lesional MS is due to 
the excess of ADAMTS cleavage. Furthermore Haddock et al, (2006) showed that high 
levels of ADAMTS-4 were observed in active MS lesions (Haddock et al., 2006).
Little is known about ADAMTS-1 in CNS or its function. This study investigated 
ADAMTS-1 in human brain tissue since it may have a potential role in MS, as it has 
been shown to be the most abundant ADAMTS with an upregulation with RetA 
treatment in the in vitro study. It is expressed in MS and normal human brain tissue as 
demonstrated by western blot method, in agreement with Haddock et al, 2006. 
However, the ADAMTS-1 IHC staining did not produce consistent results and required 
further investigation in human brain.
In other tissue types, ADAMTS-1 is involved in the development and function o f many 
organs, which is attributable to the proteoglycan processing capacity o f this protease 
(Shindo et al., 2000, Cross et al., 2005). It has been previously shown that ADAMTS-1 
is important for ECM remodeling around growing ovarian follicles (Brown et al., 2006). 
Brown et al, (2010) demonstrated that ADAMTS-1 is critical in both ovulation and 
fertilization processes in vivo (Brown et al., 2010). The protease activity o f ADAMTS-1 
mediates neomorphogenesis o f the ovulating follicle wall and cumulus-oocyte matrix 
necessary for successful ovulation and fertilization, as well as subsequent catabolism of 
versican required for degradation o f cumulus-oocyte matrix after fertilization. 
Furthermore, cardiogenesis, remodeling o f the myocardium, requires cleavage of 
versican by ADAMTS-1 (Stankunas et al., 2008), with the cleaved versican acting to 
reduce cell-cell adhesion and weaken tissue structure (Kern et al., 2007).
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6.4 Future Work
To enhance understanding of the functional role o f ADAMTSs in MS, the investigations 
in this study could be consolidated and extended.
ADAMTS-1 siRNA was transfected into SHSY-5Y cells in this study. Knockdown was 
assessed at the mRNA level by qRT-PCR and at the protein level by western blotting. 
ADAMTS-1 knockdown experiments in animal models (EAE) could be performed to 
provide more understanding o f the functional role of ADAMTS-1 in the pathogenesis 
and the progression of the disease in different stages o f MS.
More investigations could be made on the effects of ADAMTS knockdown by using 
cells plated on native ECM substrates and determine the production o f neoepitopes by 
western blotting of concentrated culture medium or looking at the breakdown of quench 
fluorescent ECM substrates, if  available, which may produce fluorescence on cleavage. 
This could add to the understanding of the functional roles of these ADAMTSs in 
breakdown of the ECM. Also the expression and modulation of ADAMTSs in animal or 
human primary neuronal cells (supplied from Neuromics) could be studied.
This study has provided evidence of a functional role of ADAMTSs via the increase in 
the expression of versican (V0/V2) neoepitope in MS compared to normal tissue which 
relates to its cleavage by ADAMTSs and possibly increased activity. Previous studies 
and the current data suggest that ADAMTS-4, as well as other described ‘GEPs’ 
(ADAMTS-1, -5 or -9), may play important roles in the processing o f this molecule and 
other lecticans, such as aggrecan and brevican, in the CNS in vivo (Westling et a l, 2004, 
Haddock et a l ,2006). To support this hypothesis, further investigations are required to 
study the co-localisation in MS brain tissue (fresh samples), o f ADAMTSs, with 
versican (V0/V2) neoepitopes produced as a result o f ADAMTS specific cleavage of 
versican. This will determine which ADAMTS enzyme correlates with the versican 
breakdown in MS. The cellular association o f ADAMTSs and their relationship to 
neoepitope production, especially with neuronal cells, could also be studied.
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Studying cleaved fragments of lecticans in the brain using their specific neoepitope 
antibodies would increase our knowledge of CNS ECM breakdown in MS. Brevican is 
a specific CNS PG with a high molecular weight (145 kDa), and is secreted by 
astrocytes and neurons (Seidenbecher et al., 1998, Jaworski et a l ,  1999). The anti- 
EAVESE antibody recognizes the neoepitope sequence generated by ADAMTS 
cleavage at the C-termini which is associated with a 55 kDa fragment o f brevican 
(Matthews et al., 2000). Aggrecan is another member of the lectican family of 
proteoglycans which is found in cartilage and brain. It is also cleaved by ADAMTSs 
and forms a C-terminus neoepitope NITEGE recognized by an antibody (Wilson et a l, 
2009, Voigt et a l, 2009). These neoepitopes could be detected with specific antibodies 
in further investigations in human brain tissue. The cleavage o f versican and other 
lecticans e.g. aggrecan and brevican by the ADAMTSs may result in a loosening o f the 
lectican-hyaluronan-tenascin matrix and promote the access o f inflammatory cells and 
cytokines increasing axonal damage (Figure 6.1).
An alteration of ECM was identified in this study and a versican V2 fragment similar to 
GHAP is produced (Westling et a l, 2004). The function of this fragment is still not 
known, however the breakdown of ECM components and the production o f GHAP may 
result in the activation o f TLRs in the same way as hyaluronan fragments or other 
endogenous ligands of TLR do (Piccinini and Midwood, 2010). These ECM fragments 
could be important playing a key role in MS pathogenesis, inducing inflammatory 
responses by TLRs induction and or stimulation. TLR expression and the effects o f 
synthetic GHAP could be studied in CNS-derived cells on parameters such as cytokine 
and protease production.
6.5 Conclusion
The main aim of this study was to elucidate a role for ADAMTS-1, -4 and -5 in the 
pathogenesis o f MS. This study has shown that ADAMTS-1, -4 and -5 are constitutively 
expressed in SHSY-5Y and SK-N-DZ neuronal cells. It also provides evidence that 
ADAMTS-1 has the potential to be implicated in MS pathogenesis, showing an
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upregulation after the RetA treatment. In the SK-N-DZ cells ADAMTS-1 mRNA 
increased with IL-ip. Further investigations on primary neuronal cells which could 
further elucidate the role o f neuronal ADAMTSs are required. Post mortem studies 
provided evidence that ADAMTSs may be implicated in the pathogenesis of MS by the 
increased versican (V0/V2) neoepitope expression generated due the cleavage of 
versican by these enzymes. This suggests ADAMTSs do appear to have a potential role 
in the pathogenesis o f MS particularly in lesion development and in ECM breakdown, 
which may be detrimental or beneficial. Further investigations are required to determine 
the importance of the versican fragment(s) generated which could be ligands of TLRs 
and may have a potential link with processes occurring in MS. The GEPs such as 
ADAMTS-1 and -4, which are produced in the CNS may be a possible future target for 
MS therapy.
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Appendix I
Amplification Plots for cDNA from
SHSY-5Y Cells
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SHSY-5Y
A) R NA P-II
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B) A D A M T S-1
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C ) A D A M T S-4
Ct
C ycles
Amplification plots of qPCR for RNAP-II (A), ADAMTS-1 (B) and -4 (C). RNAP-II 
showed constant expression following treatment (C j values 26.9-27.6) with cytokine. 
Both ADAMTS-1 and ADAMTS-4 Ct values were between 29-32.
B ackground signal
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D) A D A M T S  S
lackground signal
E ) ADAM-17 C ycles
A D A M
TIMP-3
0 5 10 15 20 25 30 35 40
F) TIMP-3 Cyc,es
0 5 10 15 20 25 30 35 40
C ycles
Amplification plots of qPCR for ADAMTS-5 (D), ADAM-17 (E) and TIMP-3 (F). 
ADAMTS-5 expression following treatment Cj  values was > 3 0 ,  ADAM-17 and 
TIMP-3 C t values variable numbers.
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Amplification Plots for cDNA from
SK-N-DZ Cells
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Amplification plots of qPCR for RNAP-II (A), ADAMTS-1 (B) and TIMP-3 (C). 
RNAP-II showed constant expression following treatment ( C t  values ~ 24-25) with 
cytokine. ADAMTS-1 showed variable Ct values and no TIMP-3 gene expression.
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Modules, Publications and 
Presentations
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Modules
Research Studies (15M Credits): During the first year (2007-2008)
Research Methods (15M Credits): 10-12th December 2007
Published Abstracts
GIBREL, G., CROSS, A.K., HADDOCK, G., BUTTLE, D.J. and BUNNING, R.A.D. 
(2011)
The Role of ADAMTSs and Versican Cleavage in Multiple Sclerosis. Poster presented
that BSMB Meeting 'Matrix Signals-Cell Matrix Interactions in Health and Disease' 8-9 
September 2011, Newcastle, UK. International Journal of Experimental Pathology.
GIBREL , G., CROSS, A.K., HADDOCK, G., BUTTLE, D.J. and BUNNING, R.A.D. 
(2010)
The Functional Role of ADAMTSs in the Pathogenesis of Multiple Sclerosis. Poster 
presented at 10th International Congress of Neuroimmunology-ISNI, Sitges (Barcelona, 
Spain) 26-30th October 2010, Journal of Neuroimmunology, 15 November 2010; 228, 
ISSUES 1-2).
GIBREL , G., CROSS, A.K, HADDOCK, G., BUTTLE, D.J. and BUNNING, R.A.D. 
(2010)
The Expression and Modulation of ADAMTS-1 and TIMP-3 in Neuronal SHSY-5Y 
Cells and CNS Tissue. Poster presented at BSMB Autumn Meeting 'Inflammation 
Meets Matrix Biology' 6-7th September 2010, Norwich, UK. International Journal of 
Experimental Pathology.
209
Departmental Oral Presentations (BMRC)
Final year presentation: 29th March 2011
thThird year presentation: 17 February 2009 
First year presentation (PhD confirmation): 22nd October 2008 
Introductory oral presentation: 31st October 2007
Posters Presentations
BMRC/MERI Winter Poster Session: 16th December 2011, Sheffield Hallam University, 
Sheffield, UK.
British Society for Matrix Biology (BSMB) Meeting: 'Matrix Signals-cell Matrix 
Interactions in Health and Disease' 8-9th September 2011, Newcastle, UK.
MS Frontiers Research Event: 21-22nd May 2009; 23-24th June 2011, London, UK.
10th International Congress of Neuroimmunology-ISNI: 26-30th October 2010, Sitges 
(Barcelona, Spain).
British Society for Matrix Biology (BSMB) Autumn Meeting: 'Inflammation Meets 
Matrix Biology' 6-7th September 2010, Norwich, UK.
Faculty of Health and Wellbeing Research Day: 17th December 2008; 17th June 2010, 
Sheffield, UK.
The 3rd Symposium for Libyan Students in the UK: 12th June 2010, Sheffield Hallam 
University, Sheffield, UK.
210
Conference Attendance
British Society for Matrix Biology (BSMB) Meeting: Matrix Signals-cell Matrix 
Interactions in Health and Disease' 8-9 September 2011, Newcastle, UK.
10th International Congress of Neuroimmunology-ISNI: 26-30th October 2010, Sitges 
(Barcelona, Spain)
British Society for Matrix Biology (BSMB) Autumn Meeting: 'Inflammation Meets 
Matrix Biology' 6-7th September 2010, Norwich, UK
The University of Sheffield Neuroscience Away Day: 19 th September 2009, Sheffield, 
UK.
The Northern Neuro-Immunology Interest Group 8th Annual Meeting: 2nd November 
2007, Nottingham, UK.
Professional Activities
Four years (2008-2011) member of a Learned Society: British Society of Matrix 
Biology (BSMB).
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Appendix IV 
Ethical Approval
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Research Ethics Committee: MREC FOR WALES
Research Tissue Bank: THE UK MULTIPLE SCLEROSIS TISSUE BANK
REC reference number: 08/MRE09/31
Name of applicant: PROFESSOR RICHARD REYNOLDS 
(DESIGNATED INDIVIDUAL : MR G. ROPER)
Date of approval: 08 MAY 2008
Ethical approval is given to the Research I issue Bank (“the Bank”) by the Research Ethics Committee 
(“the Committee”) subject to the following conditions.
1. Further com m unications w ith the Committee
1.1 Further communications with the Committee are the personal responsibility of the applicant.
2.1 Approval is given for a period of 5 years, which may be renewed on consideration of a new 
application by the Committee, taking account of developments in legislation, policy and 
guidance in the interim. New applications should include relevant changes of policy or practice 
made by the Bank since the original approval together with any proposed new developments.
3. L icensing
3.1 A copy of the Licence from the Human Tissue Authority (HTA) should be provided when 
available (if not already submitted).
3.2 The Committee should be notified if the Authority renews the licence, varies the licensing 
conditions or revokes the Licence, or of any change of Designated Individual. If the Licence is 
revoked, ethical approval would be terminated.
4. Generic ethical approval fo r projects receiving tissue
SOPs version 3.1 dated 10 January 2007
SL-AC1 Approval conditions (CTIMP)
4.1 S am p les of human tissu e or other biological material may be supplied and used in research  
projects to b e conducted within the establishm ent responsible for the Bank and/or by 
researchers and research institutions external to the Bank within the UK and in other countries 
in accordance with the following conditions.
4.1 .1  The research project should be within the fields of m edical or biomedical research  
described in the approved application form.
4 .1 .2  The Bank should be satisfied that the research has been  subject to scientific critique, 
is appropriately designed  in relation to its objectives and (with the exception of student 
research below  doctoral level) is likely to add som ething useful to existing knowledge.
4 .1 .3  W here tissu e  sam ples have been  donated with informed consent for u se  in future 
research (“broad con sent”), the Bank should be satisfied that the use of the sam ples  
com plies with the term s of the donor consent.
4 .1 .4  • All sam p les and any associated  clinical information m ust b e non-identifiable to the
researcher at the point of re lease (i.e. anonym ised or linked anonym ised).
4 .1 .5  S am p les will not be released  to any project requiring further data or tissue from 
donors or involving any other research procedures. Any contact with donors must be  
confined to ethically approved arrangem ents for the feedback of clinically significant 
information.
4 .1 .6  A supply agreem ent must be in p lace with the researcher to ensure storage, u se  and 
disposal o f the sam ples in accordance with the HTA C od es of Practice, the terms of 
the ethical approval and any other conditions required by the Bank.
4 .2  A  research project in the UK using tissu e provided by a Bank in accordance with th ese  
conditions will be considered  to have ethical approval from the Committee under the terms of 
this approval. In England, W ales and Northern Ireland this m ean s that the researcher will not 
require a licence from the Human T issue Authority for storage of the tissue for u se  in relation 
to this project.
4 .3  T he Bank may require any researcher to se e k  specific ethical approval for their project. Such
applications should normally be m ade to the Com m ittee and booked via the COREC Central 
Allocation System .
4 .4  A Notice of Am endm ent form should be subm itted to se e k  the Com m ittee’s  agreem ent to 
ch an ge the conditions of generic approval.
5 . R e c o r d s
5.1 T he Bank should maintain a record o f  all research projects to which tissue has b een  supplied. 
T h e record should contain at least the full title of the project, a summary of its purpose, the  
nam e of the Chief Investigator, the sponsor, the location of the research, the date on which the  
project w as approved by the Bank, details of the tissu e  released  and any relevant reference  
numbers.
5 .2  T he Com m ittee m ay request a c c e s s  to th e se  records at any time.
6 . A n n u a l r e p o r ts
6.1 An annual report should be provided to the Com m ittee listing ail projects for which tissu e  h as  
b een  released  in the previous year. The list should give the full title of each  project, the nam e  
of the Chief Investigator, the sponsor, the location of the research and the date of approval by 
the Bank. The report is due on the anniversary of the date on which ethical approval for the  
Bank w a s given.
SOPs version 3.0 dated June 2005
SL-AC1 Approval conditions (CTIMP)
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6 .2  T h e  C o m m it te e  m a y  r e q u e s t  add it iona l rep o r ts  on  th e  m a n a g e m e n t  of t h e  B a n k  a t  a n y  time.
7 . S u b s ta n t ia l  a m e n d m e n ts
7.1 Substantial am endm ents should b e notified to the Comm ittee and ethical approval sought 
before implementing the am endm ent. A substantial am endm ent generally m ean s a n y . 
significant ch an ge to the arrangem ents for the m anagem ent of the Bank a s described in the
. application to the Comm ittee and supporting documentation.
7 .2  T he COREC Notice of Am endm ent form should be u sed  to seek  approval. The form is 
available at http://www.corec.orq.Uk/applicants/applv/amendments.htm#other.
7.3 T he following ch an ges should alw ays be notified a s  substantial am endm ents:
7.3.1 Any significant ch an ge to the policy for u se  of the tissu e  in research, including ch an ges to the
typ es of research to be undertaken or supported by the Bank.
7 .3 .2  Any significant ch an ge to the types of biological material to be collected and stored, or the 
circum stances of collection.
7 .3 .3  Any significant ch an ge to informed consent arrangem ents, including new/modified information 
sh e e ts  and con sen t forms.
7 .3 .4  A ch an ge to the conditions of generic approval.
7 .3 .5  Any other significant ch an ge to the governance of the RTB.
8 . S e r io u s  a d v e r s e  e v e n t s
8.1 T h e Com m ittee should be notified a s  soon  a s  p ossib le of any serious adverse event or 
reaction, any serious breach of security or confidentiality, or any other incident that 
could undermine public confidence in the ethical m anagem ent of the tissu e. T he criteria for 
notifying the Comm ittee will be the sam e a s th ose  for notifying the Human T issu e Authority in 
the c a se  of research tissu e banks in England, W ales and Northern Ireland.
9 . O th er  in fo r m a tio n  to  b e  n o tifie d
9.1 T he Com m ittee should be notified of any change in the contact details for the applicant or w here  
the applicant hands over responsibility for communication with the Comm ittee to another person  
at th e establishm ent.
10 . C lo s u r e  o f  th e  B an k
10.1 Any plans to c lo se  the Bank should be notified to the Com m ittee a s  early a s  p ossib le and at 
lea st two m onths before closure. T he Comm ittee should b e informed what arrangem ents are to 
b e m ade for disposal of the tissu e  or transfer to another research tissu e  bank.
10.2 W here tissu e  is transferred to another research tissu e  bank, the ethical approval for the Bank is 
not transferable. W here the secon d  bank is ethically approved, it should notify th e responsible 
R esearch  Ethics Committee. The term s of its own ethical approval would apply to any tissu e it 
receives.
11 . B r e a c h e s  o f  a p p r o v a l c o n d it io n s
SOPs version 3.0 dated June 2005
SL-AC1 Approval conditions (CTIMP)
11.1 I h e Comm ittee should b e notified a s  soon  a s  p ossib le of any breach of th e se  approval 
conditions.
11.2  W here serious breaches occur, the Com m ittee may review its ethical approval and may, 
exceptionally, suspend  or terminate the approval.
SOPs version 3.0 dated June 2005
SL-AC1 Approval conditions (CTIMP)
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